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Preface 
 
This thesis firstly provides a narrative overview of the literature to date regarding the 
management of an Achilles tendon rupture, which leads to four specific aims. These 
four aims directly relate to the Medical Research Councils framework for developing 
complex interventions. They address the interrelated concepts of defining the 
intervention components, developing an appropriate theoretical framework to 
establish why and to what extent each of these components is important, piloting 
the interventions and assessing their effectiveness. 
 
To achieve these aims a wide range of research methods have been implemented. 
These have included systematic reviews, experimental designs, pilot clinical trials 
and outcome validation research. To successfully implement these methods, 
completion of this thesis has required research management skills including costing 
the project, applying for funding, completing and gaining NHS ethics approval, 
research and development approval and presentation of progress reports.  
 
The capacity to successfully complete the aims of this thesis using the described 
methods was achieved through appropriate supervision and a tailored programme 
of courses and conferences to develop these skills, outlined at the end of this thesis. 
Furthermore to demonstrate the original contribution of this work, selected chapters 
have been submitted and accepted for publication, in addition to being accepted for 
national and international conference presentations. 
 
This thesis will lead the reader through the development of a complex intervention 
for Achilles tendon rupture management, whilst also highlighting of the strengths 
and limitations of each chapter. This reflects my on-going development to enable 
future independent research leadership in this area.  
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Thesis Abstract 
 
Background  
Rupture of the Achilles tendon occurs in over 11,000 people annually in the UK. 
Traditional management using cast immobilisation is being slowly replaced by 
immediate weight bearing rehabilitation, but currently there is no consensus 
regarding the exact protocol to be used.  
 
The aim of this thesis was to develop an immediate weight bearing rehabilitation 
protocol for patients who have sustained an acute rupture of their Achilles tendon to 
inform a definitive evaluation of its effectiveness. To achieve this aim a framework 
(by the Medical Research Council) for defining and developing interventions with 
several components was used to underpin the structure of this thesis.  
 
Pre-Clinical Development 
The first two objectives of this thesis were focussed on the ‘pre-clinical’ 
development phase. Firstly, a systematic review of the evidence base identified the 
components that define immediate weight bearing rehabilitation. Two of these were 
evaluated in controlled gait analysis studies to inform and develop a rationale for the 
intervention to establish what changes are expected and why. The key findings 
showed that rigid orthoses designs with a large degree of plantarflexion, increased 
heel pressures, reduced forefoot pressures and decreased the amount of time spent 
in the terminal stance and pre-swing phase of the gait cycle. 
 
Feasibility and Piloting 
The first clinical phases (feasibility/piloting) followed, which included testing 
procedures, establishing likely recruitment and follow up. Alongside this, a further 
systematic review was undertaken to identify what outcome measures are used in 
research for this injury to determine effectiveness. The Achilles tendon Total 
Rupture score was the only disease specific patient reported measure identified with 
supporting validation research. Further evaluation of its measurement properties 
found the score to be internally consistent, responsive and with good construct 
validity. 
 
Conclusions 
This thesis defines the rehabilitation components, proposes a theoretical framework 
and tests this in practice. The results will ensure that rehabilitation after an acute 
Achilles tendon rupture is based on a systematically developed protocol rather than 
ad hoc practice. This will now be used to inform future definitive research in this 
area.  
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1.1  Achilles tendon: normal structure and function 
Figure 1.1 depicts the overall muscular anatomy of the lower leg. The muscles of 
the lower leg are divided into three fascial compartments; the anterior, lateral and 
posterior. They are separated by the anterior and posterior intermuscular septa and 
the interosseous membrane. The anterior compartment muscles are predominantly 
responsible for dorsiflexion at the ankle. The lateral compartment muscles 
predominantly evert the foot, and weakly contribute to ankle plantarflexion. Finally, 
the largest of the three compartments comprises of the posterior compartment 
muscles, which are the strong plantarflexors of the ankle1. 
 
(a) Posterior aspect 
 
(b) Medial aspect 
Figure 1.1: Lower leg 
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The posterior calf muscles are subdivided into a superficial and deep layer. The 
superficial layer is formed by three muscles. These muscles are the gastrocnemius, 
soleus and plantaris. The deep layer is formed by popliteus, flexor digitoum longus, 
flexor hallucis longus and tibialis posterior. Both are innervated by the tibial nerve 
(arising from S1 and S2)1.  
 
The gastrocnemius starts from the condyles of the posterior surface of the distal 
femur to approximately the mid calf. The soleus runs deep to this, with plantaris 
crossing obliquely between the two2, this is known as the triceps surae. As the 
muscles descend they enter a broad aponeurosis. Moving from the 
musculotendinous junction, distally, the tendon gradually becomes more rounded to 
4cm above the calcaneus. The tendon then attaches distally to the middle one third 
of the posterior surface of the calcaneus. This tendon is the tendo Achilles (TA)3. 
The TA is the largest tendon in the human body, it enables the forces generated by 
the triceps surae to be transmitted. In doing this the TA facilitates joint motion2.  
 
The blood supply to the TA comes from three sources. These are the 
musculotendinous junction, the paratenon and at the tendon insertion to the bone. 
There is an area of hypovascularity located 3-6 cm above the calcaneal insertion. 
This is where the tendon fibres spiral laterally through 90o, such that the anterior 
fibres become medial4. 
 
The macroscopic structure of the TA displays a hierarchical organisation 
demonstrated in Figure 1.2. The smallest sub-unit being a tropocollagen triple helix 
through to the largest macrostructure consisting of grouped fascicles within an 
epitenon envelope. This is surrounded by a fluid filled paratenon, which functions to 
minimise friction2. The collagen fibres are surrounded by a matrix ground substance, 
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of which the hydration is regulated by proteoglycons. This provides structural 
support and a medium for diffusion of nutrients and is biosynthesised by tenocytes. 
 
Figure 1.2: Tendon structure (Source: Fenwick et al 
5
) 
 
The organisation of a tendon has important characteristics which contribute to the 
biomechanical properties of it. The first of these structural features are seen 
amongst the arrangement of microfibrils (formed by five grouped tropocollagens). 
Each microfibril overlaps each other by a quarter and these cross links contribute to 
the tensile strength of the tendon. Secondly, the fibres are arranged in a parallel 
arrangement, which at rest have a crimped configuration. This crimped configuration 
straightens when the tendon is loaded. When the load is removed the stored elastic 
energy is released and fibres re-crimp2. 
 
Ultimately these characteristics work together to resist high tensile forces with 
minimal loss of energy and deformation. These mechanical responses of the tendon 
to stress and strain have been defined by the stress-strain curve6, shown in Figure 
1.3. It contains four key regions; the first is the toe region whereby the crimped fibre 
arrangement straightens up to 2% of strain. Beyond this the fibres are straight and 
respond linearly to stress up to 4% strain. Under 4% strain the tendon can return to 
its resting state. Beyond 4% the tendon begins to undergo micro-failure, involving 
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the breakage of cross-links and irreversible plastic deformation. By 8% the tendon 
undergoes complete failure6. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Stress-strain curve (Source: Evans and Stanish
2
) 
 
However, tendon characteristics are not dependent on these mechanisms alone. 
Tendons are also viscoelastic tissues (time and rate dependent). This property 
results in decreased stress with time under constant deformation (stress relaxation) 
and increased deformation with time under constant load (creep). Tendons also 
display mechanical hysteresis, which is the amount of elastic strain energy lost as 
heat during the stretch-recoil cycle7. The tension generated across the tendon is 
also dependent upon the type of muscle contraction. Eccentric loads producing the 
highest, followed by concentric and finally isometric muscle actions. These are all 
important features when considering the mechanisms of tendon injury and 
rehabilitation2. 
 
Stress N/mm
2
 
Strain % 
0%            2%            4%            6%            8% 
Physiological Range 
 
Microscopic Failure 
Macroscopic Failure: 
Rupture 
Fibres Straighten 
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1.2 Achilles tendon rupture: epidemiology, etiology and diagnosis 
The TA is the most commonly ruptured tendon in the human body8. European 
figures show that there is an incidence of approximately 18 per 100 000 people per 
year9. This common injury has a bi-modal distribution, the first peak being within 
males aged 30-40 years and the second amongst non-athletic women aged 60-80 
years10. The first peak in incidence is often associated with sport participation, 
predominantly football and racquet sports, whereas the second peak often occurs 
during normal daily activities10. However both are the result of the same 
mechanisms.  
 
The mechanism by which a rupture occurs has been broadly classified into two. The 
most common happens whilst pushing off with the foot and extending at the knee 
(e.g. sprint starts, jumping, lunging). The second occurs during forced and 
unexpected dorsiflexion of the ankle (e.g. fall, road traffic accident). In relation to the 
biomechanics of the Achilles tendon, outlined in Chapter 1.1, the first mechanism 
often occurs under 4% of strain, below the threshold for macro-failure, whereas the 
second mechanism occurs above the threshold for macro-failure11. 
 
The reasons proposed for spontaneous rupture of the TA, below the threshold for 
macro-failure, is multi-factorial11. The most widely accepted explanation is that 
spontaneous ruptures are the consequence of a previously abnormal tendon12. 
These abnormalities can result in a painful tendon condition termed ‘tendinopathy’. 
Yet, many tendons with degenerative features are asymptomatic. The degeneration 
of the tendon results in decreased cellularity, decreased matrix organisation, 
increased infiltration of blood vessels and increased type III collagen. It is 
considered to be the result of an imbalance between the protective/regenerative 
functions that metalloproteinase enzymes are thought to have a key role13. 
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The cause of tendon abnormalities have been attributed to a number of external 
factors including topical corticosteroids14, fluoroquinolone antibiotics15 and 
mechanical abnormalities of the foot16. Intrinsic factors have also been associated 
with a predisposition to tendinopathy. Examples of these include autoimmune and 
neurological conditions17. However, degenerative changes within tendons are 
common amongst the population as a whole, regardless of the presence or absence 
of any of these factors. 
 
When a patient sustains a TA rupture they typically present with sudden pain in the 
area of the TA. Often patients report a feeling of being ‘kicked’ in the back of the 
leg11. In December 2009 the American Academy of Orthopaedic Surgeons (AAOS) 
published the first guidelines on the topic of mid-substance TA ruptures. These 
guidelines included how to diagnose a TA rupture18. Following a systematic review 
of the literature the AAOS concluded there was strong evidence to support the 
diagnosis based on two, of four, physical findings. These physical findings were, a 
positive Thompson test (Simmonds squeeze test), decreased ankle plantarflexion 
strength, presence of a palpable gap or increased ankle dorsiflexion with gentle 
manipulation19. The AAOS were unable to recommend the use of routine magnetic 
resonance imaging, ultrasound or radiographs for the diagnosis of Achilles tendon 
ruptures. However, imaging has been suggested to be of use in the context of a 
selection tool for management and on-going assessment post rupture20. 
 
1.3 Achilles tendon rupture: healing, repair and common problems 
Studies regarding tendon healing have pre-dominantly been undertaken in 
transected animal models. These methods have limitations to the application of 
human models that are associated with degenerative mechanisms. However, the 
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research has consistently shown that there are three overlapping phases regarding 
the healing response. These are inflammation, proliferation and remodelling21. 
 
When the tendon ruptures, the gap quickly fills with a blood clot. By 24 hours 
monocytes and macrophages predominate and phagocytosis of necrotic tissues 
occurs. Over the next few days angiogenesis is initiated and tenocyte proliferation, 
leading to the occurrence of type III collagen synthesis. After a few days the 
proliferative phase begins. This results in a peak of type III collagen synthesis and 
organisation. By approximately six weeks, remodelling occurs which is 
characterised by decreased cellularity, decreased collagen synthesis, an increase in 
type I collagen compared to type III and a gradual change to scar-like tendon tissue. 
This process continues up to 12 months21-22. 
 
Throughout the healing process there are a number of complications that can occur. 
These commonly include, adhesions, disturbed sensibility, re-rupture, tendon 
lengthening, delayed/poor healing response, superficial/deep wound infection, 
muscle atrophy, venous thromboembolism and gait abnormalities9,23-24. Furthermore 
the physiological effects of decreased mechanical loading and immobilisation of the 
tendon result in detrimental alterations in collagen fibre organisation and decreased 
tenocyte proliferation21. Subsequently research has been focused on decreasing the 
incidence of these common problems within clinical practice, in combination with 
optimising the healing and functional recovery of this debilitating injury. 
 
1.4 Achilles tendon rupture: management options 
Management of a TA rupture was first described in the literature in 1575 by 
Ambroise Pare. The author presented a method of non-operative management, 
using none weight bearing rehabilitation (NWB). This method remained the 
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management of choice until the 1920’s. At this time an alternative approach, using 
an open operative method, to stitch the two tendon ends together, followed by 
NWB, was reported25. This method grew in popularity and by the 1970’s there was a 
strong debate regarding which method of management was superior. This was 
summarised by an editorial within the Lancet in 1973, stating that it would be difficult 
to justify a surgical procedure if non-operative methods are capable of equivalent 
results26. 
 
In 1981 Nistor et al27 published the first randomised controlled trial (RCT) to address 
this very question. They randomly allocated 105 patients to receive either operative 
or non-operative management, followed by six to nine weeks of NWB cast 
immobilisation. The results were based on strength measurements, calf 
circumference and complications.  
 
The results of this first RCT showed two deep wound infections and two re-ruptures 
within the operative group. This was in comparison to five re-ruptures within the 
non-operative group. No differences were found between all other outcomes. 
Subsequently the authors concluded that due to the minimal differences between 
the groups operative management was unnecessary.  
 
This article was very important for the development of TA rupture management. 
This is because of its RCT design, which was novel at that particular point in time. 
However the key limitation of this article was its inadequate method of 
randomisation, based upon which operating surgeon was working on the day the 
patient presented. Further limitations include inadequate reporting of inclusion and 
exclusion criteria, no defined follow-up outcome collection points and excluding trial 
protocol violations from the final analysis. 
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This land mark study was followed by the first review of the literature in 1986. This 
was reported by Wills et al25. They presented literature from the previous 25 years 
regarding operative versus non-operative management. They concluded the 
opposite to Nistor et al27, reporting much higher rates of re-rupture with non-
operatively managed patients compared to operatively managed patients (17.7% 
compared to 1.54%). This was in contrast to other complications which were 
reported to be higher within the operative group (20%) compared to non-operative 
management (10%).  
 
This article was important in that it was the first article that summarised the literature 
to date, however, this was only a narrative review. It had no systematic, 
reproducible methodology to identify appropriate articles. Therefore it is unknown if 
key articles were included or not included by the authors, leading to potential 
selection bias. Furthermore the articles were not subject to a scoring system or 
critique to determine the reliability and validity of the results reported by the included 
articles. 
 
Further randomised controlled trials were carried out comparing operative to non-
operative management to address some of the limitations within the 1981 Nistor et 
al27 study. These were carried out by Cetti et al28 in 1993, Thermann et al29, 
Majewski et al30 and Moller et al31 in 2001. Although the research question within 
each study was to compare operative to non-operative management, there was a 
common confounding factor within each one. This was the fact that within each RCT 
the operative and non-operatively managed groups received different rehabilitation 
programmes. Therefore it is not clear if the results are a reflection of a different 
rehabilitation approach or the operative/non-operative management. This is in 
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contrast to current practice involving the same rehabilitation programmes for 
operative and non-operatively managed patients32. 
 
The method of rehabilitation used post rupture has recently become a more 
pertinent research question within the literature associated with TA ruptures, rather 
than operative versus non-operative management. These RCT’s have compared 
traditional NWB cast immobilisation to an earlier weight bearing cast or a NWB cast 
followed by a weight bearing ankle foot orthoses (AFO). These were carried out by 
Saleh et al 199233, Cetti et al 199434, Mortensen et al 199935, Kangas et al 200336 
and Maffulli et al 200337. All these studies concluded favourable results for early 
weight bearing compared to prolonged NWB.  
 
The first meta-analysis, using randomised and quasi-randomised evidence, on the 
topic of TA rupture management was published in 2002 by Bhandari et al38. This 
was shortly followed by a Cochrane review on the same topic, including RCT’s only, 
published in 200439. Both meta-analyses concluded that the incidence of re-rupture 
amongst operatively managed patients was lower compared to non-operatively 
managed patients (3% compared to 12%). However this needed to be balanced 
against the increase in incidence of other complications compared to non-operative 
management (34% compared to 3%).  
 
The key finding within the Cochrane review laid within their comparison of NWB cast 
immobilisation to weight bearing protocols. This demonstrated a reduction of re-
rupture incidence from 12% to 2% within non-operatively managed patients 
(equivalent results seen in patients managed operatively). Therefore, with an 
already low incidence of other complications (3%) the authors discussed the need to 
investigate rehabilitation strategies further. 
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The Cochrane review group addressed all the previously discussed limitations of the 
earlier narrative reviews. They reported a systematic and reproducible methodology, 
with subsequent quality assessment of the articles, using a scoring system. The 
only limitation of this review was the use of re-rupture rate as the primary outcome. 
This is because although this is an important consideration, this outcome provides 
no indication of the functional results obtained with each treatment group. However, 
a meta-analysis in this topic area using functional outcomes as the primary outcome 
would not be possible secondary to the range that are currently used. 
 
As a consequence of these meta-analysis findings, accelerated rehabilitation 
strategies were progressed further. In 2006 the first RCT’s comparing NWB cast 
immobilisation to immediate weight bearing (IWB) within an AFO were published40. 
This article, by Costa et al, comprised of two separate RCT’s within the same paper. 
The first compared these two rehabilitation strategies within patients managed 
operatively and the second compared them within patients managed non-
operatively. The author’s key findings were that IWB is safe in both groups and also 
offers the practical mobility advantages of IWB as opposed to NWB using crutches. 
However, no comparisons could be made between operatively and non-operatively 
managed patients because patients were not randomised to these interventions. 
 
This resulted in a subsequent research question comparing operative to non-
operative management using IWB rehabilitation methods. This was carried out by 
Metz et al in 200841, who found no statistically significant differences between the 
two groups regarding complications or return to sport and Willits et al in 201032, who 
concluded the same regarding re-rupture rates, as the primary outcome. 
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However a number of limitations exist within the design of these studies. Firstly 
within the study by Metz et al41, although both groups used IWB rehabilitation, they 
followed different rehabilitation protocols. The reasons for these differences were 
not discussed by the authors and are a confounding factor within the study. 
Furthermore no valid patient reported outcome measure (PROM) was used by the 
authors, only a question asking patients to retrospectively re-call ‘return to sports’ at 
follow-up appointments. This is open to both re-call bias and interpretation of when 
a patient regards return to sport (i.e. first training session or first competition). This 
study also does not take into account the second peak within the bi-modal 
distribution of this injury (non-athletic women aged 60-80 years) for whom this 
outcome measure may be irrelevant.  
 
Conversely within the study by Willits et al32, the same rehabilitation method was 
used within both groups. However the key limitation of this paper is its external 
validity, secondary to the patient sample being recruited exclusively from two sports 
medicine clinics. Consequently the question regarding operative versus non-
operative management using accelerated rehabilitation currently requires further 
investigation. 
 
Alongside these two research areas, the method of operative management has also 
been debated. Due to high wound complication rates within open operative 
techniques, clinicians began to develop percutaneous approaches. This was first 
addressed by Schroeder et al42 through an RCT reported in 1997, followed by two 
further RCT’s in 2001 and 200843-44. These articles have concluded favourable 
results, regarding complication rates, towards a percutaneous approach. However it 
has been discussed within the literature that there is a higher rate of sural nerve 
injury within percutaneous approaches. Consequently a range of surgical 
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approaches that sit between the open longitudinal and fully percutaneous approach 
have been developed. These predominantly involve three transverse skin incisions 
as shown in Figure 1.4. Consequently there is currently no standard procedure 
amongst surgeons.  
 
 
Figure 1.4: Example of a semi-percutaneous approach 
 
In summary, the literature to date has focused on three areas. These have been, to 
operate or not, whether to use NWB cast immobilisation or IWB functional bracing 
and finally, methods of surgery. These have been the traditional areas of research 
for the management of a TA ruptures. However, new and emerging themes are 
developing as a result of advances in basic science and animal led research, which 
are increasingly being translated to clinical settings. 
 
One such area is improving the biology which governs tendon healing. Published 
animal studies have investigated the use of various growth factors including bone 
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morphogenetic proteins, autologous conditioned serum, fibroblast growth factor, 
vascular endothelial growth factor, platelet derived growth factor and insulin-like 
growth factor-121,45-47. There is currently a trial registered on the International 
Standard Randomised Controlled Trial database (ISRCTN) outlining a pilot RCT 
comparing the use of autologous platelet rich plasma to standard treatment within 
human participants (ISRCTN: 93608625). This demonstrates the links being made 
between basic science and clinical practice. 
 
A second area of emerging research is focused upon the methods of rehabilitation. 
Animal experiments have consistently illustrated the detrimental effects of prolonged 
NWB and immobilisation. The findings of these studies have been translated to 
clinical practice with the introduction of IWB rehabilitation48-49. 
 
However, the introduction of IWB and early active range of movement is as far as 
research into rehabilitation has been taken within the context of human clinical trials. 
This is despite a range of basic science research, which demonstrates beneficial 
effects of tendon loading, tension and movement21,50-54. Yet the implication of 
applying these mechanisms to TA rupture injuries, in a clinical setting, remains 
largely unknown. 
 
To summarise the literature to date, the next chapter of this thesis (Chapter 2) will 
aim to systematically search and review all currently published IWB functional 
bracing rehabilitation protocols used for the management of TA ruptures. This 
review, combined with the narrative overview of the literature to date, will form the 
basis of specific research questions this PhD thesis will address. 
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1.5 Achilles tendon rupture: outcome measures used in research 
To ascertain superiority of one intervention over and above another, a primary 
outcome measure must be defined on which conclusions can be based. 
Traditionally, within trauma and orthopaedics, published studies have focused on 
the technical outcomes of procedures rather than measures of function and quality 
of life55. More recently this has been highlighted by the Department of Health, who 
have outlined that effectiveness from the patients perspective is essential for putting 
quality at the centre of NHS practice56. 
 
Within the published literature regarding TA rupture management, authors have 
traditionally based their conclusions on objective measures of complication rates, 
muscle strength, range of ankle movement, calf circumference, ultrasound 
assessment and gait analysis. Additionally, some authors have recorded patient 
reported return to sport, return to work, return to stair climbing and return to 
walking27-28,31. 
 
Gradually within the orthopaedic literature the emphasis has been placed on 
PROMs. These have broadly been split into two categories. The first has been 
termed ‘quality of life measures’ and are largely used as secondary outcome scores 
for cost analysis purposes. Examples include EQ-5D and SF-36. The second 
category has been termed ‘disease specific measures’. These measures are argued 
to have greater discriminatory validity than general quality of life scores because the 
questions within them are often focused on specific problems associated with a 
specific injury/disease area56. 
 
The change in type of reported outcomes in research has led to the development of 
a range of measures specific to orthopaedic foot and ankle pathologies/injuries. 
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Examples of outcome measures that have been developed for patients who have 
sustained a TA tendon rupture are wide ranging. They include the American 
Academy of Orthopaedic Surgeons (AAOS) lower limb outcomes assessment 
instrument57, the ankle-hind-foot scale of the American Orthopaedic Foot and Ankle 
Society58, the ankle rating scale of Kaikkonen59 and the foot and ankle outcome 
score60. 
 
Yet many of these outcomes have not been evaluated against the different facets of 
validity. These facets include, but are not limited to, internal consistency, test-retest 
reliability, inter-observer reliability, responsiveness, construct validity, content 
validity and criterion validity. A key criticism of the above generic foot and ankle 
scores is that they lack discriminatory validity and often have not been evaluated 
within patients who have sustained a TA rupture. Instead they have been evaluated 
with a population of patients with a range of other foot and ankle conditions61. 
 
This issue of how to measure outcomes following a TA rupture has resulted in the 
development of TA specific outcomes. One such example is the Achilles rupture 
performance score (Leppilahti Score)62. However these scores were developed 
without any evaluation of validity or reliability. This limitation to the evaluation of 
interventions following a TA rupture has been recognised within the literature. 
Subsequently in 2007 Nilsson-Helander et al 61 published the first validity research 
into a disease specific PROMs for TA ruptures.  
 
Within this article the author’s addressed face validity, content validity, construct 
validity, convergent validity, test-retest reliability and responsiveness. However this 
is a single paper based upon a select population of patients aged 20 to 70 years, 
within a Swedish sample. This outcome has not yet been evaluated in the English 
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language, using a UK population amongst all patients who have sustained an acute 
TA rupture. These aspects of validity will be discussed in greater depth within 
chapter 7 of this thesis, which will evaluate further elements of validity of this new 
disease specific patient reported outcome score. 
 
1.6 Thesis aims and objectives 
The overall aim of this thesis is to develop an IWB intervention for patients who 
have sustained an acute rupture of their TA to inform a definitive evaluation of its 
effectiveness.  
 
To determine the effectiveness of a health care intervention, it is universally 
accepted that an RCT is the most appropriate research design63. This is relatively 
straight forward within areas such as pharmacology, in which only one component is 
changed (drug ‘A’ vs. drug ‘B’). This becomes less straight forward in other areas of 
health care, such as rehabilitation in which the ability to define, control and 
standardise the trial intervention becomes more problematic. 
 
The acknowledgement and implications of this challenge has resulted in the 
development of the Medical Research Council (MRC) framework for developing and 
evaluating complex interventions64. They use the term ‘complex intervention’ to 
define any intervention that contains a number of interacting components. These 
can manifest at either the interventional level, through multiple interacting 
components, the number of targeted groups or organisational levels or the difficulty 
of behaviours required for delivery/receiving the intervention, the key elements of 
this process are shown in Figure 1.5. 
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Figure 1.5: MRC framework for developing and evaluating complex interventions 
 
Briefly, this consists of a ‘pre-clinical’ or ‘development’ phase in which the evidence 
base is identified (ideally by systematic review), alongside exploratory work to 
develop a rationale for the intervention to establish what changes are expected and 
why. This is followed by the first clinical phases (feasibility/piloting), which include 
testing procedures, establishing likely recruitment/follow-up and evaluating outcome 
measures and their variability. These two stages are then used to inform a definitive 
trial, which is the evaluation phase, followed by getting the evidence into practice 
through the implementation phase. 
 
Feasibility/Piloting 
•Testing procedures 
•Estimating  recruitment/retention 
•Determining sample size 
Evaluation 
•Assesing effectiveness 
•Understanding change process 
•Assessing cost-effectiveness 
Implementation 
•Dissemination 
•Survaillance and monitoring 
•Long term follow up 
Development 
• Identifying the evidence base 
• Indentifying/developing theory 
•Modelling process and outcomes 
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Consequently, to develop an IWB intervention for patients who have sustained an 
acute rupture of their TA, to inform a definitive evaluation of its effectiveness, the 
following objectives will be addressed, throughout this thesis:  
 
1) Systematically identify and summarise, from clinical studies, the components 
that define IWB interventions currently documented for the treatment of 
acute TA ruptures. 
2) Evaluate how these identified IWB components affect gait parameters within 
healthy participants, to provide a theoretical basis on which to develop 
interventions within a patient population. 
3) Pilot the IWB interventions in a patient population to enable evaluation of 
patient recruitment rates, follow-up, PROM variability and CRF design. 
4) Systematically identify and critically evaluate what PROMS are used within 
the published literature, and further evaluate elements of measurement 
properties of an appropriate disease specific PROM to be used as a primary 
outcome measure within the evaluation phase. 
 
More specifically objectives one and two relate to the outlined ‘development’ phase 
and objectives three and four relate to feasibility/piloting. These objectives will then 
be summarised and discussed in the context of the subsequent phases of definitive 
evaluation and implementation within the conclusions of this thesis. 
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2 Systematic Review: Immediate Weight Bearing Protocols in Practice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Declarations 
 
This work has been presented at a national conference: 
 
Feb 2011: Society for Research in Rehabilitation: A systematic review of early 
rehabilitation methods following an Achilles tendon rupture. 
 
This work has also been published: 
 
Kearney R, J. Achten, K McGuiness, M Costa, A Systematic Review of Early 
Rehabilitation Methods Following a rupture of the Achilles tendon. Physiotherapy, 
98, 2012, 24-32. 
 
Funding Body 
 
This research was funded by Arthritis Research UK 
  
Page | 39  
 
Table of Contents 
 
2.1 Protocol ................................................................................................................... 41 
2.1.1 Objectives .......................................................................................................... 42 
2.1.2 Criteria for including studies for this review ....................................................... 42 
2.1.3 Search strategy.................................................................................................. 43 
2.1.4 Methods of review.............................................................................................. 45 
2.2 Results .................................................................................................................... 47 
2.2.1 Search results .................................................................................................... 47 
2.2.2 Description of studies ........................................................................................ 51 
2.3 Discussion .............................................................................................................. 61 
 
  
Page | 40  
 
Abstract 
 
Background 
Rupture of the Achilles tendon is a debilitating injury. Advances in management 
have led to the development of immediate weight bearing rehabilitation protocols, of 
which a range exists. The first steps towards developing a complex intervention are 
to identify and define the components that define it. In doing this, research can then 
be focused on each interacting component to develop an optimum intervention. 
 
Objectives 
The aim of this systematic review was to identify and summarise, from clinical 
studies, the individual components that define immediate weight bearing 
rehabilitation protocols for the treatment of acute Achilles tendon ruptures.  
 
Methods 
The electronic databases MEDLINE, EMBASE, CINAHL, AMED and the register of 
current controlled trials were searched up to March 2010. 
 
All study designs and languages were included. Using pre-defined inclusion and 
exclusion criteria, two independent reviewers identified all eligible articles. Eligible 
articles were summarised and critically reviewed regarding the reporting of their 
interventions using the extension of the CONSORT statement for non-
pharmacological interventions. 
 
Results 
Two hundred and fifteen articles were screened for eligibility, nine were included. 
These included articles presenting the results of 236 operatively and 188 non-
operatively managed patients. 
 
There were a range of rehabilitation protocols that were defined by four identified 
components. These components consisted of the type of ankle foot orthoses worn, 
the degree of maintained plantarflexion, how long the ankle foot  orthoses is worn 
for and whether daily range of movement exercises were permitted. 
 
Conclusions 
Within articles reporting of immediate weight bearing rehabilitation protocols, four 
components were identified. The efficacy of different immediate weight bearing 
rehabilitation protocols following an acute Achilles tendon rupture remains unclear. 
Consequently, further research is required to evaluate these identified components. 
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2.1 Protocol 
Rupture of the TA is a debilitating injury, resulting in prolonged rehabilitation65. 
Throughout history, the preferred method of rehabilitation has changed several 
times. Traditionally it has involved immobilisation within a NWB plaster cast. 
However advances in research have led to a newer method of IWB bearing within 
an AFO23,66.  
 
The benefits of IWB rehabilitation compared to NWB have been consistently 
documented within the literature by RCT’s and meta-analysis23,39. IWB rehabilitation 
has been further supported by animal studies that have evaluated the effects on 
tendon healing and muscle atrophy48-50. However, although the literature 
consistently agrees that IWB is superior to NWB immobilisation, it does not agree 
on the method of IWB rehabilitation clinicians should be implementing39. 
 
The concept of IWB rehabilitation has been translated from basic science to clinical 
practice. It is acknowledged that this new area of rehabilitation is a complex 
intervention that involves several interacting components, as defined by the MRC 
complex interventions framework64. However IWB rehabilitation strategies in this 
area have not yet been developed to optimise their potential benefits.  
 
The development of a new concept to increase effectiveness to an optimum is the 
next stage in the process of a complex intervention. This development process has 
been described in the Lancet by McCulloch et al67. This is a topic that has also been 
raised by the British Medical Journal, recognising that health research should not 
just be evaluating what complex interventions work, but to further define the 
interacting components that make up the intervention and consequently evaluate 
which of these components works or fails in specific circumstances68. 
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Subsequently the aim of this chapter is to systemically review and summarise the 
range of IWB rehabilitation protocols documented within the literature and the 
individual components that make them. In doing this, the known variations can be 
investigated further, to develop this new complex intervention.  
 
This aim will be achieved by employing a search strategy across relevant 
databases. These databases will then be assessed against eligibility criteria for 
inclusion, before finally summarising the components of the interventions using the 
consort checklist extension for complex interventions. The protocols will then be 
discussed in relation to the wider literature. 
 
2.1.1 Objectives 
This systematic review will identify and summarise, from clinical studies, the range 
of IWB interventions within AFO’s currently documented for the treatment of acute 
TA ruptures. This review will also summarise the individual components that define 
each complex intervention. This will answer the following research question:  
 
‘Following a TA rupture what IWB interventions within AFO’s are currently 
documented in the literature?’ 
 
2.1.2 Criteria for including studies for this review 
All study designs and languages were included and translated where necessary in 
this review. The review included all subjects over 18 years of age with an isolated, 
primary acute TA rupture. An acute rupture was defined as being less than 14 days 
old69. Articles reporting subjects presenting with delayed presentation (over 14 
days), re-rupture or previous TA surgery were excluded.  
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All articles had to document an IWB (within one week), AFO protocol. This would be 
after either operative or non-operative management of a ruptured TA. The minimum 
information required to define a protocol consisted of which AFO was worn, how 
long it was worn for and what degree of PF was permitted. Any articles that did not 
contain these minimum criteria, but did mention an IWB protocol were contacted for 
further information. If the authors were unable to provide further information the 
articles were excluded. 
 
2.1.3 Search strategy 
The primary search employed the electronic databases of MEDLINE, AMED and 
EMBASE, searched via Ovid. CINHL was also searched via EBSCO Host using the 
search strategies in Table 2.1 to Table 2.3: 
 
The secondary search assessed unpublished literature using the register of current 
controlled trials database for recently completed trials (http://controlled-
trials.com/isrctn). A hand search was also undertaken using the reference lists of 
review papers that were evaluated to identify any additional relevant articles. 
Relevant experts in the field were also contacted where further clarification was 
required. 
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Table 2.1: Search strategy MEDLINE and AMED 
 
Searches  
1 exp Achilles Tendon/ 
2 exp Rupture/ 
3 Achill$.m_titl. 
4 Tendo Achill$.m_titl. 
5 exp Weight Bearing/ 
6 Orthotic Devices/ or Athletic Tape/ or Braces/ or Walkers/ 
7 exp Rehabilitation/ 
8 Mobi$.m_titl. 
9 Rupture$.m_titl. 
10 1 or 3 or 4 
11 2 or 9 
12 10 and 11 
13 5 or 6 or 7 or 8 
14 12 and 13 
 
Table 2.2: Search strategy CINAHL 
 
Search 
1 MM. Achilles Tendon/  
2 Ti. Achilles Tendon 
3 1 OR 2  
4 MM. Rupture/ 
5 Ti. Rupture 
6 4 OR 5 
7 3 AND 6 
8 MM Rehabilitation 
9 MM. Foot Orthosis 
10 8 OR 9  
11 7 AND 10 
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Table 2.3: Search strategy EMBASE 
 
Search 
1 exp Achilles Tendon/ 
2 exp Rupture/ 
3 Achill$.m_titl. 
4 Tendo Achill$.m_titl. 
5 exp Weight-Bearing/ 
6 exp Rehabilitation/ 
7 Mobi$.m_titl. 
8 Rupture$.m_titl. 
9 1 or 3 or 4 
10 2 or 8 
11 9 and 10 
12 orthotics/ 
13 5 or 6 or 7 or 12 
14 11 and 13 
 
2.1.4 Methods of review 
Trials were independently assessed for inclusion by two reviewers (RK and KM). 
The second reviewer (KM) was employed by the University of Warwick as a 
research physiotherapist, within the same department and had four years 
experience of working in orthopaedic pragmatic research. The reviewers evaluated 
all identified titles and abstracts independently and excluded any clearly irrelevant 
articles at this point. The remaining articles were ordered in full and assessed 
against the eligibility criteria. Differences were resolved by discussion.  
 
Data was extracted from all included articles. This was undertaken by a single 
reviewer (RK) and verified by the second reviewer (KM). An example of the pre-
defined data extraction table is summarised in Table 2.4 and includes study design, 
sample size, population characteristics, description of the AFO intervention, follow-
up (FU) period, outcomes assessed and the author’s conclusions. 
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In addition to the data extraction table below, all studies were scored against the 
consort statement for reporting complex interventions. This score consists of three 
components. The first relates to whether or not the authors have reported a 
description of the different components of the intervention. The second details how 
the interventions were standardised and the third relates to how adherence of care 
providers with the protocol were assessed70. 
 
Table 2.4: Example of data extraction table 
Paper Study design Sample size 
Population 
characteristics 
Intervention 
Follow-up, 
outcomes & 
conclusions 
 
    
AFO type: 
Worn for: 
ROM: 
Other details: 
 
 
 
 
This research question was focused on the description of IWB interventions. 
Therefore it was anticipated that a range of study designs would be included whose 
primary research question was not focused on the evaluation of the rehabilitation 
protocols, but other aspects of TA rupture management. Such examples were 
expected to include operative versus non-operative or NWB versus IWB, in which 
the rehabilitation protocol is described but not evaluated. Consequently it was 
considered that a critical appraisal tool to assess the methodological quality of the 
overall study designs was inappropriate for this review, however it was considered 
appropriate to critically appraise the quality of intervention documentation, using the 
CONSORT statement extension for non-pharmacologic treatments71. 
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2.2 Results 
2.2.1 Search results 
The individual search strategies, carried out on 28 March 2010, for each of the 
databases, are shown in Table 2.5 through to Table 2.8. Figure 2.1 shows the 
results of the search strategy. It illustrates that once duplicates were removed, 215 
articles remained to be screened for eligibility. Of these 118 articles were excluded, 
based on title and abstract information.  
 
Ninety-seven full text articles were subsequently ordered and further assessed 
against the eligibility criteria. Of the 97 articles ordered, one non-English article 
could not be obtained from the British library; therefore 96 full text articles were 
assessed. Of these 96 articles 15 were non-English and translated (CE and PFO), 
10 articles were review articles of overall management for TA ruptures and 
excluded, however their reference lists were checked for potentially eligible articles. 
Sixty-three of the 96 articles were subsequently excluded for not using an IWB 
intervention. A further seven were excluded for including a sample who had not 
sustained an acute TA rupture and eight articles used IWB but within a below knee 
cast, these were also excluded as they do not allow the patient the capacity to carry 
out range of movement exercises. This resulted in eight included articles from the 
original 96, in addition to one article found within a reference list.  
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266 records identified through 
database searching (MEDLINE, 
AMED, EMBASE and CINAHL) 
 
 
 
 
 
Unpublished literature: 0 
  
 
 
215 records after duplicates removed and subsequently screened 
   
 
 
  
118 articles excluded based on title and abstract 
(9:letters, 25:Not IWB, 84: Not Acute TA rupture) 
 
 
   
 
 
 
97 Full text articles ordered and assessed for 
eligibility. 
 
  
Excluded 
 
63: Did not fulfil 
intervention criteria 
7:   Did not fulfil 
population criteria 
10: Reviews of Achilles 
tendon management 
8:   IWB but cast 
immobilisation 
1:   British Library unable 
to obtain 
 
 
Added 
 
1:   Text added from 
reference list.  
 
 
  
Included 
9 articles included 
 
 
 
Figure 2.1: Search strategy 
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Table 2.5: Search strategy results: MEDLINE 
 
Searches  Results 
1 exp Achilles Tendon/ 4758 
2 exp Rupture/ 30299 
3 Achill$.m_titl. 3372 
4 Tendo Achill$.m_titl. 120 
5 exp Weight Bearing/ 11026 
6 Orthotic Devices/ or Athletic Tape/ or Braces/ or Walkers/ 8042 
7 exp Rehabilitation/ 116316 
8 Mobi$.m_titl. 25945 
9 Rupture$.m_titl. 31747 
10 1 or 3 or 4 5391 
11 2 or 9 48099 
12 10 and 11 1484 
13 5 or 6 or 7 or 8 158627 
14 12 and 13 92 
 
Table 2.6: Search strategy results: AMED 
 
Searches  Results 
1 exp Achilles Tendon/ 408 
2 exp Rupture/ 283 
3 Achill$.m_titl. 458 
4 Tendo Achill$.m_titl. 30 
5 exp Weight-Bearing/ 694 
6 Orthotic Devices/ or Athletic Tape/ or Braces/ or Walkers/ 1560 
7 exp Rehabilitation/ 31554 
8 Mobi$.m_titl. 1224 
9 Rupture$.m_titl. 349 
10 1 or 3 or 4 491 
11 2 or 9 411 
12 10 and 11 155 
13 5 or 6 or 7 or 8 34161 
14 12 and 13 27 
 
  
Page | 50  
 
Table 2.7: Search strategy results: EMBASE 
 
Search Results 
1 exp Achilles Tendon/ 2663 
2 exp Rupture/ 35057 
3 Achill$.m_titl. 2523 
4 Tendo Achill$.m_titl. 102 
5 exp Weight-Bearing/ 10727 
6 exp Rehabilitation/ 115936 
7 Mobi$.m_titl. 20496 
8 Rupture$.m_titl. 19760 
9 1 or 3 or 4 4122 
10 2 or 8 42495 
11 9 and 10 1195 
12 orthotics/ 1035 
13 5 or 6 or 7 or 12 146792 
14 11 and 13 146 
 
Table 2.8: Search strategy results: CINAHL 
 
Search Results 
1 MM. Achilles Tendon/  
 
2 Ti. Achilles Tendon 
 
3 1 OR 2  687 
4 MM. Rupture/ 
 
5 Ti. Rupture 
 
6 4 OR 5 1712 
7 3 AND 6 192 
8 MM Rehabilitation 
 
9 MM. Foot Orthosis 
 
10 8 OR 9  6189 
11 7 AND 10  1 
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2.2.2 Description of studies  
Table 2.9 summarises the nine included articles from the above search strategies 
and Table 2.10 summarises the quality assessment of intervention reporting. 
 
The first report of an IWB rehabilitation intervention within an AFO was published by 
Speck et al in 199872. This was a prospective case series of 20 patients. All patients 
had an open operative procedure. Following this procedure all patients wore a rigid 
rocker bottom AFO for six weeks, locked in neutral. This series of patients were 
followed up for 12 months. The authors reported one complication during this time 
frame, a deep vein thrombosis. The remaining patients were reported to have 
returned to normal activities by six months.  
 
The conclusions of the above article had important implications because it was the 
first to describe an IWB AFO intervention. However due to its small sample size, 
research design, and lack of validated outcome measures, limited conclusions can 
be made regarding this intervention, based on this article alone. However it did 
demonstrate that IWB did not result in an increase in complications such as tendon 
lengthening or re-rupture. 
 
In 2003 Costa et al73 carried out a pilot RCT on patients operatively managed, to 
compare IWB to NWB cast immobilisation. The rehabilitation protocol differed from 
Speck et al72. Instead of using a rigid rocker bottom AFO with no heel raises, Costa 
et al73 used a flexible carbon fibre AFO with three heel raises, which were reduced 
gradually over an eight week time period. The purpose of their pilot study was to 
determine safety of the rehabilitation protocol, which was then developed into a 
larger RCT published in 200640.  
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Table 2.9: Summary of included articles 
 
Paper Sample size Study 
design/question 
Population characteristics IWB Intervention Follow up (FU), outcomes and 
authors conclusions  
 
Speck et al 
1998
72
 
 
20  
 
 
 
Case Series 
 
Operative (open) 
15 men, 5 women 
27-83 years 
Unilateral 
No previous rupture or surgery 
 
AFO Type:  
Rigid rocker 
Worn for:  
6 weeks 
ROM:  
Neutral 
Other details:  
WB Day 1, ankle exercises 4 times/day 
 
 
FU:  
6 weeks and 3,6 and 12 months 
Outcomes:  
Own scoring system, ultrasound,  
strength 
Complications: 
1 DVT 
Conclusion: 
IWB is safe. All returned to normal 6 months. 
 
 
Costa et al 
2003
73
 
 
14 per group 
 
RCT (Brace Vs Cast) 
 
Operative (any) 
24 men, 4 women 
Over 18 (average 41 years) 
Unilateral 
No previous injury or surgery 
 
 
AFO Type:  
Flexible carbon fibre 
Worn for:  
8 weeks 
ROM:  
Three 1.5cm heel raises 
One raise removed every 2 weeks 
Other details:  
WB day 1 
 
FU:  
2,4,6,8 weeks and 3,6, and 12 months 
Outcomes:  
Calf muscle bulk, ultrasound, return to sport, 
strength 
Complications: 
1 re-rupture, 1 sural nerve deficit, 1 delayed 
healing. 
Conclusion: 
IWB safe, return to sport 6 months (2 months 
sooner than cast group).  
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Paper Sample size Study 
design/question 
Population characteristics IWB intervention Follow up (FU), outcomes and 
authors conclusions  
 
Costa et al 
2006
40
 
 
23 IWB Op 
25 Cast Op 
22 IWB non-op 
26 Cast non-op 
 
2 RCT’s 
1) IWB Vs Cast Op 
2) IWB Vs Cast Non-
op 
 
1) Operative (any) 
    28-69 years 
   Unilateral 
   No previous injury or surgery 
 
2) Non-operative 
   21-79 years 
   Unilateral 
   No previous injury or surgery 
 
 
 
 
 
AFO Type:  
Flexible carbon fibre for both 
Worn for:  
8 weeks (Op) 12 weeks (Non-op) 
ROM:  
Three 1.5cm heel raises 
One raise removed every 2 weeks (Op) 
No change for first six weeks followed by 
above protocol (Non-op) 
Other details:  
Both groups WB day 1 
 
FU:  
3,6, and 12 months 
Outcomes:  
Return to sport,  walking, work, stair climbing, 
EQ-5D and strength 
Complications: 
2 re-ruptures (op group) 1 poor healing  and 
1 re-rupture(non-op) group 
Conclusion: 
IWB is safe and results in better functional 
outcomes within operatively managed 
patients compared to plaster cast.  
IWB is safe within non-operatively managed 
patients, but did not result in better functional 
outcome measures compared to a cast 
group. 
 
Hufner et al 
2006
74
 
 
125 
 
Case Series 
 
Non-operative (10mm or less 
gap) 
105 men, 20 women 
Over 18 (20-70 years) 
No previous injury or surgery 
 
 
AFO Type:  
Flexible orthotic design 
Worn for:  
8 weeks 
ROM:  
3cm elevation of heel 
Other details:  
3 days in cast, exercises out of boot at 4 
weeks, 1cm heel rise within their shoe 
for 3 months. 
 
FU:  
Not specified. 
Outcomes:  
Ultrasound, strength, return to sport 
Complications: 
3 DVT’s, 2 soft tissue discomfort, 8 re-
ruptures, 21 lengthened tendons 
Conclusion: 
Poor compliance caused complications. 
Otherwise IWB is safe. 
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Paper Sample size Study 
design/question 
Population characteristics IWBiIntervention Follow up (FU), outcomes and 
authors conclusions  
 
Jacob et al 
2007
75
 
 
36 
 
Case Series 
 
Operative (open) 
Over 18 
Unilateral 
No previous injury or surgery 
 
 
AFO Type:  
Rigid rocker 
Worn for:  
6-8 weeks 
ROM:  
Neutral 
Other details:  
WB day 1 
 
FU:  
Minimum 2.5 years-6.5years 
Outcomes:  
Calf circumference, strength, pain, walking 
limp and satisfaction 
Complications: 
None 
Conclusion: 
IWB is safe and should be standard. 
 
 
 
Majewski et al 
2008
76
 
 
14 matched 
pairs 
 
Case controlled series 
(Cast Vs IWB) 
 
Operative (percutaneous) 
13 men and 1 women 
Over 18 (25-62 years) 
Unilateral 
No previous surgery or injury 
 
AFO Type:  
Shoe, with anterior, medial and lateral 
support, high shaft. 
Worn for:  
3 months 
ROM:  
3cm heel wedge, removed gradually 
between weeks 4-7. Stabilisers removed 
7 weeks. 
Other details:  
Day one: Splint to hold the foot in 20 
degrees of plantar flexion then orthotic. 
 
FU:  
12 months 
Outcomes:  
Hannover Achilles tendon score, return to 
work, return to sport, strength, pain, ROM, 
calf circumference. 
Complications: 
6 lengthened tendons in shoe group, 5 in cast 
group. 
Conclusion: 
Earlier return to work  and sport within the 
shoe group. IWB is safe. 
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Paper Sample size Study 
Design/Question 
Population characteristics IWB intervention Follow up (FU), outcomes and 
authors conclusions  
 
Metz et al 2008
41
 
 
41 Non-
operative 
42 Operative 
 
RCT (Op Vs Non-op 
IWB) 
 
Operative (open) and non-
operative 
Over 18 (23-63 years) 
Unilateral 
No previous injury or surgery 
 
AFO Type:  
Operative: Tape bandage 
Non-operative: Rigid rocker 
Worn for:  
Both 6 weeks 
ROM:  
Operative: 2cm heel rise 
Non-operative: 2 weeks 30
0
, 2 weeks 
15
0
, 2 weeks neutral. 
Other details:  
Both had cast for one week 
Both not allowed to remove 
 
FU:  
1,3,5,7 weeks and 3 and 6 months 
Outcomes:  
Leppilahti score, ROM, strength. 
Complications: 
Non-operative: 5 re-ruptures, 1 sural nerve 
injury, 1 DVT, 13 skin complaints 
Operative: 3 re-ruptures, 3 sural nerve injury, 
1 complex regional pain, 2 skin complaints, 3 
scar adhesions. 
Conclusion: 
No functional differences between the two 
groups. Less risk of complications within the 
operative group. 
 
 
Bhattacharyya et 
al 2009
77
 
 
34 NWB 
25 IWB 
 
2 consecutive case 
series  
(IWB percutaneous Vs 
non WB open repair) 
 
Operative 
18-50 years 
Unilateral 
No previous injury or surgery 
 
AFO Type:  
Rigid rocker 
Worn for:  
8 weeks 
ROM:  
3 heel rises, reduced every two weeks. 
Other details:  
Cast immobilisation for a couple of days 
first. 
 
 
FU:  
3,6, and 12 months 
Outcomes:  
Return to normal activities as reported by the 
patient, return to sport, work and walking. 
Complications: 
None in the IWB group 
Conclusion: 
IWB safe and resulted in faster return to 
normal activities when compared to the cast 
group. 
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Paper Sample size Study 
Design/Question 
Population characteristics IWB intervention Follow up (FU), outcomes and 
authors conclusions  
 
Doral et al 2009
78
 
 
62 
 
Case Series 
 
Operative (percutaneous) 
Over 18 (27-38 years) 
No previous surgery or injury 
 
AFO Type:  
Rigid Rocker 
Worn for:  
3 weeks 
ROM:  
Neutral 
Other details:  
WB Day 1, daily exercises, resistance 
exercises from week 6, jogging week 10. 
 
FU:  
2, 6, 12, 24 weeks and 12 months 
Outcomes:  
Calf circumference, ROM, , return to sport 
and work, AOFAS, strength. 
Complications: 
None 
Conclusion: 
Calf atrophy is the biggest problem. Authors 
concluded this rehabilitation programme is 
safe. 
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Costa et al40 published a report of two separate RCT’s in 2006. One sample was 
within patients managed non-operatively (cast vs.IWB) and one was within a sample 
of patients managed operatively (cast vs. IWB). The authors concluded that IWB 
was safe in both groups and resulted in faster rehabilitation within patients managed 
operatively.  
 
However, the primary outcome measure for these RCT’s was the time taken to 
return to normal activities, as reported by the patient. This outcome measure is 
inherently flawed because firstly aspects pertaining to the validity and reliability of 
this single item question are lacking. Secondly, ‘normal activities’ will vary between 
individuals, for example those who are sedentary and work at a desk will inevitably 
return to normal activities sooner than a patient with a manual job who plays weekly 
football. Despite the problems with measuring functional outcomes, the reported 
complications within this article are of equal importance, because this was the first 
RCT to compare these two contrasting rehabilitation methods. However a difference 
may not have been found because the study was inadequately powered (type two 
error) to show such a difference in complications. 
 
Three further case series have been published using IWB rehabilitation since this 
RCT. Two evaluated the rehabilitation within patients who had received operative 
management and one within a sample who had received non-operative 
management74-75,78.  
 
Both operative case series used a rigid rocker bottom orthotic, both with no heel 
raises, however there were differences in the amount of time each orthotic was 
worn. Jacob et al75 reported 6-8 weeks within the AFO and Doral et al 78 reported a 
minimum of three weeks, but did not report the actual range of time patients wore 
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them for. In contrast the non-operative series by Hufner et al74 used the same 
rehabilitation programme proposed by Costa et al40 (carbon fibre AFO with three 
heel raises). 
 
None of these three case series reported complications above those reported in 
relation to cast immobilisation. A range of outcome measures other than 
complications were also used by the three case series. These predominantly 
included objective measures such as strength, calf circumference and presence of a 
limp on walking. This is representative of the lack of validated PROMs for this 
specific disease area. However generic validated quality of life scores, such as SF-
12 and EQ-5D could have been used to allow comparisons between studies.  
 
The two further trials outlined in Table 2.9 make comparisons of the new IWB 
rehabilitation to cast immobilisation. Majewski et al76 evaluated these contrasting 
interventions using a case controlled study design and Bhattacharyya et al77 utilised 
two consecutive case series.  
 
The first of these study designs is normally associated with epidemiology in order to 
ascertain whether exposure to any factor occurred more or less frequently in the 
cases than the controls. This choice of research method for a new intervention is 
open to selection bias, as the authors chose subjects in the new intervention group 
to match the cast group and in doing so may have neglected certain cases that 
would potentially change outcome. Furthermore, matching can only account for 
known confounding variables; unknown factors cannot be accounted for by this 
method. Consequently RCT’s are the ‘gold’ standard for comparing two 
interventions, because the process of randomisation accounts for the known and 
unknown confounding variables. 
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The second study design, using two consecutive case series also does not take into 
consideration unknown confounding variables either. However the study by 
Bhattacharyya et al 77 does provide further evidence that IWB is safe within their 
small sample of 25 patients, reporting no adverse complications. 
 
In relation to the rehabilitation protocols reported for these two studies, 
Bhattacharyya et al77, used the same protocol first outlined by Costa et al in 200373. 
Whereas Majewski et al76 used what was described as a shoe with medial and 
lateral support and a high front shell, which were removed at four weeks and the 
whole shoe removed at seven weeks, with gradual reduction of three heel raises 
during this time. 
 
The first, and only, RCT comparing operative to non-operative management using 
IWB rehabilitation was published in 2008 by Metz et al41. However, the authors 
chose to use different rehabilitation protocols for each treatment arm. The operative 
group were managed with tape bandage (bandage wrapped around the limb) and a 
2cm heel raise and the non-operative group were managed with a rigid rocker 
bottom AFO set at 300 PF being gradually reduced over a six week period. Within 
this study neither group were allowed to remove their AFO for the duration it was 
worn. This resulted in 16 skin complications over the two groups. This frequency of 
incidence has not been reported by any other study. 
 
The primary objective of this study was complications other than re-rupture, which is 
also unprecedented amongst previous literature, which has focused primarily on re-
rupture rates, a key concern for clinicians. There was no justification given by the 
authors regarding the rationale for this outcome. Taking into account that 13/15 
complications for the non-operative group were ‘skin complications’ ranging from a 
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blister to fungal infections, the clinical relevance of this measure is not only 
questionable, but the majority could have been prevented by allowing the patient to 
remove their AFO throughout the day, as other published articles have reported. 
The authors found no statistically significant differences between the two groups 
regarding complications other than re-rupture. However, the clinical relevance of 
this is limited and provides no information regarding what is most important, which is 
what the patient is functionally capable of achieving and how soon after the 
procedure this is achievable by. 
 
Table 2.10 illustrates the quality of reporting for each of the nine included studies. 
From this table it is evident that none of the included articles described any aspects 
of standardising or adherence to the administration of the interventions. Such 
methodological examples include written instructions or a documented training 
programme, however all articles did fully describe the intervention components. 
 
Table 2.10: Assessment of reporting quality 
  
Paper: 
Description of 
components 
(Yes/No) 
Details 
standardisation 
(Yes/No) 
Details of 
adherence 
(Yes/No) 
Total score 
(max: 3 
points) 
Speck et al 
72
 Yes No No 1 
Costa et al 73 Yes No No 1 
Costa et al 
40
 Yes No No 1 
Hufner et al 
74
 Yes No No 1 
Jacob et al 
75
 Yes No No 1 
Majewski et al 
76
 Yes No No 1 
Metz et al 
41
 Yes No No 1 
Bhattacharyya et al 
77
 Yes No No 1 
Doral et al 
78
 Yes No No 1 
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2.3 Discussion 
The aim of this systematic review was to identify and summarise, from clinical 
studies, the range of IWB AFO interventions currently documented for the treatment 
of acute TA ruptures. This was to answer the research question: ‘What IWB AFO, 
rehabilitation interventions are acknowledged in the literature for patients following 
an acute rupture of their Achilles tendon?’ 
 
This systematic review has outlined nine articles that have described an IWB AFO 
rehabilitation programme. These articles were published between 1998 and 2009 
and consisted of four case series designs, ranging in sample size from 20 to 125 
patients. These were predominantly concerned with the safety of this new 
intervention. Articles which were not case series designs were a combination of 
RCT’s, case-controlled studies and parallel case series to answer research 
questions regarding IWB compared to cast immobilisation. The only study not 
posing this question was an RCT by Metz et al41 which compared operative to non-
operative management using IWB rehabilitation protocol’s in both groups. 
 
There were no articles that had compared different IWB rehabilitation protocols. 
This is despite the wide range of protocols published. This review has identified four 
variables which account for this range. The first is the type of AFO worn. There were 
two predominant designs within the literature, a flexible in-shoe AFO and a rigid 
rocker bottom style AFO. The second variable is the degree of fixed PF the patient’s 
foot is maintained in within the AFO. This variable ranged from a 4.5cm heel raise to 
no fixed PF but restriction from DF only. The third variable consists of how long the 
AFO is worn for, all but one study used 6-8 weeks. One study recommended a 
minimum of three weeks, but gave no information regarding how long they were 
actually worn for. The final variable is whether or not the patient can remove the 
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AFO during the AFO wearing phase; this was allowed by all but one article. Within 
this article a high proportion of patients acquired skin complaints such as fungal 
infections and blisters, which were not evident amongst the other articles. 
 
This systematic review has demonstrated the development of IWB rehabilitation 
from concept to clinical practice over an eleven year time frame. This process has 
been described by McCulloch et al67 within the IDEAL recommendations. He 
proposed that for new complex interventions that are not governed by the strict 
standards used within the area of drug development, there should be a clear 
process of idea and development through to assessment and long term study. 
 
The IDEAL recommendations proposed that the first stage involved in delivering a 
new intervention should be the description of the intervention, which occurs as a 
solution to a clinical problem. In this case the clinical problems have consistently 
been documented to include muscle atrophy, resulting in prolonged rehabilitation 
and functional deficits, in combination with the clinical complications mainly 
consisting of re-rupture, tendon lengthening, adhesions and infection9. 
 
The first report of functional IWB rehabilitation by Speck et al in 199872 was 
prompted by the possible solution to the clinical problem presented, within a range 
of animal studies. These studies were based predominantly upon rabbit, dog and rat 
models79-82. In all cases these studies were able to demonstrate the positive effects 
of load and movement on, tendon characteristics, healing orientation of collagen 
fibres and calf strength. Conversely they also demonstrated the detrimental effects 
of immobilisation on both tendon and muscle tissues. Consequently Speck et al72 
put theory into clinical practice with their case series. Publications since 1998 have 
all supported the safety of functional IWB rehabilitation.  
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The next stage involved in delivering a new complex intervention according to the 
IDEAL recommendation is development of the new intervention to ascertain what 
aspects of it are more effective. In doing so, the intervention evolves and should be 
reported in relation to validated PROMs. This systematic review has demonstrated 
that this next stage of complex intervention development has not yet been 
addressed. There have been no studies comparing different IWB rehabilitation 
protocols.  
 
The IDEAL recommendations have been further supported by the MRC complex 
intervention framework and expansion of the CONSORT statement to improve 
reporting of non-pharmacologic interventions. More specifically, the need for health 
care research to be directed towards not only evaluating what works best, but to 
further investigate what specific components of the complex intervention work best 
and why. In doing this, interventions can be optimised. The MRC complex 
intervention framework has outlined that such interventions should be developed 
systematically with a series of pilot studies embedded within the biological 
plausibility of results found. In following this process research can be directed, 
leading to a definitive evaluation of a complex intervention. 
 
Based on the review of the literature to date regarding TA rupture rehabilitation it 
can be concluded that ultimately IWB is safe. However the type of AFO that should 
be worn, the degree of PF the foot should be maintained in and amount of time it 
should be worn for, are all variables which have not been evaluated within the 
literature. The second conclusion from this review is that the uses of validated 
PROMs are not widely reported within this specific disease area, allowing 
comparisons to be problematic. Finally this review has also highlighted the poor 
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standards of published articles regarding the reporting of adherence and 
standardisation of the interventions. 
 
Following the recommendations outlined in this chapter for developing a complex 
intervention the next stage from identifying the individual components is to evaluate 
these components and their interactions. In doing so a theoretical framework can be 
developed that will direct what complex interventions are trialled in clinical practice. 
Consequently the next chapter of this thesis will further investigate these identified 
components and their interactions, to develop a theoretical framework, upon which 
future clinical research in this area can be based. 
 
 
 
 
 
  
Page | 65  
 
3 Experimental Design: Gait Analysis Using Different Orthoses Designs  
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Abstract 
 
Background 
Advances in Achilles tendon rupture management have led to the development of 
immediate weight bearing protocols. These protocols vary regarding which ankle 
foot orthoses is used and the number of inserted heel wedges used within them.  
 
Objectives 
The primary purpose of this investigation was to evaluate plantar pressure 
measurements and temporal gait parameters, under different pre-defined 
conditions, within healthy participants. The secondary purpose was to draw 
inferences from these measurements to the application of Achilles tendon rupture 
rehabilitation. 
 
Methods 
Fifteen healthy subjects were evaluated using three different ankle foot orthoses 
designs, with four differing levels of inserted heel wedges. Subsequently, a total of 
12 conditions were evaluated, in a sequence that was randomly allocated to each 
subject.  
 
Pressure and temporal gait parameters were measured using an in shoe F scan 
pressure system, and range of movement was measured using an 
electrogoniometer.  
 
Results 
Ankle foot orthoses that were restrictive in design, combined with a higher number 
of inserted heel wedges, prevented production of forefoot pressures, increased heel 
pressures and decreased the amount of time spent in the terminal stance and pre-
swing phase of the gait cycle (p=0.029, 0.002 and <0.001 respectively). 
 
Conclusions 
The choice of ankle foot orthoses design and number of inserted heel wedges has a 
significant impact on plantar pressure measurements and temporal gait parameters. 
The purpose of an ankle foot orthoses for this injury is to provide weight bearing 
within a protected range of movement. However, the findings of this study suggest 
that the balance between protected weight bearing and functional loading require 
further research within a clinical context. 
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3.1  Protocol  
Rehabilitation following a TA rupture is often prolonged, with persistent functional 
deficits9. To address this clinical problem, research has focused on accelerated 
methods of rehabilitation. Chapter 2 illustrated that the first AFO IWB protocol was 
published in 199872, followed by the first RCT comparing IWB to NWB in 200373. In 
2009 the first guidelines18 were published for TA rupture management, also 
advocating IWB management. It is clear that there is an overall clinical consensus 
regarding the use of IWB AFO protocols, supported by clinical evidence 
demonstrating lower re-rupture rates and reduced muscle atrophy9,23,40. 
 
Chapter 2 also demonstrated that there is currently a wide range of IWB AFO 
protocols used in practice. The guiding principles behind IWB AFO management 
have been to balance the proposed advantages against the risks of tendon re-
rupture and lengthening. This has been achieved through restricting the degree of 
DF, and subsequently the contractile activity of the plantarflexors83. However, there 
is debate regarding the amount of restriction imposed and where this balance lies. 
 
In addition to the degree of DF restriction inherent within the AFO design, a number 
of IWB protocols have also maintained the ankle in various degrees of PF, within 
the AFO’s, using heel wedge inserts. This component may also have implications 
for subsequent recovery. For example, animal research has demonstrated that 
muscles immobilised in less than resting length atrophy at a faster rate than 
muscles fixed in stretched positions84. Furthermore, allowing a range of loaded 
movement has been shown to increase the biomechanical properties of the scar 
tissue, decrease excessive adhesion formation and subsequently enhance the 
gliding function of the tendon48,85. Consequently, the degree of permitted range of 
loaded movement requires further investigation. 
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Currently, there is no literature directly comparing different AFO designs within a 
range of fixed PF positions in clinical practice. Chapter 2 enabled the identification 
of the components which define an AFO IWB protocol. The next step outlined by the 
MRC64 for systematically developing a complex intervention is to develop 
appropriate theory to guide what is piloted in a clinical context. 
 
Consequently, to guide what could be developed and piloted in clinical practice the 
aim of this study was to investigate gait parameters under different pre-defined 
conditions, within participants with no previous lower limb injuries.  
 
3.1.1 Objectives, research question and null hypotheses 
The objectives of this study were: 
1) To quantify plantar pressure measurements and temporal gait parameters from 
healthy participants IWB in three different AFO designs. 
2) To quantify plantar pressure measurements and temporal gait parameters from 
healthy participants IWB within four different maintained ankle positions, using 
inserted heel lifts. 
3) To quantify the interactions between the above two components (AFO design 
and ankle position). 
4) To draw inferences from these findings to propose developments of IWB AFO 
protocols to be piloted in a clinical context. 
 
These objectives would answer the following research question:  
 
‘How does changing the position of the ankle or the AFO design within healthy 
participants, change plantar pressure measurements at the heel and forefoot, 
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cadence and amount of time spent in the terminal stance and pre-swing phases of 
the gait cycle, and is there an interaction between these two components?’ 
 
Therefore, the null hypotheses were: 
1) There are no differences of the three AFOs trialled (first factor) regarding 
plantar pressure measurements and temporal gait parameters within healthy 
participants. 
2) There are no differences between the four different maintained ankle positions 
(second factor) regarding plantar pressure measurements and temporal gait 
parameters within healthy participants. 
3) There is no interaction difference of the first and second factor regarding plantar 
pressure measurements and temporal gait parameters within healthy 
participants. 
 
Further information regarding the justification and definition of the above outcomes 
are detailed later, within Chapter 3.1.5.  
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3.1.2 Trial summary and trial flow diagram 
Participants were assessed, using in-shoe pressure analysis at one visit. They 
trialled three different AFOs, with the ankle set in four different levels of maintained 
PF. (Figure 3.1). For each analysis, an in-shoe pressure sensor was placed inside 
the AFO and the participant was asked to walk at normal walking pace down a flat 
corridor. Plantar pressures produced at the heel and forefoot, cadence, speed and 
amount of time spent in the terminal stance and pre-swing phases of the gait cycle 
were recorded. Range of movement permitted within the AFO throughout the gait 
cycle was also measured using an electro-goniometer.  
 
Recruitment of participants and data collection was expected to take place over a 
period of three months. The final analysis and interpretation was expected to be 
complete within one month from the final data collection point. 
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Figure 3.1: Trial flow diagram 
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3.1.3 Patient inclusion/exclusion criteria, recruitment and consent 
This study had ethical approval from the Coventry Research Ethics Committee. All 
men and women over the age of 18 years working within the University Hospitals of 
Coventry and Warwickshire and the University of Warwick, with no history of lower 
limb pathologies or injuries, were invited to take part.  
 
Participants with a history of lower limb pathology or injury were excluded because 
the effect of these past pathologies and/or injuries on the specified outcome 
measures is unknown and therefore a potential confounding variable. Participants 
under 18 years of age were excluded because this age group is not typical of the 
population who sustain a TA rupture39.  
 
The sample was limited to employees of the University Hospitals of Coventry and 
Warwickshire and the University of Warwick following discussions with the local 
ethics committee. During these discussions, it was decided that a sufficient number 
of eligible participants, representative of the population who sustain TA ruptures, 
was available within these departments to fulfil this convenience sample. 
 
Recruitment of participants took place within the University Hospitals of Coventry 
and Warwickshire. I delivered presentations to the Trauma and Orthopaedic clinical 
teams and Research Department teams. This presentation outlined the background 
and purpose to the study, as documented within the participant information sheet 
(Appendix A) approved by the local ethics committee. Potential participants were 
then invited to register their interest. 
 
Participants who had registered their interest were then screened using the 
predefined inclusion and exclusion criteria. Those who were both eligible and willing 
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were then provided with the approved participant information sheet (Appendix A). 
Once participants had read the participant information sheet, they then had the 
opportunity to ask any questions and have those questions answered to their 
satisfaction. If they were still willing, they then signed two consent forms. An 
example of the consent form can be found in Appendix B. The first copy was given 
to the participant for their information, and the second copy was stored as per the 
trial oversight and data management plan detailed in Chapter 3.1.9. 
 
Eligible and willing participants were advised that they could withdraw from the 
study at any time without prejudice. Alternatively, participants were also advised that 
they could be withdrawn from the study at the discretion of the investigator and/or 
PhD supervisors due to concerns, such as health or environmental considerations. 
 
3.1.4 Intervention 
Following the consent of willing and eligible participants, plantar pressure 
measurements and temporal gait parameter data to be collected for the above 
objectives was gathered using the F-Scan system (Tekscan Incorporated, Boston, 
Massachusetts). The F-Scan system allows for evaluation of gait rather than 
isolated steps, which is the main advantage over force plate measurements86. Force 
plate measurements also have the additional disadvantage of ensuring correct 
‘targeting’ of the foot strike, which has been reported to create unnatural gait 
patterns87. 
 
The F-Scan system uses a two layer ultra thin (0.18mm) flexible foot sensor. Each 
layer is made of a flexible polyester film and an electrically conductive ink is printed 
on the film and coated with a pressure sensitive resistive ink88. This is arranged in 
rows of electrodes that respond to an applied pressure resulting in an electrical 
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output. There are 960 individual pressure-sensing locations, at a sampling 
frequency of 50Hz (Figure 3.2).  
 
Studies of the F-Scan in-shoe system have demonstrated reliability and validity of 
the equipment88-90. Previous research has quoted inter-class correlation coefficients 
of 0.83 for pairs of repeated measures89 and coefficient variations of between one 
and eight percent for heel measurements when known forces were applied. 
Additionally, the discreet in-shoe sensors have been reported to be easier and more 
reliable to calibrate than larger force plates86,91-92. 
 
There was no internal testing of reliability and validity of the equipment used. 
However the manufacturers guidelines were followed during testing procedures in 
addition to following the international guidelines for plantar pressure measurements. 
These protocols in measurement and analysis procedures ensured the 
maximisation of intra reliability. 
 
Each participant had a new set of foot sensors individually prepared for them, as 
recommended by the manufacturers. This involved sizing the foot sensors to the 
participants own shoe size following the manufacturer’s guidelines. This process 
consisted of trimming within the non-conductive rows and columns only (indicated 
by a darker colour within the sensor). This method ensured that no partial cells 
 
Figure 3.2: In-shoe foot sensors 
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existed within the sensor which is known to give inaccurate readings when loaded. 
Once the sensors had been sized accordingly, they were then placed inside the 
AFO. All participants wore socks as recommended by the international guidelines 
for plantar pressure measurements93. This is recommended because previous 
research has shown that warm, damp footwear can result in poor data86. The 
sensors were then connected to a ‘cuff unit’ and linked to the research software via 
a ten metre cable inserted from the cuff unit to a laptop containing the software.  
 
Following the manufacturer’s guidelines and the international protocol guidelines for 
plantar pressure measurements, the in-shoe pressure sensors were then 
conditioned by walking 20 steps on each sensor and then calibrated. Calibration is 
the method by which the raw digital output of the sensor is converted to actual 
pressure units; each sensor is calibrated individually. This process involved 
inputting the participants’ weight into the gait analysis software and then asking 
them to stand on one leg for a period of one second. 
 
Once each sensor had been conditioned and calibrated, each participant was asked 
to walk along a level, carpeted, pre-marked, six metre walkway at their normal 
walking speed. A six metre walkway was selected to allow some slack to remain 
within the cables. ‘Normal’ walking speed was implemented because enforcing the 
same absolute speed for each subject, via a treadmill or metronome, has been 
shown to result in altered gait patterns86,94. 
 
It is known that speed affects a variety of gait parameters and is therefore a 
confounding factor95-96. With increasing speeds, the literature consistently confirms 
that electromyography activity is altered, stance phase and double limb support time 
decrease and stride length increases95,97-101. Furthermore, increasing speed results 
Page | 76  
 
in higher ground reaction forces97,102. Speed is therefore an important factor and will 
be measured, but not controlled, for the reasons outlined above. Speed will be 
determined by timing the amount of time it takes each participant to walk the six 
metre walk way. It is also known that the type of flooring can alter the sensor 
outputs, with a relation between increased outputs with increased floor hardness, 
therefore this remained the same for each trial88. 
 
Each gait cycle was recorded for 500 frames (50 frames/second for 10 seconds). 
Based on an average cadence of 118 steps/minute for normal walking, this would 
allow approximately 19 steps to be recorded per cycle, which is sufficient for the 
analysis, and is explained and detailed further in the following section103. For each 
condition tested, five trials were recorded, as per international guidelines for plantar 
pressure measurements93. 
 
Two separate variables were assessed using the above method. The first variable 
was the AFO design.  
 
It is current practice, within the University Hospital of Coventry and Warwickshire, 
for patients who have sustained a rupture of their TA, to be managed within a rigid 
rocker bottom style AFO (Donjoy, Guildford, UK, Figure 3.3). This AFO design is 
frequently documented for the IWB management of TA ruptures75,104-105. A carbon 
fibre dorsum AFO design has also been reported within the literature as an 
alternative to the rigid, rocker bottom AFO73. There are currently no studies 
comparing these different designs, as demonstrated by the systematic review 
outlined in Chapter 2.  
Page | 77  
 
 
 
Figure 3.3: Rigid rocker bottom AFO design 
 
To achieve the first objective of this study, participants’ gait patterns were assessed 
within a rigid rocker bottom AFO currently used within the hospital Trust (Figure 3.3) 
and with two alternative carbon fibre dorsum AFOs. The carbon fibre dorsum AFOs 
to be tested were chosen after discussions with the on-site hospital Trust appliances 
department regarding which companies currently supplied the hospital Trust. Those 
companies were then either invited to talk through their products or alternatively 
were seen at appropriate conferences. 
 
Three companies were identified as supplying carbon fibre dorsum AFOs and all 
responded to the invitation. These companies were; Gilbert and Mellish, Ossur UK 
Ltd and Chaneco. Following demonstrations carried out by the company 
representatives, one company’s design was regarded as being inappropriate 
because it was not designed to prevent DF. Preventing DF is important within the 
context of TA rupture management for preventing complications such as tendon 
lengthening106. 
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Consequently, two carbon fibre dorsum AFO designs, from two separate companies 
were chosen to be tested within this convenience sample. The first, by Gillbert and 
Mellish, is named ‘ToeOFF’ (Figure 3.4) the second, by Ossur UK Ltd, is named 
‘AFO dynamic’ (Figure 3.5). The AFOs are designed to wear within a participant’s 
own footwear. However, for the purposes of standardisation, the AFOs in this study 
were worn within a standard shoe, but normal footwear was worn on the 
contralateral limb 
 
  
Figure 3.4: ‘ToeOFF’ Figure 3.5: ‘AFO Dynamic’  
 
The second variable to be assessed, outlined within the second objective, was the 
effect of four different levels of PF within the above three described AFOs. 
 
NWB management of TA ruptures has traditionally involved serial casting, with the 
foot initially positioned in PF and gradually being reduced to neutral over a set 
period of time40. Since the introduction of IWB protocols, the same management 
principles of patients beginning their rehabilitation in PF and gradually reducing this 
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to neutral has remained the same104. Yet there is no known clinical indication why 
the TA needs to remain in a large degree of PF during the initial phases of 
rehabilitation. Furthermore, animal studies have shown that muscles which are 
immobilised in shortened positions undergo faster rates of muscle atrophy than 
muscles that are immobilised at resting lengths (neutral position)104. Therefore it is 
important to establish the effects of different degrees of PF, currently achieved with 
1cm heel wedges, in clinical practice. 
 
To establish the effects of different degrees of PF, participants’ gait patterns were 
assessed within the above three described AFOs. They were assessed using three 
1cm heel inserts, two 1cm heel inserts, one 1cm heel insert and no heel inserts. The 
effects which were measured are described in detail within the analysis plan. The 
uppermost range of three heel inserts was decided upon because this reflected 
current practice within the NHS Trust and the degree of PF achieved with three heel 
inserts has been shown to be sufficient enough to significantly reduce EMG activity 
of the triceps surae and decrease vertical ground reaction forces107. Therefore a 
higher number of inserted heel wedges would have no additional benefit.  
 
There were, therefore, a total of four different ankle positions assessed within each 
of the three AFO designs, and one assessment with no AFO or heel wedge inserts, 
resulting in a total of 13 assessed conditions. The assessment of ‘normal’ gait 
without an AFO or heel wedge insert was taken first in all participants. Then, to 
account for known confounding factors such as learning effects and fatigue and all 
unknown confounding factors, the 12 intervention conditions were randomised using 
a row and column design108 (Figure 3.6). 
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The row and column design, outlined in Figure 3.6, systematically randomises the 
order of AFO usage so that each is used first, second or third the same number of 
times  (B1 = Rigid rocker bottom AFO, B2 = AFO dynamic, B3 = AFO ToeOff). 
Consequently, the sample size has to be a factor of three to achieve this. 
Additionally, along the side of each AFO condition are the terms W1, W2, W3 and 
W0. These relate to the randomised order and number and of inserted heel lifts 
within each trialled AFO (W1=one heel wedge, W2=two heel wedges etc).  
 
In addition to the randomisation of AFOs and heel wedge inserts, a further 
randomisation sequence was used to allocate the participant to wear the AFO on 
either their left or right leg (R or L). Randomisation to the left or right leg was carried 
out because differences of between 9-16% in lower limb strength, within healthy 
participants, has been recorded within the literature109 and is therefore a known 
confounding factor that needed to be taken into consideration. 
 
The randomisation sequence below was generated by an independent researcher 
within the department and was accessed by telephone at the point of each 
participant arriving for data collection. Informed written consent for entry into the 
study was obtained prior to randomisation (Appendix B).  
 
Researcher bias was reduced through including consecutive participants. This was 
in addition to randomisation of participants to trial conditions implementing a 
sequence which ensured that each AFO/heel wedge combination was used first or 
last the same number of times to account for any learning or fatigue effects. The 
randomisation sequence was concealed until the point of allocation.  
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R         L        L         L        R        R        L        R         L         L        L         R        L        R        R 
 
Figure 3.6: Randomisation sequence 
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In addition to the plantar pressure recordings, ROM permitted within the AFO was 
measured using an electrogoniometer system (Biometrics Ltd, Gwent). This 
measurement would allow comparisons to be made regarding the degree of DF and 
PF permitted across the different conditions. This is an important measure for the 
previously described clinical complication of tendon lengthening, which will manifest 
if there is no restriction of movement.  
 
The electrogoniometer works via two end blocks connected by a spring and 
composite wire that has a series of strain gauges. As the angle between the end 
blocks changes, so does the strain along the wire, resulting in a measurement of 
angular displacement. Following the manufacturer’s guidelines, double sided 
adhesive tape was used to attach the end blocks anterior to the ankle joint in line 
with the tibia and second metatarsal. With the knee at 90 degrees and the 
participant in a sitting position, the electrogoniometer reading was set to zero. This 
was carried out prior to placing the feet inside the specified footwear.  
 
3.1.5 Analysis plan and outcome measures  
For each condition, five cycles were recorded as per the international guidelines for 
plantar pressure measurements. The third recording was subsequently analysed.  
Within the third recording the second, third and fourth steps were analysed (Figure 
3.7). This method has been advocated because current literature has demonstrated 
that there is no increase in reliability after the aggregation of three steps. The first 
and last steps were disregarded to account for the effects of acceleration and 
deceleration90,93. Recordings were rejected if they were considered under stridden, 
over stridden, hesitant or targeted, which has been accepted as a valid method by 
the foot pressure interest group93. 
Page | 83  
 
All data was collected by the researcher. All data was recorded and saved for each 
test condition. The researcher analysed the data at the end of all testing 
procedures. As the researcher was both collecting and analysing the data, waiting 
to analyse the data at the end of testing procedures was one method of increasing 
reliability. However this method is limited because ideally the individual analysing 
the data would be blinded to the test conditions to further limit researcher bias.  
 
 
Figure 3.7: Example of the recorded data output 
 
The TA connects the gastrocnemius and soleus muscles to the posterior aspect of 
the calcaneus to permit transmission of plantarflexion torque during the terminal 
stance and pre-swing phases of the gait cycle110-111. Therefore the first outcome to 
be assessed was the duration of the terminal stance and pre-swing phases as a 
proportion of the total stance component on the gait cycle. The beginning of terminal 
stance was defined as the point at which the patient’s centre of gravity lay over the 
centre of the foot and the end of pre-swing was defined as the point at which the 
toes left contact with the floor.   
 
Page | 84  
 
The second outcome was quantification of plantar pressure measurements at the 
heel and forefoot. The forefoot and heel areas were defined as the distal 40% and 
proximal 30% respectively93 (Figure 3.8). Each measurement was reported as a 
percentage of the value recorded for the contralateral limb because the absolute 
measurements vary between individuals based on height and weight parameters, 
enabling comparisons to be problematic. The analysis was therefore based upon 
the difference between the two lower limbs. 
 
Figure 3.8: Example of a pressure recording 
 
The third outcome to be assessed was cadence, defined as the number of steps 
within a set time. This was documented because previous research has suggested 
that the amount of PF within the AFO is important because it reduces cadence and 
consequently decreases vertical ground reaction forces. However, this previous 
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research did not compare different levels of PF, AFO designs or measure/control for 
speed107. Consequently, this outcome measure is being recorded to enable 
comparison with this previous study. 
 
As previously stated, the second, third and fourth steps were analysed. The mean of 
these three separate recordings was then analysed as per previous 
recommendations90. The datasets were analysed using descriptive statistics 
including the mean, standard deviation and range of each condition. The descriptive 
dataset analysis was carried out using Microsoft Excel 2007. Inferential statistical 
analysis was performed using SPSS 17.0 to perform a two-way analysis of variance 
(ANOVA). This analysis determines firstly the effect of the number of heel wedge 
inserts regardless of the AFO design, secondly the effect of the AFO design 
regardless of the number of heel wedge inserts and thirdly the AFO and heel wedge 
number interaction.  
 
Following the analysis of variance amongst the two factors (AFO design and 
number of heel wedge inserts) a post hoc analysis using ‘Tukey’ was used to 
differentiate where the exact differences lie. This test is designed to give only one 
type one error per 20 analyses when the null hypothesis is true, as opposed to 
doing a t-test for each pair of groups, which gives one error per 20 comparisons 
when the null hypotheses is true112. Final analysis included scatter plots and 
accompanying Pearson correlation coefficients to further explore relationships 
between the parameters. 
 
To achieve the second part of this study’s aims (to draw inferences from the above 
observations to the application of TA rupture management), the above analysis will 
be discussed in relation to previous literature within the field of TA rupture 
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rehabilitation. As previously outlined, there are many areas of TA rupture 
rehabilitation that remain unknown. To add to this complexity, it is beyond the scope 
of this study to conclude if these findings will translate to a clinical setting, within 
patients who have sustained this injury, secondary to using healthy participants. 
Further research will be required to determine if the findings within healthy 
participants translate to a clinical setting. 
 
However, what is known in relation to the above recorded objective measures, is 
that the AFO needs to prevent pressures produced at the heel and forefoot beyond 
those recorded for normal walking104. In the case of forefoot pressures, this is 
because increased pressure relates to increased force production by the triceps 
surae. These forces are transmitted by the TA. The forces transmitted by the TA 
during the terminal stance and pre-swing phases of the gait cycle result are 
equivalent to 2.4 times an individual’s body weight. One study found that 
approximately 553 Newton’s (SD 182) are produced at the TA during normal 
walking83. Therefore, an AFO needs to prevent ankle DF or reduce the need for the 
posterior calf muscles to contract107.  
 
It is not known how much force is required to re-rupture a healing tendon or to 
separate the tendon ends, causing tendon lengthening. It is known that WB during 
the early phases of healing stimulates fibroblast activity and type III collagen 
synthesis48. Therefore, the purpose of the AFO is to provide ‘protected’ WB that 
represents normal gait parameters, within the limits of decreased permitted 
movement. In the case of heel pressures, clinically, it is observed that patients often 
report heel pain. It is thought that this is possibly related to the increased pressures 
reported in the heel area113. 
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Furthermore, the AFO needs to reflect the normal proportions for the amount of time 
spent in terminal stance and pre-swing phases of the gait cycle as a percentage of 
the total stance phase. This is important because the triceps surae works 
eccentrically during this phase of the gait cycle, to prevent the tibia rotating forwards 
over the talus111. Therefore if this phase of the gait cycle is reduced it may lead to 
disuse atrophy of the triceps surae. Additionally, it is possible that patients may 
acquire a learned motor pattern during the time the AFO is worn114, however this 
dimension is beyond the scope of this work. 
 
If all the AFO designs fulfil these criteria, the AFO that most represents a normal 
gait cycle, within the limits of restricted movement, will be implemented within 
clinical practice to be compared to current practice. 
 
3.1.6 Sample size  
An appropriate sample size was obtained by Nicholas Parsons (Statistician) using R 
software, http://www.r-project.org/. This software demonstrated that a sample size 
of at least 14 participants was needed to achieve 90% power at the 5% significance 
level for this study design. This calculation used an effect size of 0.4 (medium to 
large). To allow flexibility, for potential outlying results, and to round to the nearest 
multiple of three, for reasons described previously, 15 participants were planned to 
be assessed. This assumed normally distributed data and that variability between 
groups was the same115. 
 
The R software calculated the sample size estimation for a two-way ANOVA, based 
on k groups, with n observations, effect size f and significance level α the power 
was calculated as follows:  
Power = pf (qf (α,k-1,k (n-1) ),k-1,k (n-1),λ);  (1) 
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Where pf (q,v1,v2,ϕ) is the F distribution function, q is a quantile, v1 and v2 are 
degrees of freedom, ϕ is the non-centrality parameter and qf (α,v1,v2) is the F  
quantile function with significance level α. To determine sample sizes at set power 
levels (e.g. 90%), Equation (1) is solved to find values of n that give powers equal to 
0.9 for known k, f and α. For 90% power, k=12, f=0.4 and α=0.05, then n≈13.5; 
which was rounded up to 15 for this study. 
 
An effect size of 0.4 was chosen based on two separate unpublished case series of 
gait parameters following a TA rupture. (One from the University Hospital of 
Coventry and Warwickshire, that uses the rigid rocker bottom AFO as standard 
practice and a second within a separate hospital within the UK that uses the flexible 
carbon fibre dorsum AFO as standard practice.) Mean forefoot pressures two weeks 
following removal of the respective AFOs showed mean differences of 49% and 
33% between the injured and uninjured limbs within the two samples. The standard 
deviation of both samples was 20%. Using this information, the mean of the first 
sample was subtracted from the mean of the second sample and divided by the 
standard deviation. This calculation indicated a possible effect size of 0.8 between 
the rigid rocker bottom and dorsum carbon fibre AFO designs. It was estimated that 
recruitment and data collection would take place over a three month time period. 
 
3.1.7 Adverse event management 
After the first and final visit, each participant was asked whether they had 
experienced any adverse events. Adverse events were defined as any untoward 
medical occurrence in a clinical trial subject, which does not necessarily have a 
causal relationship with the treatment. All reported adverse events would be listed 
on the appropriate case report form and reported centrally.  
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Serious adverse events were defined as any untoward and unexpected medical 
occurrence that results in death, is life-threatening, requires hospitalisation or 
prolongation of existing hospitalisation, results in persistent or significant disability or 
incapacity, is a congenital anomaly or birth defect or any other important medical 
condition, which although not included in the above, might require medical or 
surgical intervention to prevent one of the outcomes listed. 
 
All serious adverse events will be entered onto the Serious Adverse Event reporting 
form. Once received by the Principal Investigator, causality and expectedness 
would be determined. Serious adverse events that were deemed to be unexpected 
and related to the trial would be notified to the main Research Ethics Committee 
within 15 days for a non life-threatening event and within seven days for a life-
threatening event. All participants experiencing serious adverse events would be 
followed-up as per protocol until the end of the trial.  
 
3.1.8 End of trial 
The end of the trial was defined as the final visit of the last participant. 
 
3.1.9 Trial  organisation, oversight and data management 
This was a small, healthy subject study so no formal TSC or DMC was necessary. 
All case report forms will be held in a secure, locked filing cabinet within the 
restricted area of the Clinical Sciences Research Laboratory. Participants will be 
identified by a code number only. All paper and electronic data will be retained for at 
least five years after completion of the study. 
 
During the development of this study the PhD supervisors were responsible for 
critically reviewing and discussing key methodological considerations during 
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supervision meetings. Statistical and sample size advice was provided by Nicholas 
Parsons (statistician). All trial procedures (recruitment, consent, data collection, data 
recording, analysis and interpretation) were completed by myself and reviewed 
during PhD supervision meetings. 
3.1.10 Resource use 
To complete this study access was required to Microsoft office software, SPSS, F-
Scan system, 15 pairs of Tekscan foot sensors and the electrogoniometer system. 
 
3.2 Results 
Fifteen participants consented to take part in this study. No participants were 
excluded or did not meet the inclusion criteria and 15 participants data were 
analysed. 
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Gait analysis under pre-defined 
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Analysed (n = 15 ) 
    
      
          
 
Figure 3.9: Flow chart of participant flow 
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3.2.1 Control group data  
Table 3.1 illustrates the baseline demographics for the 15 included participants. The 
mean age of the sample was 31.3 years. Eight men and seven women took part; 
eight left and seven right lower limbs were randomised accordingly. 
 
Table 3.1: Baseline demographics of control group 
 Healthy participants (n=15) 
Mean age in years (SD) 31.3 (4.7) 
Male/Female 8/7 
Left/Right 8/7 
Mean height in cm (SD) 172.3 (8.7) 
Mean weight in Kg (SD) 70.4 (14.5) 
 
Figure 3.10 through to Figure 3.13 illustrate the speed, heel pressures, forefoot 
pressures, amount of time spent in terminal stance and pre-swing phase as a 
proportion of the stance phase and ROM during normal walking conditions. Each of 
these will be discussed in turn. 
 
Each participant was asked to do five trials for each condition. Figure 3.10 shows 
the mean speeds and SD for each individual trial. To assess if participants’ speed 
changed with increasing trial walks, a one-way analysis of variance was carried out. 
This result was non-significant (p=0.435), demonstrating that there were no 
differences between test walk speeds.  
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Figure 3.10:  Mean and SD for each test walk speed (metres/second) control 
 
Further analysis of the data showed that the average cadence for the control 
condition was 104 steps per minute (SD 11). The mean heel and forefoot pressures 
are shown in Figure 3.11 for each limb (± 2 SD). Mean heel pressures for each foot 
were 59 (KPa) and 64 (KPa) (~8% difference) and mean forefoot pressures were 65 
(KPa) and 62 (KPa) (~ 5% difference). Figure 3.12 also shows the percentage of 
time spent in the terminal stance and pre-swing phases of the gait cycle as a 
proportion of the total stance phase. The figures are 48% and 49% for the control 
condition. The final parameter, ROM, is illustrated in Figure 3.13, showing that the 
average measure of DF in degrees at its peak was 7º and the average measure of 
PF at its peak was 12º. 
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Figure 3.11: Mean and SD heel and forefoot pressures (KPa) control 
 
 
Figure 3.12: Mean and SD for % duration of terminal stance and pre-swing control 
  
Heel Pressure 
Forefoot Pressure 
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Figure 3.13: Mean and SD for ROM (degrees) control 
 
In addition to the descriptive statistics carried out for the control condition, pair-wise 
correlations, with scatter plots, were produced to further investigate the relationships 
between these parameters within the control condition. Table 3.2 shows the 
Pearson Correlation Coefficients for each paired comparison, with significance 
values. Figure 3.14 through to Figure 3.19 illustrate the scatter plots for the following 
Pearson Correlation Coefficient analyses. 
 
Speed was not significantly correlated to any assessed parameter except cadence 
(p < 0.001). Cadence was also significantly correlated with the amount of time spent 
within the terminal stance and pre-swing phase of the gait cycle as a proportion of 
the total stance phase (p = 0.023). As cadence increased so did the amount of time 
spent within the terminal stance and pre-swing phase of the gait cycle as a 
proportion of the stance phase.  
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Heel and forefoot pressures were not significantly correlated with speed or cadence. 
However they were correlated to each other (p=0.006). As heel pressures increased 
forefoot pressures decreased. Heel pressures were not significantly correlated to 
any other parameter. Conversely forefoot pressures were increased as the time 
spent within the terminal stance and pre-swing phase of the gait cycle increased            
(p< 0.001). (The p value in this analysis is in comparison to the assumption that the 
population correlation is zero, so if the p value is small you can conclude that the 
sample correlation is incompatible with zero correlation). 
 
Table 3.2: Pearson correlation coefficients for pre-defined gait parameters control 
 
Paired comparisons 
 
Pearson 
correlation 
coefficient 
 
Significance 
Heel pressure & speed 0.05 0.794 
Forefoot pressure & speed 0.07 0.697 
Heel pressure & terminal stance and pre-swing %  -0.06 0.728 
Forefoot pressure & terminal stance and pre-swing % 0.59 <0.001 
Terminal stance and pre-swing % & speed -0.25 0.170 
Forefoot pressure & heel pressure 0.48 0.006 
Speed & cadence -0.71 <0.001 
Terminal stance and pre-swing % & cadence 0.41 0.023 
Heel pressure & cadence 0.08 0.669 
Forefoot pressure & cadence 0.21 0.261 
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Figure 3.14: Scatter plot of pressure (KPa) and speed (metres/second) control 
 
 
Figure 3.15: Scatter plot of pressure (KPa) and % duration of terminal stance and pre-
swing phase control 
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Figure 3.16: Scatter plot of terminal stance and pre-swing phase % and speed 
(metres/second) control 
 
 
Figure 3.17: Scatter plot of forefoot pressure (KPa) and heel pressure (KPa) control 
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Figure 3.18: Scatter plot of speed (metres/second) and cadence (steps/minute) control 
 
Figure 3.19: Scatter plot of terminal stance and pre-swing phase % and cadence 
(steps/minute) control 
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Figure 3.20: Scatter plot of pressure (KPa) and cadence (steps/minute) control 
 
3.2.2 Trial conditions: speed, range of movement and cadence 
Once the control walking trials had been completed, each participant then 
completed five walking trials under twelve different conditions, as previously 
described within the methods section. There were two key variables assessed; the 
first was the type of AFO design and the second was the number of heel wedge 
inserts within each AFO design. 
 
There were three AFO designs assessed. These were a rigid rocker bottom AFO 
(Donjoy, Guildford, UK, Figure 3.3) and the two dorsum carbon fibre AFO designs 
(AFO Dynamic, Ossur, UK and ToeOFF, Gilbert and Mellish, Figure 3.4 and Figure 
3.5). Throughout the analysis, these are referred to as B1, B2 and B3 respectively. 
Within each AFO design, participants walked with three, two, one and no heel 
wedge inserts within them. These are referred to as W3, W2, W1 and W0 
respectively. 
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Figure 3.21 and Figure 3.22 illustrate the mean recorded speed and ANOVA F 
probability for the first variable (AFO design) regardless of the number of heel 
wedge inserts and conversely, for the second variable (number of heel wedge 
inserts) regardless of the AFO design.  
 
The results show that there were no significant differences in recorded speed 
between AFO designs across all conditions (ANOVA: F Probability 0.368). However, 
there were significant differences between the number of heel wedge inserts used 
regardless of AFO design (ANOVA: F Probability < 0.001).  
 
ANOVA: F Probability  0.368 
 
Figure 3.21: Mean speed (metres/second) for B1, B2, B3, with ANOVA F probability  
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ANOVA: F Probability  <0.001 
 
Figure 3.22: Mean speed (metres/second) for each heel wedge condition, with ANOVA 
F probability  
 
Post-hoc analysis (using Tukey’s Honestly Significant Difference112) showed that 
walking with three heel wedge inserts within an AFO is significantly different from 
walking with two, one and no heel wedge inserts. There were no differences 
between other pair wise comparisons as Table 3.3 demonstrates.  
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Table 3.3: Post hoc analysis for Figure 3.22 showing, mean difference, upper and 
lower limits and p-value for each comparison 
Wedges Difference Lower Upper Significance 
0 - 1 0.0 -0.1 0.0 0.103 
0 - 2 0.0 0.0 0.0 0.946 
0 - 3 0.0 0.0 0.1 0.006 
1 - 2 0.0 0.0 0.1 0.301 
1 - 3 0.1 0.0 0.1 <0.001 
2 - 3 0.1 0.0 0.1 <0.001 
 
Table 3.4 and Table 3.5 show the mean degrees of DF and PF permitted within 
each AFO design regardless of the number of heel wedge inserts and movement 
permitted across heel wedge inserts regardless of AFO design. The F Probability for 
DF and PF within the three AFOs regardless of the number of heel wedge inserts 
was statistically significant (0.002 and 0.026). Further post hoc analysis is shown in 
Table 3.4. This shows that there is a significant difference between B1 and B2 only 
for both DF and PF (Difference of 8º and -5º respectively).  
 
Table 3.4: Mean difference, upper and lower limits, and p-value for each comparison 
 B1 B2 B3  
Mean DF (SD) -3.4 (10.1) 5.1 (7.1) 1.1 (7.8)  
Mean PF (SD) 10.9 (9.7) 5.4 (7.4) 9.2 (7.9)  
DF Difference Lower Upper Significance 
B1 - B2 8.5 3.2 13.7 <0.001 
B1 - B3 4.4 -0.8 9.6 0.110 
B2 - B3    -4.1 -9.3 1.2 0.150 
PF        
B1 - B2 -5.5 -10.4 -0.7 0.022 
B1 - B3 -1.8 -6.6 3.1 0.640 
B2 - B3    3.8 -1.1 8.6 0.148 
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Range of permitted movement across the number of heel wedge inserts regardless 
of AFO design was also significant (F probability <0.001 and <0.001). Table 3.5 
shows the results for the post hoc analysis, which were statistically significant for 
each comparison within measures of DF. At the extreme of no wedge inserts 
compared to three, there was a mean difference of seven degrees. The removal of 
each heel wedge insert was equivalent to approximately a two degree increase in 
DF. For PF, the mean difference between no heel wedge inserts and three was five 
degrees. With each heel wedge removed, the differences were small (between one 
to two degrees) and non-significant. However, the differences between none and 
two heel wedge inserts, one and three and none and three were larger (between 
three and five degrees) and were statistically significant.  
Table 3.5: Mean difference, upper and lower limits and p-value for each comparison  
 W0 W1 W2 W3 
Mean DF (SD) 4.5 (8.3) 2.5 (8.0) 0.0 (9.2) -3.2 (9.3) 
Mean PF (SD) 5.9 (7.9) 7.5 (8.0) 9.2 (9.1) 11.4 (8.9) 
DF Difference Lower Upper Significance 
0 - 1 -2.0 -3.8 -0.2 0.025 
0 - 2 -4.5 -6.3 -2.7 <0.001 
0 - 3 -7.6 -9.4 -5.8 <0.001 
1 - 2 -2.5 -4.3 -0.7 0.003 
1 - 3 -5.6 -7.4 -3.8 <0.001 
2 - 3 -3.1 -4.9 -1.3 <0.001 
PF         
0 - 1 1.6 -0.5 3.7 0.215 
0 - 2 3.3 1.2 5.5 0.001* 
0 - 3 5.4 3.3 7.6 <0.001 
1 - 2 1.7 -0.4 3.9 0.165 
1 - 3 3.8 1.7 6.0 <0.001 
2 - 3 2.1 0.0 4.3 0.051 
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ANOVA: F Probability  0.042 
 
Figure 3.23: Mean cadence (steps/minute) for B1, B2 and B3, with ANOVA F 
probability  
 
Figure 3.23 demonstrates that there is a statistically significant difference between 
AFO designs. The post hoc analysis in Table 3.6 shows that the difference lies 
between AFOs B2 and B3 only, and there is a three steps per minute difference. 
Figure 3.24 shows no significant difference regarding cadence across heel wedge 
inserts.  
 
Table 3.6: Post hoc analysis for Figure 3.23 showing the mean difference, upper and 
lower limits and p-value for each comparison  
 Difference Lower Upper Significance 
B1 - B2 1.6 -1.3 4.5 0.382 
B1 - B3 -1.6 -4.5 1.4 0.389 
B2 - B3    -3.2 -6.1 -0.2 0.032 
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ANOVA: F Probability  0.063 
 
Figure 3.24: Mean cadence (steps/minute), with ANOVA F probability for heel wedge 
inserts  
 
3.2.3 Trial conditions: control limb and AFO limb raw values 
For each of the 12 conditions, participants wore the AFO and heel wedge 
combinations on either their left or right lower limb, as per the randomisation 
sequence. The side wearing the AFO shall be referred to as the ‘AFO limb’ and the 
side not wearing the AFO shall be referred to as the ‘control limb’.  
 
For this next section of analysis, raw values recorded for the control limb were 
compared across AFO designs and the number of heel wedge inserts to evaluate if 
the control limb varied across conditions. The AFO limb was also initially evaluated 
in the same way. 
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Figure 3.25 shows the differences between the control limb measurements across 
AFO designs and differences between the AFO limb across the AFO designs for 
heel pressures. Analysis of variance showed significant differences for both the 
control and AFO limb. The significance was greater for the AFO limb. Table 3.8 
summarises the post hoc analysis for these separate lower limb heel pressures. The 
control limb had a statistically significant mean difference of 8 KPa between B1 and 
B2; no other differences were found. The AFO limb showed larger differences 
between both dorsum carbon fibre AFO designs (B2 and B3) compared to the rigid 
rocker bottom AFO orthotic design (B1) of 20 and 12 KPa less on average. There 
was also a difference between the two dorsum carbon fibre AFO designs, although 
this was a smaller 8KPa difference. 
 
Across the number of inserted heel wedges, regardless of the AFO design, the heel 
pressure measurements recorded for the control limb were not significant. The 
difference across the AFO limb was significant and post hoc analysis showed 
significance across all comparisons except none compared to one inserted heel 
wedge and two compared to three. Overall, a difference in two heel wedge levels 
resulted in approximately 12 KPa difference in heel pressure.  
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ANOVA: F Probability (Control) 0.004 
ANOVA: F Probability (AFO) <0.001 
 
Figure 3.25: Mean heel pressures (KPa) across B1 B2 and B3 for control and AFO 
limb, with ANOVA F probability  
 
Table 3.7: Post hoc analysis for Figure 3.25 showing the mean difference, upper and 
lower limits and p-value for each comparison 
AFO Limb Difference Lower Upper Significance 
B1 - B2 -20.8 -29.2 -12.4 <0.001 
B1 - B3 -12.1 -20.5 -3.7 0.004 
B2 - B3    8.6 0.2 17.0 0.044 
Control Limb        
B1 - B2 8.2 2.8 13.6 0.002 
B1 - B3 4.0 -1.4 9.4 0.179 
B2 - B3    -4.2 9.6 1.2 0.151 
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ANOVA: F Probability (Control) 0.492 
ANOVA: F Probability (AFO) <0.001 
 
Figure 3.26: Mean heel pressures (KPa) for control and AFO limb across heel wedge 
inserts, with ANOVA F probability  
 
 
Table 3.8: Post hoc analysis for Figure 3.26 showing the mean difference, upper and 
lower limits and p-value for each comparison 
AFO Limb Difference Lower Upper Significance 
0 - 1 1.8 -4.7 8.3 0.890 
0 - 2 11.1 4.5 17.6 <0.001 
0 - 3 13.9 7.3 20.4 <0.001 
1 - 2 9.3 2.7 15.8 0.002 
1 - 3 12.1 5.5 18.6 <0.001 
2 - 3 2.8 -3.7 9.3 0.678 
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Forefoot pressures across AFO design for the control limb did not significantly differ. 
However, the forefoot pressure measurements across AFO designs for the AFO 
limb did differ significantly. These differences were again largest between the rigid 
rocker bottom AFO (B1) and two dorsum carbon fibre AFO designs (B2 and B3). 
There was a 28 KPa and 16 KPa deficit on average within B1 compared to B2 and 
B3 (Table 3.9). Again there are significant differences between the two dorsum 
carbon fibre AFO designs, but this was a smaller difference of 12 KPa, as shown in 
Figure 3.27 and Table 3.9. 
 
Forefoot pressure measurements across heel wedge inserts for the control and 
AFO limb are significantly different as shown by Figure 3.28 and Table 3.10. For the 
control limb, forefoot pressures were increased when three heel wedges were 
inserted in the AFO limb. There were no differences between any other 
combinations. For the AFO limb, the differences were larger than the control and 
significantly different with no heel wedge inserts compared to one, two and three 
heel wedge inserts. 
 
Figure 3.29 demonstrates that terminal stance and pre-swing percentage across 
AFO designs, regardless of the number of heel wedge inserts was significantly 
different for the control limb. However, post hoc analysis showed that this difference 
was only between B1 when compared to AFO’s B2 and B3. Furthermore, the 
difference was small (2.7 to 3.6%) when compared to the differences across the 
AFO limb. Again the biggest difference here was found between the comparisons 
made between B1 and AFO’s B2 and B3, the differences being 22.8 and 13.4% 
respectively. There were also significant differences found between B2 and B3; 
however this difference was smaller (4.2%). 
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Figure 3.30 demonstrates that the control limb was also significantly different across 
heel wedge conditions regardless of AFO design. Post hoc analysis shows that this 
difference was found between W0 and W2, W1 and W3 and W0 and W3 with a two 
heel wedge difference being equivalent to approximately a 3% difference. These 
differences were again much larger across the AFO limb with a two wedge 
difference being equivalent to approximately a 10% difference (p<0.001). 
 
ANOVA: F Probability (Control) 0.167 
ANOVA: F Probability (AFO) <0.001 
 
Figure 3.27: Mean forefoot pressures (KPa) for control and AFO limb across B1 B2 
and B3, with ANOVA F probability  
 
Table 3.9: Post hoc analysis for Figure 3.27 showing the mean difference, upper and 
lower limits and p-value for each comparison  
AFO Limb Difference Lower Upper Significance 
B1 - B2 28.7 21.7 35.8 <0.001 
B1 - B3 16.5 9.5 23.6 <0.001 
B2 - B3    -12.2 -19.2 -5.1 <0.001 
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ANOVA: F Probability (Control) <0.001 
ANOVA: F Probability (AFO) <0.001 
 
Figure 3.28: Mean forefoot pressures (KPa) for control and AFO limb across heel 
wedge inserts, with ANOVA F probability  
 
Table 3.10: Post hoc analysis for Figure 3.28 showing the mean difference, upper and 
lower limits and p-value for each comparison  
AFO Limb Difference Lower Upper Significance 
0 - 1 -11.4 -19.3 -3.5 <0.001 
0 - 2 -17.0 -24.9 -9.1 <0.001 
0 - 3 -12.3 -20.2 -4.4 <0.001 
1 - 2 -5.6 -13.5 2.3 0.261 
1 - 3 -0.9 -8.8 7.0 0.990 
2 - 3 4.6 -3.3 12.5 0.423 
Control Limb        
0 - 1 1.7 -3.7 7.2 0.844 
0 - 2 4.1 -1.3 9.6 0.203 
0 - 3 10.4 5.0 15.9 <0.001 
1 - 2 2.4 -3.0 7.9 0.657 
1 - 3 8.7 3.3 14.2 <0.001 
2 - 3 6.3 0.9 11.8 0.016 
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ANOVA: F Probability (Control) 0.002 
ANOVA: F Probability (AFO) <0.001 
Figure 3.29: Mean terminal stance and pre-swing phase% for AFO and control limb 
across B1 B2 and B3, with ANOVA F probability  
 
 
Table 3.11: Post hoc analysis for Figure 3.29 showing the mean difference, upper and 
lower limits and p-value for each comparison  
AFO Limb Difference Lower Upper Significance 
B1 - B2 22.9 17.5 28.2 <0.001 
B1 - B3 13.4 13.4 24.0 <0.001 
B2 - B3    -4.2 -9.5 1.2 0.147 
Control Limb        
B1 - B2 -3.7 -6.1 -1.2 0.002 
B1 - B3 -2.8 -5.2 -0.4 0.020 
B2 - B3    0.9 -1.6 3.3 0.657 
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ANOVA: F Probability (Control) <0.001 
ANOVA: F Probability (AFO) <0.001 
Figure 3.30: Mean terminal stance and pre-swing phase% for control and AFO limb 
across number of heel wedge inserts, with ANOVA F probability  
 
Table 3.12: Post hoc analysis for Figure 3.30 showing the mean difference, upper and 
lower limits and p-value for each comparison  
AFO Limb Difference Lower Upper Significance 
0 - 1 -4.6 -10.2 0.9 0.135 
0 - 2 -11.3 -16.9 -5.8 <0.001 
0 - 3 -14.5 -20.0 -9.0 <0.001 
1 - 2 -6.7 -12.2 -1.2 0.011 
1 - 3 -9.9 -15.4 -4.3 <0.001 
2 - 3 -3.2 -8.7 2.4 0.447 
Control Limb        
0 - 1 1.1 -1.2 3.3 0.616 
0 - 2 2.9 0.7 5.2 0.005 
0 - 3 4.4 2.1 6.6 <0.001 
1 - 2 1.9 -0.4 4.1 0.136 
1 - 3 3.3 1.0 5.6 <0.001 
2 - 3 1.4 -0.8 3.7 0.366 
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3.2.4 Trial conditions: analysis of AFO limb as a proportion of the control limb 
This section presents the analysis of raw values recorded for the control limb as a 
proportion of the AFO limb across AFO design, regardless of the number of heel 
wedge inserts and conversely, number of heel wedge inserts regardless of AFO 
design. This section will analyse the AFO limb heel pressure, forefoot pressures and 
amount of time spent in terminal stance and pre-swing phases as a proportion of the 
control limb. 
 
For the analysis to be valid, the data should follow a normal distribution and have 
some variance throughout the range. It is assumed that the relationships which are 
modelled are linear. However this is an assumption, therefore to ensure normal 
distribution of the ratio data, the data set was log transformed for analysis purposes. 
Once analysed the data was then back transformed to allow the actual figures to be 
presented in the following charts and tables to allow evaluation of clinical relevance 
of the statistical significance112. The equation used to back transform the analysed 
data was: 100 x EXP (Value). 
 
Figure 3.31 shows the heel pressure (red bar) forefoot pressure (green bar) and 
terminal stance and pre-swing phase as proportion of the total stance phase (blue 
bar) for the AFO limb as a proportion of the control limb. Therefore 0% indicates no 
difference between the control limb and AFO limb. A positive percentage indicates a 
larger value within the AFO limb when compared to the control limb and a negative 
percentage indicates a larger value within the control limb. 
 
Across AFO designs all measured parameters were statistically significant. Post hoc 
analysis showed that when assessing the terminal stance and pre-swing phases of 
the gait cycle the significant differences lay between the comparisons of the rigid 
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rocker bottom AFO (B1) when compared to the two dorsum carbon fibre AFOs. The 
same pattern occurs for forefoot pressures with larger differences between B1 when 
compared to B2 and B3 and a smaller (but still significant) difference between B2 
and B3. Heel pressures were significantly higher in the AFO limb for B1 compared 
to B2 and B3. The largest difference was found between B1 and B2. B2 was the 
only AFO to produce heel pressures lower than the control limb. 
 
 
Figure 3.32 shows the same proportional data across the number of heel wedge 
inserts. There is a clear trend that the amount of time spent in the terminal stance 
and pre-swing phases of the gait cycle increases, to match that of the control limb, 
as the number of heel wedge inserts decreases. Post hoc analysis also shows that 
these differences are statistically significant, with deficits of 56% with W3 when 
compared to the control limb. Figure 3.32 also shows that with decreasing heel 
wedge inserts, heel pressures decrease and forefoot pressures increase. These 
differences are statistically significant with forefoot deficits of 28% between W0 and 
W3 and heel pressures 24% greater than the control limb at W3 compared to W0 
decreasing to 2% between W0 and W1. 
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ANOVA: F Probability (Terminal Stance) <0.001 
ANOVA: F Probability (Forefoot) <0.001 
ANOVA: F Probability (Heel) <0.001 
 
Figure 3.31: Mean % difference between control and AFO limb across B1 B2 and B3, 
with ANOVA F probability  
 
Table 3.13: Post hoc analysis for Figure 3.31 showing the mean difference, upper and 
lower limits and p-value for each comparison  
Terminal 
Stance 
% Difference Lower Upper Significance 
B1 - B2 72.2 58.1  81.6 <0.001 
B1 - B3 69.2 53.5  79.6 <0.001 
B2 - B3    -10.9 -67.3 26.5 0.807 
Forefoot         
B1 - B2 59.3 43.6 76.8 <0.001 
B1 - B3 35.1 21.7 50.0 <0.001 
B2 - B3    -15.2 -23.6 -5.9 0.002 
Heel         
B1 - B2 -33.2 -40.7 -24.8 0.000* 
B1 - B3 -18.4 -27.5 -8.0 0.001* 
B2 - B3    22.2 8.5 37.7 0.001* 
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ANOVA: F Probability (Terminal Stance) <0.001 
ANOVA: F Probability (Forefoot) <0.001 
ANOVA: F Probability (Heel) <0.001 
 
Figure 3.32: Mean % difference between control and AFO limb across number of heel 
wedge inserts, with ANOVA F probability  
 
Table 3.14: Post hoc analysis for Figure 3.32 showing the mean difference, upper and 
lower limits and p-value for each comparison  
Terminal Stance % Difference Lower Upper Significance 
0 - 1 -12.0 -43.3 36.7 0.875 
0 - 2 -43.3 -63.5 -11.9 0.006 
0 - 3 -56.3 -71.8 -32.0 <0.001 
1 - 2 -35.6 -58.5 0.1 0.051 
1 - 3 -50.3 -68.0 -22.8 <0.001 
2 - 3 -22.9 -50.4 19.8 0.419 
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Forefoot % Difference Lower Upper Significance 
0 - 1 -16.0 -24.6 -6.3 <0.001 
0 - 2 -25.6 -33.3 -17.1 <0.001 
0 - 3 -28.8 -36.1 -20.7 <0.001 
1 - 2 -11.5 -20.6 -1.3 0.021 
1 - 3 -15.3 -24.0 -5.6 <0.001 
2 - 3 -4.3 -14.1 6.7 0.718 
Heel         
0 - 1 2.3 -9.1 15.2 0.957 
0 - 2 17.4 4.2 32.2 0.003 
0 - 3 24.0 10.1 39.6 <0.001 
1 - 2 14.7 1.9 29.1 0.017 
1 - 3 21.2 7.6 36.4 <0.001 
2 - 3 
5.7 -6.2 19.0 0.622 
3.2.5 Trial conditions: analysis of AFO and heel wedge interaction 
The first sub-chapter of this results section has assessed the control data only. The 
second part of the results section has evaluated the raw values of the AFO limb 
compared to the control limb and the third part has assessed these raw values as a 
proportion of each other. So far this has been carried out on the AFO design 
regardless of the number of heel wedge inserts and secondly on the number of heel 
wedge inserts regardless of the AFO design. This section will explore the 
‘interaction’ between the individual AFO designs combined with W0, W1, W2 and 
W3. The next three figures demonstrate the AFO and heel wedge interaction for the 
pre-defined gait parameters for B1, B2 and B3 respectively. 
Table 3.15: Analysis of variance results for the interaction between AFO design and 
heel wedge number 
 
ANOVA: F Probability (Terminal Stance) <0.001 
ANOVA: F Probability (Forefoot) 0.029 
ANOVA: F Probability (Heel) 0.002 
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Figure 3.33 clearly demonstrates that within B1, recorded heel pressures are 
highest with W3. This figure decreases with decreasing heel wedge inserts, to that 
of the control limb with no W0 (A statistically significant difference of 61% between 
W0 and W3). The reverse of this pattern is seen with forefoot pressures and the 
amount of time spent in terminal stance and pre-swing phases of the gait cycle. 
Deficits in forefoot pressures compared to the control limb are seen throughout W3 
to W0 with statistical significance between two heel wedges (i.e. W0 and W2, W1 
and W3). The pattern of increasing amount of time spent in terminal stance and pre-
swing phase of the gait cycle with decreasing heel wedge inserts is also statistically 
significant across pair wise comparisons, except between W0 and W1 and W2 and 
W3. There were no differences in forefoot pressures and terminal stance phase 
duration between W0 and W1 indicating that the foot can be placed in a small 
amount of PF without detrimental reduction within these gait parameters.  
 
From Figure 3.34 and Table 3.17, it is evident that within B2 the values for all three 
gait parameters change significantly between W3, W2 and W1. With no heel wedge 
inserts, forefoot pressures are significantly increased compared to W1, W2 and W3, 
however, this is the only statistically significant difference. 
 
From Figure 3.35 and Table 3.18 it is evident that the values for heel pressures and 
terminal stance phase of the gait cycle do not significantly change between heel 
wedge conditions, however forefoot pressures do. They follow the same pattern as 
B1 regarding lower pressures being recorded in comparison to the control limb at 
W3 and gradually increasing towards W0.  
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Figure 3.33: Mean % difference between control and AFO limb for gait parameters 
across B1 with all heel wedge conditions 
 
Table 3.16: Post hoc analysis for Figure 3.33 showing the mean difference, upper and 
lower limits and p-value for each comparison 
Terminal Stance B1 % Difference Lower Upper Significance 
0 - 1 -18.6 -62.1 74.5 0.896 
0 - 2 -72.8 -87.3 -41.6 <0.001 
0 - 3 -85.1 -93.1 -68.1 <0.001 
1 - 2 -66.5 -84.4 -28.2 0.002 
1 - 3 -81.7 -91.5 -60.8 <0.001 
2 - 3 -45.4 -74.6 17.0 0.170 
Forefoot B1         
0 - 1 -12.6 -27.6 5.5 0.250 
0 - 2 -26.7 -39.3 -11.5 <0.001 
0 - 3 -33.2 -44.6 -19.3 <0.001 
1 - 2 -16.1 -30.5 1.2 0.076 
1 - 3 -23.5 -36.7 -7.7 0.002 
2 - 3 -8.8 -24.5 10.0 0.577 
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Heel B1 % Difference Lower Upper Significance 
0 - 1 22.9 0.1 50.9 0.049 
0 - 2 50.2 22.3 84.4 <0.001 
0 - 3 61.7 31.7 98.6 <0.001 
1 - 2 22.2 -0.5 50.1 0.058 
1 - 3 31.6 7.2 61.6 0.004 
2 - 3 7.7 -12.3 32.3 0.784 
 
 
Figure 3.34: Mean % difference between control and AFO limb for gait parameters 
across B2 with all heel wedge conditions 
 
Table 3.17: Post hoc analysis for Figure 3.34 showing the mean, upper and lower 
limits and p-value for each comparison 
Terminal Stance B2 % Difference Lower Upper Significance 
0 - 1 -11.1 -58.6 90.5 0.978 
0 - 2 -18.1 -61.8 75.6 0.904 
0 - 3 -21.9 -63.6 67.5 0.834 
1 - 2 -7.8 -57.0 97.7 0.992 
1 - 3 -12.1 -59.0 88.5 0.972 
2 - 3 -4.6 -55.5 104.6 0.999 
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Forefoot B2 % Difference Lower Upper Significance 
0 - 1 -18.2 -32.2 -1.2 0.032 
0 - 2 -17.1 -31.4 0.0 0.050 
0 - 3 -16.1 -30.5 1.3 0.078 
1 - 2 1.2 -16.1 22.2 0.998 
1 - 3 2.6 -15.0 23.8 0.985 
2 - 3 1.3 -16.1 22.3 0.998 
Heel B2 % Difference Lower Upper Significance 
0 - 1 -10.1 -26.8 10.4 0.531 
0 - 2 6.8 -13.0 31.2 0.838 
0 - 3 5.7 -13.9 29.8 0.897 
1 - 2 18.8 -3.2 45.9 0.133 
1 - 3 17.6 -4.3 44.4 0.174 
2 - 3 -1.0 -19.4 21.5 0.999 
 
 
 
Figure 3.35: Mean % difference between control and AFO limb for gait parameters 
across B3 with all heel wedge conditions 
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Table 3.18: Post hoc analysis for Figure 3.35 showing the mean difference, upper and 
lower limits and p-value for each comparison 
Terminal Stance B3 % Difference Lower Upper Significance 
0 - 1 -5.7 -56.0 102.3 0.997 
0 - 2 -18.2 -61.8 75.5 0.903 
0 - 3 -27.9 -66.4 54.6 0.680 
1 - 2 -13.2 -59.5 86.1 0.962 
1 - 3 -23.6 -64.4 63.9 0.796 
2 - 3 -11.9 -58.9 88.9 0.973 
Forefoot B3        
0 - 1 -17.1 -31.3 0.1 0.051 
0 - 2 -32.3 -43.9 -18.2 <0.001 
0 - 3 -35.7 -46.7 -22.4 <0.001 
1 - 2 -18.3 -32.3 -1.4 0.030 
1 - 3 -22.5 -35.8 -6.4 0.003 
2 - 3 -5.1 -21.4 14.5 0.887 
Heel B3        
0 - 1 -2.9 -21.0 19.2 0.982 
0 - 2 0.8 -17.9 23.8 0.999 
0 - 3 11.6 -9.1 37.0 0.508 
1 - 2 3.9 -15.4 27.5 0.964 
1 - 3 15.0 -6.4 41.2 0.294 
2 - 3 10.7 -9.9 36.0 0.572 
 
3.2.6 Trial intervention: correlation analysis 
In addition to the two-way-analysis of variance and post hoc Tukey analysis, scatter 
plots for the measured gait parameters with Pearson Correlation Coefficients were 
evaluated to further explore potential relationships between the parameters. Table 
3.19 illustrates the pair wise correlations with significance values. 
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Table 3.19: Pearson correlation coefficients 
 
Paired Comparison 
 
Pearson 
correlation 
coefficient 
 
Significance 
% Difference forefoot pressure  & % difference 
heel pressure 
-0.36 <0.001 
% Difference forefoot pressure & % difference 
terminal stance phase 
0.71 <0.001 
% Difference forefoot pressure & plantar flexion -0.39 <0.001 
% Difference forefoot pressure & speed 
 
-0.23 0.002 
% Difference forefoot pressure & cadence 
 
0.18 0.016 
% Difference heel pressure & % difference 
terminal stance phase 
-0.64 <0.001 
% Difference heel pressure & plantar flexion 
 
0.37 <0.001 
% Difference heel pressure & speed 
 
0.01 0.877 
% Difference heel pressure & cadence 
 
-0.40 0.598 
% Difference terminal stance phase & speed 
 
-0.13 0.810 
% Difference terminal stance phase & plantar 
flexion 
-0.36 <0.001 
% Difference terminal stance phase & cadence 0.51 0.497 
Plantarflexion & speed 
 
0.01 0.866 
Plantarflexion & cadence 
 
-0.16 0.836 
Speed & cadence 
 
-0.72 <0.001 
Speed & dorsiflexion 
 
-0.03 0.672 
Cadence & dorsiflexion 
 
-0.02 0.781 
% Difference heel pressure & dorsiflexion 
 
-0.39 <0.001 
% Difference terminal stance phase & 
dorsiflexion 
0.45 <0.001 
% Difference forefoot & dorsiflexion 
 
0.45 <0.001 
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Figure 3.36 through to Figure 3.40 demonstrate the relationship between ROM, heel 
pressure, forefoot pressure, terminal stance phase, speed and cadence. The gait 
parameters were analysed as the percentage increase or decrease compared to the 
control limb. Figure 3.36 and Figure 3.38 show that as the amount of permitted DF 
increases, so does the amount of forefoot pressure and amount of time spent in the 
terminal stance phase within the AFO limb when compared to the control limb (p < 
0.001). The scatter plots also show a reverse pattern for PF, regarding the two gait 
parameters. Therefore, as the foot is maintained in increased PF, forefoot pressures 
within the AFO limb decrease and the amount of time spent in terminal stance also 
decreases (p < 0.001).  
 
Figure 3.37 further demonstrates the relationship between pressure and ROM 
showing that as the foot is maintained in PF, heel pressures increase and as the 
foot is allowed into DF, heel pressures reduce to those equal to the control limb (p < 
0.001). There were, however, no significant correlations found between permitted 
ROM, speed and cadence as Figure 3.39, Figure 3.40 and Table 3.19 show. 
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Figure 3.36: Scatter plot of % difference in forefoot pressure against ROM (degrees) 
within the AFO 
 
Figure 3.37: Scatter plot of % difference in heel pressure against ROM (degrees) 
within the AFO   
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Figure 3.38: Scatter plot of % difference in terminal stance phase and ROM (degrees) 
within the AFO 
 
Figure 3.39: Scatter plot of speed (metres/second) and ROM (degrees) within the AFO 
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Figure 3.40: Scatter plot of cadence (steps/minute) and ROM (degrees) within the AFO 
 
The next correlations from Figure 3.41 to Figure 3.43 demonstrate the correlation 
between heel pressure, forefoot pressure and terminal stance phase independent of 
permitted range of movement. As the first scatter plots have suggested, there is a 
significant correlation between these parameters. As heel pressures increase above 
those recorded for the control limb, forefoot pressures decrease in comparison and 
so does the amount of time spent in terminal stance and pre-swing phases of the 
gait cycle. 
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Figure 3.41: Scatter plot of % difference in heel pressure and forefoot pressure within 
the AFO 
 
Figure 3.42: Scatter plot of % difference in heel pressure and terminal stance phase 
within the AFO 
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Figure 3.43: Scatter plot of % difference in forefoot pressure and terminal stance 
duration within the AFO 
 
The correlations between speed, cadence and amount of time spent within the 
terminal stance phase of gait were then analysed. Figure 3.44 and Figure 3.45 
illustrate no correlation between the parameters. There were also no significant 
correlations found between heel pressure, speed and cadence (Figure 3.49 and 
Figure 3.50). However, a significant correlation was found between forefoot 
pressures, speed and cadence (Figure 3.47 and Figure 3.48). As speed increased, 
forefoot pressure decreased and cadence decreased. There was also a significant 
correlation found between speed and cadence (Figure 3.46).  
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Figure 3.44: Scatter plot of speed (metres/second) and % difference in terminal stance 
within the AFO 
 
Figure 3.45: Scatter plot of cadence (steps/minute) and % difference in terminal 
stance phase within the AFO 
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Figure 3.46: Scatter plot of cadence (steps/minute) and speed (metres/second) within 
the AFO 
 
Figure 3.47: Scatter plot of speed (metres/second) and % difference in forefoot 
pressure within the AFO 
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Figure 3.48: Scatter plot % difference in forefoot pressure and cadence (steps/minute) 
within the AFO 
 
Figure 3.49: Scatter plot of speed (metres/second) and % difference in heel pressure 
within the AFO 
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Figure 3.50: Scatter plot % difference in heel pressure and cadence (steps/minute) 
within the AFO 
 
3.3 Discussion 
The first aim of this study was to investigate plantar pressure distributions of the foot 
and temporal gait parameters under different pre-defined conditions within 
participants with no previous lower limb injuries. The second aim of this chapter was 
to draw inferences from these measurements to the application of TA rupture 
rehabilitation.  
 
The discussion of this study will firstly focus on the null hypotheses in relation to the 
analysis and results. This will then be followed by an explanation of the possible 
mechanisms for these findings, within the context of previous literature. These 
concepts will then be discussed in relation to the application of TA rupture 
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rehabilitation and the clinical implications. Finally, the limitations of this study will be 
outlined alongside the methods which were used to minimise these. 
 
3.3.1 Null hypothesis: there is no effect of the trialled AFOs on gait parameters  
The first hypothesis was that the population means of the three AFOs (B1, B2 and 
B3) were equal regarding plantar pressure distributions and temporal gait 
parameters within healthy participants. This hypothesis was true for the 
measurement of speed only, which did not differ between AFO designs (p >0.05). 
Range of movement, cadence, heel pressures, forefoot pressures and the amount 
of time spent in terminal stance and pre-swing phase of the gait cycle were 
significantly different between AFO designs (p <0.05). 
 
For the measurement of ankle ROM there was a mean difference of eight degrees 
of DF between B1 (rigid rocker bottom style AFO) and B2 (AFO dynamic) across all 
conditions evaluated. This shows that B1 is very restrictive regarding movement and 
B2 is the opposite, being within normal limits when compared to the ‘normal’ data. 
B3 (ToeOff AFO) was not significantly different from either B2 or B1 (mean 
difference of approximately four degrees less than B2 and four degrees more than 
B1). 
 
This is an important observation because permitted movement was also found to be 
strongly correlated to the production of forefoot pressures within the AFOs. As DF 
was restricted, so was the capacity to load the forefoot. This correlation was 
inversely related to heel pressures, which were increased with decreased forefoot 
pressure production (Figure 3.36, Figure 3.37 and Figure 3.41). Range of 
movement was also correlated with the third gait parameter evaluated, amount of 
time spent in terminal stance and pre-swing phase as a proportion of the total 
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stance phase. As the amount of permitted DF was increased, so was the amount of 
time spent in this phase of the gait cycle, as a proportion of the stance phase. This 
finding also correlated inversely to heel pressure measurements (Figure 3.38, 
Figure 3.42 and Figure 3.43). Therefore these four parameters were significantly 
interlinked. 
 
These trends were also reflected within the analysed raw values for the AFO limb 
and control limb (Chapter 3.2.3). The data clearly demonstrates that B1 (rigid rocker 
bottom AFO), which restricts DF the most, also has much higher heel pressures 
than the control limb, lower forefoot pressures and a decreased amount of time 
spent in terminal stance and pre-swing phase of the gait cycle as a proportion of the 
total stance phase. 
 
Chapter 3.2.4 shows the analysis of the data of the AFO limb as a proportion of the 
control limb. Again the largest differences were found between B1 (rigid rocker 
bottom AFO) when compared to the two dorsum carbon fibre AFOs, B2 and B3. The 
B1 AFO design, across all conditions, had on average approximately 70% less time 
spent within the terminal stance and pre-swing phase of the gait cycle, 20% less 
forefoot pressures compared to the control limb and 40% greater heel pressures. 
This is in contrast to the dorsum carbon fibre AFO’s (B2 and B3), of which B3 
(ToeOff AFO) demonstrated values proportionally closer to the control limb, and this 
was a statistically significant difference from the B2 AFO. 
 
3.3.2 Null hypothesis: there is no effect of different PF levels on gait parameters 
The second hypothesis assessed was that the population means of four differing 
maintained PF levels were equal regarding plantar pressure distributions and 
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temporal gait parameters within healthy participants. This null hypothesis was 
rejected in relation to all pre-defined measured gait parameters.  
 
Firstly, speed was found to be statistically significant when three heel wedge inserts 
were compared to two, one and none, respectively. However, the largest difference, 
between three and one heel wedge insert, was a difference of only 0.079 
metres/second and this was not affected by AFO design.  
 
Secondly, ROM was found to be statistically significant between each heel wedge 
condition, with the range of DF increasing with decreasing heel wedges used. As 
previously highlighted, this is significantly correlated with forefoot pressures, heel 
pressures and the amount of time spent in terminal stance and pre-swing phase of 
the gait cycle. Table 3.3 clearly demonstrates how DF increases with decreasing 
heel wedge inserts and PF decreases with a decreasing number of heel wedge 
inserts. 
 
As with the data analysing AFO design regardless of the number of heel wedge 
inserts, the raw values analysing heel wedge inserts regardless of AFO design, 
follow the same patterns associated with ROM. Consequently, Figure 3.26 shows 
how heel pressure decreases with decreasing heel wedge number. Figure 3.28 and 
Figure 3.30 show how forefoot pressures and the amount of time spent in terminal 
stance and pre-swing phase increase with decreasing heel wedge number. 
 
When this data was analysed as a proportion of the control limb (Figure 3.32) the 
same patterns presented consistently. Post hoc analysis showed that within heel 
pressures and forefoot pressures, these differences were not significant between 
three and two heel wedge inserts but were for all other comparisons, except one, 
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and no heel wedge inserts for heel pressures. Between individual wedges, the 
largest difference was observed when participant’s heel wedges were changed from 
two to one (15% mean difference in heel pressures and 11% mean difference in 
forefoot pressures). This was also the largest difference between individual heel 
wedge conditions within the amount of time spent in terminal stance and pre-swing 
phase (35% difference). 
 
3.3.3 Null hypothesis: there is interaction effect on gait parameters 
The above data supports statistically significant differences between both AFO 
designs and the number of inserted heel wedges used. The final null hypothesis 
stated that there were no interactions between the above two factors (AFO design 
and inserted heel wedge number) regarding plantar pressure distributions and 
temporal gait parameters within healthy participants. This analysis is demonstrated 
graphically by Figure 3.33 through to Figure 3.35.  
 
Within all three AFO designs the amount of time spent in terminal stance and pre-
swing phase of the gait cycle was highest with no heel wedge inserts and lowest 
with three heel wedge inserts. However, across B1 (rigid rocker bottom AFO) this 
difference remained below the value of the control limb throughout, whereas for B3 
(ToeOff AFO) this begins below the value for the control limb rises above it with one 
and no heel wedge inserts, whereas within B2 (AFO Dynamic) this value was never 
below that of the control limb.  
 
Forefoot pressure differences between the number of inserted heel wedges follow 
the same trends for B1 (rigid rocker bottom AFO) and B3 (ToeOff AFO), reaching 
statistical significance. However, B2 (AFO Dynamic) did not follow this trend for 
forefoot pressures. Instead, there are minimal differences between changing from 
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three to two to one heel wedge insert, with only 1-2% difference between them, all 
higher than the control limb. This then rises by 18% when changed from one to no 
heel wedge inserts.  
 
Finally, heel pressures again follow similar trends described previously for B1(rigid 
rocker bottom AFO) and B3(ToeOff AFO). However, for B3 the difference between 
heel wedges is only small and does not reach statistical significance. Whereas 
within the B1, AFO heel pressures are much higher than the control limb with three 
heel wedge inserts gradually reaching values equivalent to the control limb with no 
heel wedge inserts. These values are significant between a two wedge difference. 
For B2 (AFO Dynamic) heel pressures were consistently below those recorded for 
the control limb and were not significantly different from each other. 
 
3.3.4 Theoretical concepts and previous literature in relation to study findings 
The purpose of tendons is to transmit muscular force to bone and in doing so allow 
the limb to move2. More specifically, the TA connects the gastrocnemius and soleus 
muscles to the posterior aspect of the calcaneus to permit transmission of 
plantarflexion torque, during the terminal stance and pre-swing phases of the gait 
cycle110-111. During this phase of the gait cycle the triceps surae works eccentrically 
to prevent the tibia rotating forwards over the talus resulting in forces equivalent to 
2.4 times of an individuals’ body weight being applied through the TA107,111. The 
degree of loading is dependent on a combination of permitted ROM at the ankle and 
contractile activity of the triceps surae83. 
 
Within healthy participants, Akizuki et al83 demonstrated these mechanisms in 
practice. They found that by increasing the amount of PF the ankle is positioned in 
(using heel wedge inserts), whilst restricting DF, plantarflexion torque was reduced. 
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However, the design of this study was not randomised and only two heel wedge 
conditions were tested within a single rigid AFO design.  
 
In contrast, Frőberg et al104 tested the same hypothesis, that restricting DF is 
associated with decreased triceps surae activity, but found the opposite to Akizuki et 
al83. The reason for the two opposite results is that the second study allowed IWB, 
but without heel wedge inserts. Instead participants were mobilising on the forefoot 
only, therefore although DF was restricted the full force required for walking was 
being transmitted though the forefoot. Whereas, the first study was achieving the 
opposite effect by using heel wedge inserts and subsequently preventing forefoot 
load. 
 
A third study evaluating a more flexible AFO design with one heel wedge 
condition107 found minimal differences between mean vertical ground reaction forces 
between normal walking and walking with a single heel wedge. However, the results 
of this study are questionable as they only used four healthy participants, the trials 
were not randomised and no details were provided regarding the analysis of gait 
data or methods of statistical analysis.  
 
There have been no studies evaluating the effect of different AFO designs within 
healthy participants throughout a range of heel wedge conditions. Furthermore the 
small numbers of studies that have evaluated heel wedge conditions within a single 
AFO design have not been randomised, have used small samples, with no 
justification of this decision and evaluated a limited range of heel wedge conditions.  
 
This study implemented an experimental design, using randomisation to account for 
known confounding factors such as learning effects and fatigue and unknown 
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confounding factors. The results of this study show that B1 (rigid rocker bottom 
AFO) imposed a greater degree of DF restriction when compared to the two dorsum 
carbon fibre AFO’s (B2 and B3). This led to decreased forefoot pressures and 
subsequent increased heel pressures. These relationships are demonstrated within 
the scatter plots and accompanying Pearson correlation coefficients within the 
results section. They show that decreasing forefoot pressures and restricting DF 
lead to a statistically significant correlated decrease in the terminal stance phase of 
the gait cycle.  
 
These findings are in keeping with the study by Akizuki et al 83 and the 
biomechanics of tendon loading outlined earlier. This is because if DF is restricted, 
the TA is unable to transfer forces from the heel to the forefoot, as the tibia is unable 
to rotate forwards. Subsequently, the terminal stance phase of the gait cycle is 
reduced because there is limited transmission of load to the forefoot. 
 
Within the dorsum carbon fibre designs (B2 and B3) the same principles can be 
applied. B2 (AFO Dynamic) was the opposite of B1 (rigid rocker bottom AFO), in 
that it permitted a statistically significant greater degree of DF. Therefore, when the 
interaction between heel wedges and AFO design were analysed, there were no 
significant effects regardless of the number of heel wedge inserts because the AFO 
did not restrict movement. Whereas B3 (ToeOFF AFO) was found to be not 
significantly different from B1 or B2. This is apparent within the results 
demonstrating the heel wedge and AFO interaction which gradually allows 
increased production of forefoot pressures with decreasing number of heel wedge 
inserts. This is accompanied by a gradually increasing amount of time within the 
terminal stance phase of the gait cycle and decreasing amount of heel pressures. 
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The changes in heel wedge number did not produce equal differences. For both B1 
(rigid rocker bottom) and B3 (ToeOff AFO), the change from three heel wedges to 
two heel wedges produced only minimal differences across all three gait parameters 
(forefoot pressure, heel pressure and amount of time spent in terminal stance 
phase). However, the change from two to one heel wedge inserts was much greater 
(double the effect of three to two heel wedges, across all gait parameters). A 
possible explanation for this can be hypothesised from Table 3.4. This shows that 
between three and two heel wedge inserts, DF is restricted to neutral, whereas 
between two and one heel wedge inserts some movement into DF is permitted, 
therefore allowing some forefoot loading and increasing the amount of time spent in 
terminal stance and pre-swing phases of the gait cycle. 
 
3.3.5 Application of study findings to Achilles tendon rupture rehabilitation 
Rehabilitation after a TA rupture is prolonged, with reports of plantar flexor strength 
deficits between limbs still evident two years post rupture, and only 50-60% of 
patients returning to previous sporting levels110. One of the key factors limiting 
recovery is an abnormality of gait, which is not surprising given the relevance of the 
triceps surae muscle function during the gait cycle111,116. Development of clinical gait 
analysis and assessment of kinetic and kinematics parameters are becoming more 
valuable in clinical decision making, partly due to advancements in technology, 
resulting in more accurate analysis117.  
 
If a ruptured TA is not clinically managed immediately following the injury (within 2 
weeks) the two ends of the ruptured tendon retract and there is a fibrous tissue in-
growth, which fills the previously palpable gap between the two tendon ends. 
Therefore, if unmanaged, a ruptured TA will heal118. However, this results in gross 
tendon lengthening, which has severe functional consequences119. Therefore the 
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first characteristic of an AFO to be used within clinical practice needs to restrict the 
amount of permitted DF, specifically within the immediate phase following the injury. 
This criteria was not met by the B2 AFO (AFO Dynamic). 
 
In addition to preventing gross tendon lengthening, commonly seen within late 
presentations, controversy also exists regarding the development of ‘gap formation’ 
during the early healing phases. This is thought to be secondary to constant cyclic 
loading during weight bearing rehabilitation, subsequently pulling the two tendon 
ends apart20,85.  
 
The phases of tendon healing can be divided into inflammation (first week), 
proliferation (weeks 2-8) and remodelling (up to 12 months)120. Throughout these 
phases, the tendon’s tensile strength gradually increases, but remains inferior to the 
uninjured tissue. This is because the properties of the newly formed scar tissue are 
biomechanically inferior, displaying increased stiffness and subsequently decreased 
visco-elastic properties2. Some authors therefore believe that limiting gap formation, 
and subsequently the amount of the inferior scar tissue is of the up-most 
importance20,41. 
 
The clinical implications of this study demonstrate that the B1 AFO (rigid rocker 
bottom) with three heel wedge inserts provides the greatest restriction to DF and 
keeps the foot in the up-most PF. Consequently, this AFO could offer a theoretical 
decrease in the risk of developing ‘gap formation’. Some literature would suggest 
that the practice of using a rigid support in a high degree of PF is the safest and 
most effective form of rehabilitation. Indeed, this has been the preferred method 
within my own department, due to its close representation to ‘traditional’ casting. 
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This very rigid approach is not however without problematic consequences. Animal 
studies have consistently demonstrated that allowing early protected loaded 
movement increases the biomechanical properties of the scar tissue, decreases 
excessive adhesion formation and subsequently enhances the gliding function of 
the tendon85. Further literature has also demonstrated that exact end-to-end 
opposition of a ruptured tendon, achieved by surgery, is no different in its bio-
mechanical properties at two weeks compared to tendon ends not in exact end-to-
end opposition using non-operative functional bracing in a rat model121. Therefore, 
the relevance of a small degree of tendon gapping is questionable.  
 
In addition to the considerations of the effects of rigid mobilisation on tendon 
healing, there is also the consideration of the effects on the gait cycle. This study 
showed that the B1 AFO (rigid rocker bottom) consistently demonstrated increased 
heel pressures, over 50% more than those recorded for the control limb, large 
forefoot pressure deficits and a decrease in time spent in the terminal stance and 
pre-swing phase of the gait cycle. The consequence of this is potential development 
of heel pad pain, secondary to the increase in heel pressures, disuse atrophy of the 
triceps surae, secondary to decreased forefoot loading and decreased time spent in 
the terminal stance phase of the gait cycle.  
 
These same observations have also been seen in clinical practice following cast 
immobilisation or a combination of immobilisation and functional bracing, following a 
TA rupture113,122-123. Previous research has also reported decreased forefoot 
pressures, increased heel pressures and decreased push off time. These were 
recorded from two weeks post cast removal, up to 24 months. This highlights how 
the problem is not just during the AFO wearing phase, but persists into the midterm. 
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Therefore, the B1 AFO design (rigid rocker bottom) with three heel wedge inserts, 
although the most restrictive combination, may not be the most appropriate for the 
rehabilitation of TA ruptures. The B2 AFO (AFO Dynamic), with no heel wedge 
inserts, is at the other extreme. Although this AFO design demonstrates normal gait 
parameters, it does so without restriction of movement. The clinician is therefore 
ultimately faced with the dilemma of preventing disuse atrophy, within the limits of 
permitted ankle movement that will protect the tendon from gapping at the repair 
site whilst minimising adhesions. 
 
A further consideration to the application of these results to clinical practice is the 
problem associated with tendon re-ruptures in combination with the previous 
factors39. It is known that WB during the early phases of healing stimulates fibroblast 
activity and type III collagen synthesis 48. It is also known that full WB is clinically 
safe, not resulting in an increased re-rupture rate23. Furthermore, approximately 553 
Newtons are produced at the TA during normal walking83. But it is not known how 
much force is required to re-rupture a TA during, or even after, the early stages of 
healing. Therefore, the results of this study cannot make any assumptions regarding 
this factor. 
 
Consequently, the purpose of the AFO is to provide ‘protected’ WB that represents 
normal gait parameters, within the limits of decreased range of permitted 
movement. These criteria were not met by B1 (rigid rocker bottom AFO), which 
consistently produced forefoot pressure deficits compared to the control limb and 
increased heel pressures across three and two heel wedge insert conditions, but not 
one. The AFO design of B2 (AFO Dynamic) did not produce heel pressures over 
and above the control limb and forefoot pressures were consistently higher than the 
control limb, however this was achieved within minimal limits of movement. The B3 
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AFO design (ToeOff) began with high heel pressures and forefoot pressure deficits, 
but only in combination with three heel wedge inserts. These values then gradually 
returned to values equivalent to the control limb with two, one and no heel wedge 
inserts. Therefore the B3 AFO was capable of loading the forefoot within the 
restraints of DF, as it was not significantly different from B1. 
 
3.3.6 Trial summary, limitations and recommendations for future research 
In summary, this study is the largest and only randomised study to evaluate the 
effects of changing the heel wedge height and AFO design, for the rehabilitation of a 
TA rupture. However, as previous literature has demonstrated, there are many 
methods for evaluating gait parameters, of which plantar pressure measurements is 
only one. Furthermore, these results have limited external validity because they 
were assessed within healthy participants, rather than patients who have sustained 
the injury.  
 
This study has demonstrated significant differences within gait parameters for 
different AFO designs and the number of incorporated heel wedges. However, it is 
beyond the scope of this study to conclude if these findings will translate to a clinical 
setting within patients who have sustained this injury. Additionally, there is a 
balance that needs further investigation regarding the potential benefits of 
increasing movement and forefoot loading, against the potential complications 
(discussed previously), before gaining clinical acceptability. Finally, the results of 
this study cannot determine if differences within gait parameters will lead to 
improved patient reported functional outcome measures, or to what extent these 
differences will be.  
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Further research is required within the context of patient reported functional 
outcome measures and the practicalities of these changes in practice. In line with 
the MRC framework and the development of an intervention, this theoretical basis 
would be taken forward. Having completed a systematic review to define the 
components of an accelerated rehabilitation programme (Chapter 2) and developed 
a theoretical basis on which to direct developments (Chapter 3), the next steps 
involve piloting and feasibility studies of these components in practice. 
 
It is acknowledged that these next steps of piloting and feasibility will not answer the 
question regarding the ‘best’ rehabilitation method. This can only be achieved by an 
adequately powered randomised controlled trial comparing these different 
interventions. However, these next stages are imperative to test their acceptability in 
a clinical setting, estimating likely patient consent rates for future research, 
alongside expected loss to follow-up within this patient population and acquiring 
additional data on which to guide sample size calculations. Consequently, the next 
chapter of this thesis will focus on aspects of piloting and feasibility of these 
components within a clinical context. 
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4 Pilot Study: Immediate Weight Bearing Interventions in Practice 
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Abstract 
 
Background  
Following an Achilles tendon rupture there is evidence to support immediate weight 
bearing management. This management consists of two key interacting 
components. The first is the type of ankle foot orthoses to be worn and the second 
is the range of movement to be used within it. To determine what should be used 
healthy subject studies have investigated gait parameters on which to develop a 
theoretical framework. However, clinical studies are required to determine if these 
results will translate into practice. To inform a clinical study, a pilot study is required. 
 
Objectives 
The primary objective was to quantitatively evaluate trial processes to determine 
aspects of feasibility of future research; including patient recruitment, follow up rates 
and variability within a proposed primary outcome measure. 
 
The secondary objective was to trial the clinical processes of changing one 
component of an established rehabilitation programme. 
 
Methods 
Following local presentations, clinical teams consented to implementing a stepwise 
reduction in the number of heel wedge inserts, within the currently used rigid rocker 
bottom orthoses. Ethical approval was gained to evaluate three groups consisting of 
five consecutive patients with three initial heel wedge inserts, followed by a further 
five managed with two heel wedge inserts and a final five, managed with one heel 
wedge insert. All patients were reviewed every two weeks for twelve weeks and at 
six and nine months. At these time points the Disability Rating Index, Achilles 
tendon Total Rupture Score and EQ-5D questionnaires were collected, alongside in-
shoe gait analysis and clinical complications. 
 
Results 
The results of this study demonstrated a consistent referral rate of 2.5 patients per 
month; with low refusal rate (16 patients were eligible, of which one refused). There 
were 11 men and 4 women, aged 21 to 65 years. One patient was lost to follow-up. 
All three groups gradually returned to pre-injury functional scores by nine months 
and the standard deviation at this primary outcome point was 15 points within the 
Achilles tendon Total Rupture Score. There were four adverse events, two within 
the second consecutive group and two within the third consecutive group (two and 
one heel wedge inserts).  
 
Conclusions 
This feasibility phase has provided invaluable information on expected referral rates, 
loss to follow up and variability in outcome measures. These are all essential 
elements required for designing a definitive clinical trial. The secondary outcome of 
changing one component of the rehabilitation protocol did not pose any 
implementation challenges. 
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4.1 Protocol  
The functional impact of sustaining a TA rupture is prolonged, requiring extensive 
rehabilitation10. Chapter 2 highlighted that many facets of the rehabilitation of this 
injury still remain unknown. The key variations identified were the AFO design, the 
degree of permitted movement within the AFO and the amount of time the AFO is 
worn for.  
 
Experimental models have shown that allowing early movement in combination with 
early loading prevents detrimental alterations in muscle characteristics and 
favourably influences maturation of collagen48-49. In addition to these experimental 
models, investigations using human healthy subjects (including the work published 
from Chapter 3 of this thesis) provide a further theoretical framework on which to 
direct the development of clinical interventions for this injury. 
 
Identifying the evidence base and developing theory are important steps towards 
developing an intervention, as outlined by the MRC complex intervention 
framework64. However, at this point it is beyond the scope of this thesis to conclude 
if these findings will translate to a clinical setting within patients who have sustained 
this injury. This can only be achieved by an appropriately designed clinical study. 
 
The highest level of clinical study design is universally accepted as an RCT63. 
However, appropriately designed RCTs in an orthopaedic setting are both time and 
cost intensive. Recent examples of such trials include the Ankle Injury Management 
trial (AIM) and the Distal Radius Acute Facture Fixation Trial (DRAFFT)124. These 
have planned study periods of 5 and 4 years respectively, costing £2,260,183 and 
£1,432,708. Secondary to these associated timescales and costs with definitive 
clinical studies in orthopaedics, it is imperative to pilot procedures to assess how 
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they work in practice and ensure that estimated recruitment rates, loss to follow up 
and variance within outcome measures are acceptable, achievable and appropriate. 
 
4.1.1 Objectives and research questions 
The primary objective was to quantify patient recruitment rates, follow up rates and 
variability within a proposed primary outcome measure. This will address the 
following research questions: 
 
1. What is the throughput of eligible patients? 
2. What proportion of patients will be lost to follow-up at the primary outcome point? 
3. To inform a sample size, what is the standard deviation of the primary outcome 
measure at the primary outcome point? 
4. What percentages of administered Clinical Reporting Forms are completed? 
 
The secondary objective was to trial the clinical processes of changing one 
component of an established rehabilitation programme. This would address the 
following research questions: 
 
1. Are the rehabilitation protocols feasible in clinical practice? 
2. What proportion of patients complete the allocated rehabilitation protocols? 
 
4.1.2 Trial summary and trial flow diagram 
Following consultation with clinical teams there was a consensus that only one 
component of the established rehabilitation protocol should be evaluated using a 
stepwise approach. Consequently at this stage of piloting there was no change in 
AFO design or implementation of randomisation procedures.  
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Following this initial consultation period, all patients who presented with an acute TA 
rupture to the University Hospitals Coventry and Warwickshire NHS Trust fracture 
clinic, were potentially eligible to take part in this trial. The only eligibility criteria 
were that they had no other serious injuries to either lower limb or a previous history 
of tendon rupture. These broad eligibility criteria were used to ensure that the 
results of the study could be readily generalised to the wider population. 
 
All patients, whether treated operatively or non-operatively were then placed in the 
currently used rigid rocker bottom AFO for eight weeks. During this period of time 
heel wedges were inserted into the AFO to maintain the foot in a PF position. Within 
this study, the first five consecutive patients initially had three heel wedge inserts, 
the second five consecutive patients had two heel wedge inserts and finally a third 
consecutive group of patients had one heel wedge insert.  
  
Every two weeks, for twelve weeks, then at six and nine months, all participants 
returned to fracture clinic for routine clinical assessment. At these time points in-
shoe pressure sensors were used to collect gait parameters (using the same 
methods outlined in Chapter 3). In addition to these outcome measures, at baseline, 
two weeks, six weeks, three months, six months and nine months three patient 
reported outcome scores and complications were recorded (Figure 4.1). 
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Figure 4.1: Expected flow of participants 
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4.1.3 Eligibility, recruitment, allocation and consent 
This study had ethical approval from Coventry research ethics committee. All 
patients over 18 years presenting at the University Hospitals Coventry and 
Warwickshire NHS Trust fracture clinic, with a primary acute rupture of their TA, 
(within ten days of rupture) were eligible to take part. 
 
Patients presenting after ten days from injury or with a history of previous TA 
rupture were excluded because these are considered a separate population, with 
different management requirements. These differences in management are 
secondary to the quality of the tendon tissue and retraction of the tendon ends125. 
Patients who had other serious injuries to either lower limb that would alter the 
intervention and subsequent rehabilitation were also excluded116. This was in 
addition to patients who were unable to give informed consent or adhere to trial 
procedures, with explicit reasons documented and reported.  
 
If a patient taking part in the study sustained a contralateral rupture during the trial 
period the second rupture would not be included in the study because the result of 
this intervention would not be independent from the first intervention. 
 
Recruitment of participants took place within the fracture clinic setting at University 
Hospitals Coventry and Warwickshire NHS Trust. Each patient was initially treated 
in an equinus plaster cast (for their comfort) and then referred to the next clinic run 
by the principal investigator. These clinics took place once each week. The 
investigator then assessed eligibility of potential participants. 
 
A TA rupture was diagnosed by the researcher and then confirmed by the principal 
investigator by subjective history and physical examination, confirming a palpable 
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gap and a positive Thompson test126. Once clinical diagnosis and eligibility had been 
confirmed the patient was then presented with a patient information sheet (Appendix 
C) and was verbally informed of what the trial would involve. The patients were then 
given the opportunity to discuss any issues with the research team, their consultant, 
friends and family. 
 
After allowing sufficient time for the patient to consider their decision and ask 
questions about the trial, eligible and willing participants signed a consent form, 
approved by Coventry ethics committee (Appendix D). Prior to this a list of 
information to be covered before consent was obtained was checked to ensure that 
all essential information had been provided to the potential participant. Any eligible 
and unwilling participants were recorded and presented within the final report. Once 
eligible patients had consented to take part in the study they attended routine 
clinical follow up every two weeks for twelve weeks and then at six and nine 
months.  
 
Any new information during the trial that may have affected a participant’s 
willingness to take part was reviewed by me and my allocated supervisors. As 
necessary this information was communicated to all participants, and a revised 
consent form then completed as required. Participants were also advised that they 
could withdraw from the trial treatment, and/or whole trial at any time without 
prejudice. If participants withdrew from the trial treatment, they were followed up 
wherever possible and data collected as per protocol until the end of the trial. The 
only exception to this was when the participant had also explicitly withdrawn 
consent for follow up. 
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To ensure minimal loss to follow up, contact addresses, telephone numbers and 
email addresses were collected from participants. In the event of a patient not 
attending clinic, a system of reminders was instituted. The system included an initial 
phone call to reschedule the appointment. If contact was not possible by telephone 
after one week an email was sent along with a letter outlining the rescheduled 
appointment. If there was no contact within two weeks a further phone call was 
made to an alternative point of contact given by the participant at their initial 
consent. If no contact was made with the alternative contact a letter was sent to 
them. If there was no response from the participant, or their alternative point of 
contact, within these time frames they were recorded as lost to follow up. 
 
Following discussions with the clinical teams, allocation to the number of inserted 
heel wedges within the AFO was carried out in a consecutive manner, as opposed 
to randomisation. This allowed for a gradual reduction in heel wedge inserts across 
three consecutive groups. The implications from Chapter 3 being a greater degree 
of forefoot pressure production, a corresponding decrease in heel pressure 
production and an increase in the amount of time spent in the terminal stance and 
pre-swing phase of the gait cycle. As previously highlighted these changes in gait 
parameters need to be balanced against the potential clinical risks of re-rupture and 
tendon lengthening. 
 
The sample size for this study was too small to determine the ‘safety’ of the 
intervention. It was discussed amongst the teams that this would not be feasible to 
assess, secondary to the low incidence of re-ruptures and tendon lengthening. 
Consequently using such outcomes would require a large sample size, beyond the 
scope of a pilot sample. This same topic of using uncommon complications as 
outcome measures has also been recently highlighted within a multi-centre RCT, 
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comparing operative to non-operative management for TA ruptures32. However, 
adverse events would be monitored throughout, as detailed in chapter 4.1.6.  
 
Consequently the first stage of three consecutive groups would not evaluate the 
safety of the intervention or patient acceptability to be randomised to the different 
conditions. This first stage would allow evaluation of trial procedures, including the 
provision of data to later determine achievable recruitment rates, loss to follow up, 
sample size calculations and testing of clinical procedures. 
 
4.1.4 Sample size and intervention 
As discussed, ideally the participants’ would have been randomised to the different 
treatment groups, and a corresponding sample size would be calculated to 
sufficiently power the study. However at this stage of interventional development 
randomisation was not undertaken, to gain acceptance from the clinical team. 
Secondly the primary research questions at this stage are focussed on trial 
feasibility/procedures and currently there is no method for determining sample sizes 
for feasibility studies. Therefore a sample size of five for each group was chosen 
based on discussions with experts in the field in the hospital, and what was 
achievable within the given time constraints. 
 
Previous experience of providing a service for patients post TA rupture showed that 
two patients would be recruited per month. Therefore fifteen patients would require 
eight months to recruit. Within this population, with the above mechanisms in place 
for preventing loss to follow up it was expected that there would be less than 10% 
loss to follow up. 
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Once consent had been obtained from relevant participants the first consecutive 
group of five patients were placed within the rocker bottom AFO with three heel 
wedge inserts, which were reduced to two at two weeks, one at four weeks, none at 
six weeks and the AFO removed at eight weeks. Group two received two heel 
wedges, being reduced to one at four weeks, none at six weeks and the AFO 
removed at eight weeks. Group three received one heel wedge, being reduced to 
none at six weeks and the AFO removed at eight weeks.  
 
During the AFO wearing phase all patients were advised not to IWB without wearing 
their AFO. Furthermore all patients were advised to remove their AFO daily to 
perform ankle ROM exercises, as tolerated. Elevation of the injured limb was 
recommended intermittently throughout the day, to control swelling. At eight weeks 
all patients were referred for routine physiotherapy offered within the hospital, for 
which there is a standard guideline. All participants then continued to attend clinic at 
standard follow up time points of ten weeks, three, six and nine months. 
 
At baseline all pre-existing concomitant illnesses and medications were recorded in 
addition to specific questions regarding conditions and medications known to 
predispose to tendon rupture. These included specifically the presence of tendinosis 
(pain, swelling or thickening within the tendon), the use of fluroquinolone antibiotics, 
steroids, disease modifying anti-rheumatic drugs and diabetic medication9. 
Additionally patient demographics (age, height, weight, ethnic minority and gender) 
were recorded along with the date and mechanism of injury. This information was 
used to assess the baseline characteristics of the groups. 
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4.1.5 Outcome measures, method of assessment and analysis 
As discussed earlier, using uncommon complications such as re-rupture rate or 
tendon lengthening within a definitive study has been recently highlighted by a multi-
centre study as being ‘unfeasible’. However, in addition to the considerations given 
to sample size calculations, there is also the consideration of whether or not 
complications are the most appropriate outcome. 
 
The primary outcome of this piloting phase was a PROM. Such a measure would 
also be planned as the primary outcome within the design of a subsequent definitive 
RCT investigating an IWB intervention, following an acute TA rupture. This choice of 
primary outcome was chosen in contrast to clinical measures such as complication 
rates and quantification of gait parameters secondary to a combination of factors 
that have been outlined within the orthopaedic literature, and more recently the 
Department of Health’s 2009/10 operating framework56. These documents outline 
that ultimately the most important outcome is from the patient’s perspective. 
 
The primary outcome measure would ideally need to be disease specific to allow for 
greater discriminatory validity. The Achilles tendon Total Rupture score (ATRS) is 
the only such validated measure available for use with patients post TA rupture61, as 
discussed in more detail within Chapter 6. However, this outcome measure has only 
recently been published, and has only been validated within a Swedish population 
between the ages of 20-70 years. Therefore further data is required within a UK 
population across all age ranges before this may be appropriate to be used as a 
primary outcome measure. This score is therefore being collected as part of a wider 
validation study, outlined in Chapter 7, as part of this PhD thesis (Appendix E). 
With no validated disease specific PROMs to choose from the next most 
appropriate currently validated PROM for this population is the Disability Rating 
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Index (DRI)127, the reasons for this are discussed in greater detail within Chapter 6. 
Although not disease specific, it has been validated within an orthopaedic clinic 
setting for a range of orthopaedic presentations. It is a self-administered form with 
twelve questions regarding common physical activities, to which patients respond 
using a 100mm visual analogue scale. There are two anchor points ‘without difficulty 
= 0’ and ‘not at all = 100’. The twelve questions are subdivided into three broad 
categories; common basic activities of daily life, more demanding daily physical 
activities and work-related or more vigorous activities (Appendix F). This was asked 
in conjunction with a more generic quality of life measure (EQ-5D questionnaire)128.  
 
The EQ-5D is a standard instrument for use as a measure of health outcome. It is 
self-completed and comprises of five domains, mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression. These combined domains result in a single 
health index score; there are 243 possible health states, plus unconscious and 
death. The second part of the outcome is a visual analogue scale of 0-100 that asks 
participants to rate how good or bad their own health state is, no points being ‘worst 
imaginable health state’ and 100 being ‘best imaginable health state’. This outcome 
measure has been validated within an orthopaedic context and in a range of 
populations and languages (Appendix G). 
 
Within the study of healthy participants, outlined in Chapter 3, altering the number of 
heel wedge inserts had an effect on heel and forefoot pressures as well as the 
proportion of time spent in the terminal stance and pre-swing phase of the gait cycle 
as a proportion of the total stance phase. It was not known if these changes in 
planter pressure distribution would translate into clinical practice. Therefore 
measurement of in-shoe plantar pressures took place during each visit, using the 
same protocol outlined in Chapter 3 to provide important secondary observations. 
Page | 162  
 
As discussed in Chapter 3 the interventions being assessed will allow increased 
movement and potentially increased force production within the healing tendon. 
However, there is a balance between subjecting a healing tendon to enough 
stress/strain to promote the healing response (discussed in Chapter 1) and 
subjecting it to too much, resulting in complications. Expected serious adverse 
events commonly associated with TA rupture rehabilitation include re-rupture, 
tendon lengthening, adhesion, disturbed sensibility, keloid scarring and infection. 
These adverse events would be recorded and reported to the trial sponsor and 
ethics committee, in line with the trial protocol. 
 
The time points at which to record these outcomes was based on knowledge 
surrounding healing time frames, as well as routine practice follow up appointments. 
Patients were reviewed every two weeks for the first twelve weeks predominantly to 
screen for the development of any complications. Two further clinic appointments 
were then made at six and nine months, to review progress with return to activities 
of daily living; complications were also evaluated at these time points. Patient 
reported outcomes were collected at 2,6,12, 24 and 36 weeks to allow evaluation of 
functional recovery during both the acute and mid-term phases. At nine months 
patients have normally returned to previous levels of activity, therefore outcomes 
were not recorded beyond this time point129.  
 
The datasets were analysed using descriptive statistics only. No inferential 
statistical analysis was planned because no conclusions would be drawn between 
these three consecutive groups of patients, this would not be appropriate to the 
objectives of this study. 
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4.1.6 Adverse event management 
At each visit following initial consent procedures each patient was asked whether 
they had experienced any adverse events since their last visit. An adverse event 
was defined as any untoward medical occurrence in a clinical trial subject which 
does not necessarily have a causal relationship with the treatment. All adverse 
events were listed on the appropriate CRF for routine return to the central office 
(Appendix H). 
  
A serious adverse event (SAE) was defined as any untoward and unexpected 
medical occurrence that resulted in death, was life-threatening, required 
hospitalisation or the prolonging of existing hospitalisation, resulted in persistent or 
significant disability or incapacity, was a congenital anomaly or birth defect, any 
other important medical condition, which although not included in the above, may 
require medical or surgical intervention to prevent one of the outcomes listed, as per 
the Universities standard operating procedures. 
 
All SAEs events were entered onto the SAE reporting form. Once received by the 
principal investigator causality and expectedness was determined. Serious adverse 
events that were deemed to be unexpected and related to the trial were notified to 
the main Research Ethics Committee within 15 days for a non-life-threatening event 
and within seven days for a life-threatening event. All participants experiencing 
SAEs were followed up as per protocol until the end of the trial.  
 
4.1.7 End of trial 
The end of the trial was defined as the final visit to the clinic of the last participant. 
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4.1.8 Data management, statistical analysis and trial organisation 
The CRFs were designed in conjunction with the principal investigator (PhD 
supervisor, Mr Matthew Costa) and guidance from the trial’s statistician. All CRFs 
were also completed with the participant present and inputted and stored centrally. 
All CRFs can be found in Appendix H. 
 
All electronic patient-identifiable information was held on a secure, password-
protected database accessible only to essential personnel. Paper forms with 
patient-identifiable information were held in secure, locked filing cabinets within a 
restricted area of Warwick Medical School. Patients were identified by a code 
number only. Data was entered by the research physiotherapist onto the electronic 
database immediately following each research clinic.  
 
Direct access to source data/documents was required for trial related monitoring 
and analysis only.  All paper and electronic data will be retained for at least five 
years after completion of the trial. As part of my on-going PhD supervision, the 
supervisors had reviewed the protocol for this study and had received progress 
reports at their request. Accumulating data was monitored at frequent intervals to 
identify and facilitate the early remedial action of certain problems that may include 
recruitment, data collection and compliance. Yearly progress reports were also 
submitted to the funders of this project (Arthritis Research UK), as outlined in the 
terms and conditions of the awarded grant.  
 
The day to day management of this project was overseen by the PhD supervisors. 
There was standard NHS cover for negligent harm in place. There was no cover for 
non-negligent harm. Insurance was in place until 31/07/10 and renewed 
accordingly. Ethical and research and development approvals were in place. 
Page | 165  
 
Additionally a contract was in place with the University of Warwick and an honorary 
contract for research services with the University Hospitals Coventry and 
Warwickshire NHS Trust. 
 
The principal investigator was Mr Matthew Costa, who had undertaken relevant 
mandatory training in GCP and the University of Warwick ‘Chief Investigators’ 
course. Clinically Mr Costa is also an orthopaedic consultant and all trial participants 
were under his clinical care as per NHS practice. This role involved Mr Costa 
overseeing and being ultimately responsible for the trial conduct. However he had 
no role in the set up and implementation of the trial. 
 
As a research physiotherapist, mandatory GCP training had been undertaken, in 
addition to non-mandatory training to facilitate this role including ‘how to consent 
participants for clinical research’ and an MSc in Trauma and Orthopaedic Surgery. 
Health Professions Council registration was also up to date. The principal 
investigator delegated duties as appropriate to the research team, and these were 
recorded on a delegation of authority log within the trial site file. 
 
Financial support for this project had been awarded by Arthritis Research UK. 
Treatment costs associated with this study had been reviewed by the NHS research 
and development department and in line with trust policy they had agreed that there 
were no service support costs for this project and identified additional treatment 
costs would be paid via normal commissioning arrangements. The project timetable 
and milestones are outlined in Table 4.1. 
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Table 4.1: Project timetable 
 
 
 
4.2 Results 
The primary objective of this study was to evaluate patient recruitment rates, follow 
up and variability within the proposed primary outcome measure. The secondary 
objective was to trial the clinical processes of changing one component of an 
established rehabilitation programme and measure gait parameters.  
 
Recruitment took place between January 2009 and June 2009 at a recruitment rate 
of 2.5 per month. Twenty-six patients were screened, ten were not eligible. Eight 
were secondary to being musculotendinous junction ruptures, one patient presented 
with a delayed presentation and one patient was unable to adhere to trial 
procedures secondary to chronic emphysema, preventing assessment of gait 
analysis.  
 
Sixteen patients were eligible and 15 consented to take part. One patient refused to 
take part on the basis of not wanting to complete questionnaires, leaving 15 eligible 
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and consenting patients. One patient consented to take part and subsequently 
received private health care and therefore no longer wished to be followed up. 
There were no further losses to follow up as shown in Figure 4.2. 
 
The baseline demographics for the three groups of five participants are shown in 
Table 4.2. This shows that the groups were comparable with regards to age, weight, 
height, foot involvement, ethnic background and smoking history. There were more 
males in the two and one heel wedge insert group compared to the three heel 
wedge insert group. Furthermore, within the three heel wedge insert group, three 
patients had pre-existing pathologies, which was higher than the groups with one 
and two heel wedge inserts; this was reflected within the baseline functional 
outcome scores. The mechanism of injury was predominantly sport related (9/15) 
and the mean number of days from injury to study consent was three (SD was two). 
 
Within the single heel raise group there were two SAEs, which occurred at the three 
month time point. The first was a re-rupture, resulting in operative management and 
a further 12 weeks within an AFO. The second event was the result of a sprain to 
the tendon two months post rupture, resulting in wearing an AFO for an additional 
five weeks. There were two other SAEs, both within group two, one was a 
superficial wound infection managed with a short course of antibiotics and the 
second an unrelated episode of back pain which resolved within one month, with a 
course of pain medication. Neither of these events resulted in a deviation from the 
rehabilitation protocol. 
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Loss to follow up 
(n=0)  
 
 
 
Loss to follow up 
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Excluded from 
analysis (n=0) 
 
 
          
Figure 4.2: Flow chart of participants through the trial 
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Table 4.2: Baseline demographics for the three study groups 
 Three heel raises Two heel raises One heel raise 
Mean age in years (SD) 46 (9) 35 (9) 39 (7) 
Male/Female 3/2 4/1 4/1 
Left/Right 2/3 2/3 3/2 
Mean height in cm (SD) 173 (13) 177 (6) 174 (10) 
Mean weight in Kg (SD) 81 (7) 82 (13) 77 (14) 
Smokes (Y/N) 0/5 0/5 1/4 
Smoked in past (Y/N) 1/4 1/4 1/4 
Ethnic background White: 5 
 
White: 4 
Chinese: 1 
White: 5 
 
Current medication 5 patients: No 
medications 
3 patients: No 
medications 
 
2 patients: Steroid 
inhaler for asthma 
4 patients: No 
medications 
 
1 patient: B12 
injections every 3 
months for 
anaemia 
Pre-existing ipsilateral 
problem  
2 patients: No 
problems 
 
1 patient: MTP 
arthritis 
 
2 patients: Prior 
Achilles pain 
4 patients: No 
problems 
 
1 patient: Prior 
Achilles tendon 
pain and swelling 
 
5 patients: No 
problems 
 
Pre-existing contralateral 
problem 
4 patients: No 
problems 
 
1 patient: MTP 
arthritis 
5 patients: No 
problems 
 
5 patients: No 
problems 
 
Any other new injuries None None None 
Mechanism of injury Sport: 3 
RTA: 1 
Stairs: 1 
Sport:5 
 
 
Sport:1 
Lifting: 2 
Dancing:1 
Unknown:1 
Management (Op/Non-Op) 2/3 4/1 1/4 
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To provide further information on variability of the PROM’s data, to inform a sample 
size calculation, Figure 4.3 through to Figure 4.5 provide graphical illustrations of 
the functional outcome scores for the three groups as a change from median 
baseline scores. The ranges of results around the median change from baseline are 
shown in a table underneath each figure. Furthermore, Figure 4.6 through to Figure 
4.13 demonstrate the mean and standard deviation for each accumulating patient, 
as a collective of the three groups, at each time point within the DRI and ATRS 
scores. 
 
Figure 4.6 illustrates the SD gradually increasing to approximately patient 9 and 
then stabilising through to the 15th patient for baseline, two and six week scores 
within the DRI. Figure 4.7 shows how this changes at the three, six and nine month 
time points. At these later time points the SD again gradually reduces with each 
additional patient, up until the 12th patient, from this point onwards the SD increases 
but remains constant through to the 15th patient. This is possibly secondary to the 
adverse events reported previously. The ATRS scores shown in Figure 4.8 and 
Figure 4.9 show the same patterns described for the DRI score.  
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Range of results at 
each time point (As 
change from median 
baseline score) 
Three heel raises Two heel raises One heel raise 
Two weeks -80 to -92 -59 to -84 -69 to -88 
Six weeks -41 to -92 -23 to -73 -46 to -81 
Three months -54 to -69 -29 to -78 -30 to -80 
Six months -18 to -66 2 to -25 -10 to -75 
Nine months -4 to -43 2 to -10 -2 to -39 
 
Figure 4.3: Median change from baseline for ATRS scores with table demonstrating 
the range of values at each time point for the three groups 
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Range of results at 
each time point (As 
change from median 
baseline score) 
Three heel raises Two heel raises One heel raise 
Two weeks 47 to 76 25 to 70 49 to 73 
Six weeks 22 to 58 28 to 65 26 to 54 
Three months 19 to 39 10 to 34 4 to 48 
Six months 4 to 14 0 to 11 3 to 49 
Nine months 0 to 16 0 to 5 0 to 30 
 
 
Figure 4.4: Median change from baseline for DRI scores with table demonstrating the 
range of values at each time point for the three groups 
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Range of results at 
each time point (As 
change from median 
baseline score) 
Three heel raises Two heel raises One heel raise 
Two weeks -0.29 to -0.71 0 to -0.81 -0.31 to -0.81 
Six weeks -0.19 to -0.48 -0.12 to -0.88 -0.12 to -0.48 
Three months -0.19 to -0.38 0 to -0.38 -0.15 to -0.38 
Six months 0 to -0.31 0 to -0.24 0 to -0.38 
Nine months 0 to –0.2 0 to 0 0 to -0.27 
 
 
Figure 4.5: Median change from baseline for EQ-ED scores with table demonstrating 
the range of values at each time point for the three groups 
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 Figure 4.6: Mean and SD DRI scores for each accumulating participant, from 
top to bottom: baseline, 2 and 6 weeks follow up results 
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 Figure 4.7: Mean and SD DRI scores for each accumulating participant, from 
top to bottom: 3, 6 and 9 month follow up results 
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 Figure 4.8: Mean and SD ATRS scores for each accumulating participant, from 
top to bottom: baseline, 2 and 6 week follow up results 
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 Figure 4.9: Mean and SD ATRS scores for each accumulating participant, from 
top to bottom: 3, 6 and 9 month follow up results 
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Alongside PROMs, gait parameters were also evaluated as a secondary objective. 
Figure 4.10 demonstrates the mean heel pressures (KPa) and standard deviations 
for the injured and uninjured limb at each time point for each group. It is clearly 
demonstrated that heel pressures are above those recorded for the uninjured limb 
within all three groups. These high recordings all return to within 10% of the 
contralateral limb, by the nine month time point. Heel pressures within the uninjured 
limb rise slightly across time, but remain largely unchanged. 
 
Figure 4.11 demonstrates the mean forefoot pressures (KPa) for the three groups, 
with standard deviations. It is clear that the opposite pattern is apparent to that of 
heel pressures. The forefoot pressures for the injured limb are consistently below 
those recorded for the uninjured limb. Again there is a trend towards return to foot 
pressures equivalent to the contralateral limb by the nine month time point. It is also 
noticeable that forefoot pressures in the uninjured limb over time also increase. 
However it is not possible from this gait parameter alone to determine the 
mechanisms for this. 
 
Figure 4.12 shows the percentage amount of time spent in terminal stance and pre-
swing phase as a proportion of the total stance phase. These figures show the 
same patterns as those seen within the injured forefoot pressures. The injured limb 
is consistently below the value recorded for the uninjured limb, returning to within 
10% of the contralateral limb by nine months. The uninjured limb remains 
unchanged across time for this parameter. 
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Figure 4.10: Mean and SD for heel pressure measurements (KPa) for injured (blue line) and uninjured (green line) limb at each time point. From left to 
right: Three heel raise group, two heel raise group and the one heel raise group 
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Figure 4.11: Mean and SD for forefoot pressure measurements (KPa) for injured (blue line) and uninjured (green line) limb at each time point. From left to right: 
Three heel raise group, two heel raise group and the one heel raise group 
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Figure 4.12: Mean and SD for terminal stance and pre-swing (%) for injured (blue line) and uninjured (green line) limb at each time point. From left to right: Three 
heel raise group, two heel raise group and the one heel raise group 
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Scatter plots for the above measured gait parameters along with Pearson 
Correlation Coefficients were evaluated to explore if the same relationships found 
within chapter 3, within healthy participants, also existed within participants who had 
sustained the injury. These are shown in Table 4.3 and Figure 4.13 to Figure 4.15, 
which clearly demonstrate the same relationships as those found in chapter 3 with 
significant correlations between the three parameters. 
Table 4.3: Pearson correlation coefficients 
Paired comparison 
Pearson 
correlation 
coefficient 
Significance 
Heel pressure & forefoot pressure (KPa) 
 
-0.42 <0.001 
Forefoot pressure (KPa) & terminal stance and 
pre-swing % 
0.69 <0.001 
Heel pressure (KPa) & terminal stance and pre-
swing %  
-0.81 <0.001 
 
 
Figure 4.13: Scatter plot of forefoot pressure and amount of time spent in terminal 
stance and pre-swing phase % 
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Figure 4.14: Scatter plot of heel pressure and terminal stance and pre-swing phase% 
 
 
Figure 4.15: Scatter plot of heel pressure and forefoot pressure 
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4.3 Discussion 
The primary objective of this study was to evaluate patient recruitment rates, follow 
up rates and variability within a proposed primary outcome measure. The secondary 
objective was to trial the clinical processes of changing one component of an 
established rehabilitation programme. These aspects of piloting are necessary for 
the appropriate development of future clinical studies. 
 
With the outlined trial processes in place, patient recruitment was achieved at a rate 
of 2.5 per month and resulted in <10% loss to follow up. This was due in part to the 
CRF design which incorporated the collection of multiple contact points, including 
telephone number, email and postal address. Regarding collection of all other 
outlined data, including PROMs and SAEs, the CRF designs (Appendix H) enabled 
100% collection of data from patients, illustrating their ease of use in practice. Only 
one patient refused to take part based on the need to complete the questionnaires. 
 
Variability of PROM’s data for the whole group within the disease specific ATRS 
score ranged from nine (at two weeks) to twenty three (at six months). If the ATRS 
were to be used as a primary outcome measure for an RCT the sample size would 
be based on a predefined minimally clinical important difference, SD, significance 
level and power at the primary outcome point between the intervention and control 
groups115. 
 
The SD at the primary outcome point (nine months in this study) was 15 points on 
the 100 point scale. The authors of the ATRS have suggested that a ten point 
difference is clinically relevant. Regarding the determination of sample size 
calculations the loss to follow up rate also needs to be considered. Loss to follow up 
in this patient group was <10%. There is also the consideration of the number of 
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treatment arms within the RCT design, the greater the number of comparative 
interventions, the greater the required sample size will be. Consequently the 
discussion regarding possible sample size requirements will be based on both the 
preliminary information collected as part of this study and the proposed design of 
future proposed research, based on the work to date. This will be outlined further 
within the conclusion section of this thesis (Chapter 8) 
 
In addition to the PROMs data, on which sample sizes will be based, gait data was 
also collected as a secondary outcome. The collected gait parameters 
demonstrated increased heel pressures, decreased forefoot pressures and 
decreased amount of time spent in terminal stance and pre-swing phase as a 
proportion of the stance phase in relation to the uninjured limb, as seen within 
Chapter 3. These findings were present, not only within the AFO wearing phase of 
rehabilitation, but persisted through to a minimum of six months in all three groups. 
Although these patterns were demonstrated within healthy participants wearing the 
rocker bottom style AFO within Chapter 3, there is a further question to be 
addressed, regarding why these patterns persisted into the mid-term.  
 
Costa et al113 and Neumann et al123 have demonstrated gait abnormalities in 
keeping with these results at two weeks, six months and one year following NWB 
rehabilitation. Further authors have evaluated gait parameters post rupture in the 
longer term between two and fourteen years, these studies have found no 
differences in comparison to the contralateral limb105,116,122,130. There are a number 
of possible mechanisms for these mid and long-term differences post AFO removal.  
 
One possible explanation is the inability of the triceps surae to restrain forward 
rotation of the tibia on the talus during the stance phase of the gait cycle (eccentric 
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muscle action), resulting in increased knee flexion and consequently a longer heel 
contact time (decreased time spent in the terminal stance and pre-swing phase as a 
proportion of the total stance phase). This mechanism was proposed by Sutherland 
et al, who assessed gait parameters within healthy participants following a tibial 
nerve block to assess the role of plantarflexors111. A further explanation was put 
forward by Neumann et al123 who proposed that in addition to muscle atrophy, 
muscle innervation patterns are equally important. Their research showed that 
compared to healthy controls, patients presenting one year post TA rupture had 
different innervation patterns. These changes were higher activity recordings during 
the landing and stance phase and lower activity recordings during the push-off 
phase, resulting in a time shift in innervation patterns, which remains at one year.  
 
Due to the small sample size of five in each group this case series was not powered 
to detect any differences between the three groups, and unlike the healthy 
participant sample this was not a randomised sample and therefore does not 
account for confounding variables. Consequently it was not appropriate to perform 
any formal analysis to determine any differences between inserted heel raise 
conditions. 
 
To summarise, these consecutive case series have provided data on recruitment 
rates, loss to follow up rates and outcome measure variability on which to base 
decisions for future research. Furthermore, secondary data on gait analysis has 
shown similar patterns in gait parameters to those observed within healthy 
participants wearing a rocker bottom AFO design. Further pilot research is required 
to evaluate using an alternative dorsum carbon fibre AFO in clinical practice and to 
explore the interaction between the AFO and heel wedge insert interaction, using 
appropriate methodology.   
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Abstract 
 
Background  
Systematically developing complex interventions, combined with appropriate theory 
and evidence are the guiding principles within the Medical Research Council’s 
complex intervention framework. These principles form the foundations of the 
previous chapters within this thesis. The next steps require further piloting of the 
orthoses/heel wedge interactions to inform the development of future clinical 
studies. 
 
Objectives 
To measure patient reported outcomes between the interaction of three different 
orthoses and heel wedge insert combinations.  
 
To trial the clinical processes of using the different orthoses/heel wedge 
combinations; measure the level of patient acceptance of randomisation to these 
interventions, and measure pre-defined gait parameters. 
 
Methods 
Following an acute Achilles tendon rupture, fifteen patients were randomly allocated 
to receive three, two or one heel wedge insert within an alternative carbon fibre 
orthoses. Post randomisation, all patients were reviewed every two weeks for twelve 
weeks and at six and nine months. At these time points the Disability Rating Index, 
Achilles tendon Total Rupture Score and EQ-5D questionnaires were collected, 
alongside in-shoe gait analysis and clinical complications. 
 
Results 
Twenty-six patients were screened to take part in this trial, of which fifteen were 
eligible and consented to take part. Six were male and nine were female, ages 
ranged from 30 to 75 years. All patients who were approached to take part in the 
study consented to be randomised; one patient declined the intervention post 
randomisation. The one heel raise group consistently achieved higher scores on 
collected PROMs than the two and three heel raise group. 
 
Conclusions 
This pilot study has provided invaluable information on the potential interaction of 
heel wedge insert/AFO interaction on PROMs data. This pilot study has also 
highlighted that the intervention is feasible in clinical practice. However, issues 
surrounding acceptability and attitudes to changing rehabilitation practice require 
further research from a qualitative perspective.  
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5.1 Protocol  
Chapter 2 highlighted that although IWB is a widely documented rehabilitation 
protocol following a rupture of the TA, the individual components which constitute 
this treatment modality vary within the literature. The key variations identified were 
the design of the AFO, the degree of permitted movement and the amount of time 
for which the AFO is worn. 
 
Chapter 3 evaluated the effect of two of these variables on gait parameters within 
healthy participants. The first variable evaluated was the effect of AFO design and 
the second was the effect of inserted heel wedge number within the AFOs. The 
research found statistically significant differences within both variables. However it 
was beyond the scope of that research to conclude if the gait analysis findings 
would translate into patient benefit within a clinical setting. Secondly, the results 
could not determine if the differences found between the identified variables would 
lead to subsequent improved PROMs, or to what extent these differences would be.  
 
Chapter 4 was the first step towards addressing the limitations of Chapter 3. Within 
this chapter the common obstacles associated with clinical trials were discussed, 
and the subsequent need to evaluate parameters such as patient recruitment rates, 
follow-up rates and variability within the proposed primary outcome measures to 
develop future clinical trials. The results of Chapter 4 illustrated a recruitment rate of 
2.5 patients per month with a <10% loss to follow up rate, using the outlined trial 
processes. The SD of the proposed primary outcome measure (ATRS) was found to 
range from nine to twenty three points, on the 100 point scale, across a nine month 
time period.  
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However, in line with the MRC recommendations, a further stage of piloting is 
necessary, prior to planning definitive clinical trials in this complex clinical area. The 
aims of further piloting work would be to evaluate the interaction of the AFO and 
heel wedge insert number through an appropriate interventional study design. 
 
5.1.1 Objectives  
The primary objective was to measure patient reported outcomes between the 
interaction of three different AFO and heel wedge insert combinations. 
 
The secondary objectives were to trial the clinical processes of using these 
AFO/heel wedge combinations; measure the level of patient acceptance of 
randomisation to these interventions, and measure pre-defined gait parameters. 
 
5.1.2 Trial summary and trial flow diagram 
Following ethical committee approval all patients who presented with an acute 
rupture of their TA to the University Hospitals Coventry and Warwickshire NHS 
Trust fracture clinic were potentially eligible to take part in this trial. The only 
eligibility criteria were that they had no other serious injuries to either lower limb or a 
previous history of tendon rupture. These broad eligibility criteria were used to 
ensure that the results of the study could be readily generalised to the wider 
population.  
 
All patients, whether treated operatively or non-operatively were placed in a carbon 
fibre AFO (Toe OFF, Gilbert and Mellish) for eight weeks. All included patients were 
then randomly allocated to receive either three, two or one inserted heel wedge to 
wear inside the AFO. Five patients were randomly allocated to each group. 
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Every two weeks, for twelve weeks, then at six and nine months, all participants 
returned to fracture clinic for routine clinical assessment. At these time points in-
shoe pressure sensors were used to collect gait parameters (using the same 
methods outlined in Chapter 3). In addition to these outcome measures, at baseline, 
two weeks, six weeks, three months, six months and nine months, three patient 
reported outcome scores were collected alongside complications (Figure 5.1). 
 
      Assessed for 
eligibility  
    
      
 
    
      Excluded  
 
Did not meet eligibility  
Refused to participate  
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receive one, two or 
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Figure 5.1: Expected flow of participants 
Page | 213  
 
5.1.3 Eligibility, recruitment, allocation and consent 
This study had ethical approval from the Coventry research ethics committee. All 
patients over 18 years presenting at the University Hospitals Coventry and 
Warwickshire NHS Trust fracture clinic, with a primary acute rupture of their TA 
(less than ten days) were eligible to take part.  
 
Patients presenting after ten days from injury or with a history of previous tendon 
rupture were excluded because these are a separate population, with different 
management requirements. These differences in management are secondary to the 
quality of the tendon tissue and retraction of the tendon ends125. Patients who had 
other serious injuries to either lower limb that would alter the intervention and 
subsequent rehabilitation were also excluded116. This was in addition to patients 
who were unable to give informed consent or adhere to trial procedures, with explicit 
reasons documented and reported.  
 
If a patient taking part in the study sustained a contralateral rupture during the trial 
period, the second rupture would not be included in the study because the result of 
this intervention would not be independent from the first intervention. 
 
Ethical approval was obtained by Coventry Research Ethics Committee prior to the 
start of this study. Recruitment of participants took place within the fracture clinic 
setting at University Hospitals Coventry and Warwickshire NHS Trust. This was 
achieved by the researcher checking the new patient fracture clinic list daily. On 
identifying potentially eligible patients, they were then approached in clinic to 
determine eligibility. If eligible, patients were then provided with a patient information 
sheet and provided with the opportunity to ask questions with family, friends, 
consultant or research team. If willing, patients were then asked to sign a consent 
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form prior to any trial procedures. Each participant was provided with time in the 
clinic to read the consent information and was informed that they could make the 
decision the following day after taking time to discuss with family or friends as they 
required 
 
A TA rupture was diagnosed by the researcher in the first instance and then verified 
by the principal investigator by subjective history and physical examination, 
confirming a palpable gap and a positive Thompson test41,126. 
 
Once clinical diagnosis and eligibility had been confirmed the patient was then 
presented with a patient information sheet by the researcher. This was the same as 
that outlined in Appendix C with the additional sentence inserted under the heading 
‘research practice’. This additional sentence required a notice of substantial 
amendment to the ethics committee, which was approved 3rd August 2010. The 
additional sentence was as follows:  
 
‘Within the orthotic differing numbers of heel wedges are normally inserted, but at present 
we do not know what the optimum number is. If you take part in the trial the number of 
inserted heel wedges inside the orthotic will be randomly allocated to you’  
 
In addition to the written patient information sheet, a lay summary was also verbally 
provided to patients. The patients were given the opportunity to discuss any issues 
with the research team, their consultant as well as members of their family and 
friends. Additionally a list of information to be covered before consent was obtained 
was checked to ensure that all essential information had been provided to the 
potential participant. Any eligible and unwilling participants were recorded at this 
point. 
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After allowing sufficient time for the patient to consider their decision and ask 
questions about the trial, eligible and willing participants signed a consent form. This 
form was approved by the Coventry ethics committee, and reflected the new version 
number of the amended patient information sheet being used. Once eligible patients 
had consented to take part in the study they attended routine clinical follow up every 
two weeks for twelve weeks and finally at six and nine months. 
 
Any new information during the trial that may have affected a participant’s 
willingness to take part was reviewed by the research team. As necessary, this 
information was communicated to all research participants, and a revised consent 
form then completed. Participants were also advised that they may withdraw from 
the trial treatment, and/or whole trial at any time without prejudice. If participants 
withdrew from the trial treatment, they were followed up wherever possible and data 
collected as per protocol until the end of the trial. The only exception to this was 
when the participant also explicitly withdrew consent for follow up. 
 
To ensure minimal loss to follow up, contact addresses, telephone numbers and 
email addresses were collected by the researcher. In the event of a patient not 
attending clinic, a system of reminders was instituted. The system included an initial 
phone call to reschedule the appointment. If contact was not possible by telephone, 
after one week, an email was sent along with a letter outlining the rescheduled 
appointment. If there was no contact within two weeks, a further phone call was 
made to an alternative point of contact given by the participant at their initial 
consent. If no contact was made with the alternative contact, a letter was sent to 
them. If there was no response from the participant or their alternative point of 
contact within these time frames they were recorded as lost to follow up. 
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Patients were then placed in a carbon fibre AFO; the allocation of inserted heel 
wedges was randomised. The randomisation sequence was generated on a 1:1:1 
basis by an independent trial statistician. The randomisation sequence was 
allocated via telephone following consent of each individual participant and 
administered by the researcher. This randomised trial design was chosen to 
account for all known and unknown confounding factors. It was not possible to blind 
the participant to the trial intervention. 
 
Based on previous research using this population, the baseline demographics were 
expected to be similar across the three groups but were recorded at baseline to 
assess this. 
 
5.1.4 Sample size and intervention 
A formal sample size calculation was not carried out because this was a pilot study, 
and therefore not appropriate at this stage. As there are no methods for determining 
sample sizes for pilot studies, a sample size of five for each group was chosen 
based on discussions with experts in the field. Our previous experience was that 
two patients can be recruited per month. Therefore fifteen patients would require 
eight months to recruit. With the above mechanisms in place for preventing loss to 
follow up, it was expected that there would be <10% loss to follow up. Indeed within 
chapter 4 there was only one patient lost to follow up, of the fifteen included 
participants (7%). 
 
Once consent had been obtained participants were placed within the carbon fibre 
AFO (Toe OFF, Gilbert and Meillish) and randomly allocated to receive three, two or 
one heel wedge insert. If allocated to three heel wedges, they were reduced to two 
at two weeks, one at four weeks, none at six weeks and the AFO removed at eight 
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weeks. If allocated to two heel wedges, they were reduced to one at four weeks, 
none at six weeks and the AFO removed at eight weeks. Finally if allocated to one 
heel wedge, they were reduced to none at six weeks and the AFO removed at eight 
weeks.  
 
During the AFO wearing phase all patients were advised not to IWB without wearing 
their AFO. Furthermore all patients were advised to remove their AFO daily to 
perform ankle ROM exercises, as tolerated. Elevation of the injured limb was 
recommended intermittently throughout the day, to control swelling. At eight weeks 
all patients were referred for routine physiotherapy offered within the hospital, for 
which there is a standard guideline. All participants then continued to attend clinic at 
standard follow up time points of ten weeks, three, six and nine months.  
 
At baseline all pre-existing concomitant illnesses and medications were recorded in 
addition to specific questions regarding conditions and medications known to 
predispose to tendon rupture. These included specifically the presence of tendinosis 
(pain, swelling, thickening within the tendon), the use of fluroquinolone antibiotics, 
steroids, disease modifying anti-rheumatic drugs and diabetic medication9. 
Additionally patient demographics (age, height, weight, ethnic minority and gender) 
were recorded along with the date and mechanism of injury. This information was 
used to assess the baseline characteristics of the groups. 
 
5.1.5 Outcome measures, method of assessment and analysis 
The primary outcome of this pilot RCT phase was a PROM. Such a measure would 
also be planned as the primary outcome within the design of a subsequent definitive 
RCT investigating an IWB intervention, following an acute TA rupture. This choice of 
primary outcome has been chosen in contrast to clinical measures such as 
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complication rates and quantification of gait parameters secondary to a combination 
of factors that have been outlined within the orthopaedic literature, and more 
recently the Department of Health’s 2009/10 operating framework56. These outline 
that ultimately the most important outcome is from the patient’s perspective. 
 
The primary patient reported outcome measure to be used would ideally need to be 
disease specific to allow for greater discriminatory validity. The ATRS is the only 
such validated measure available for this population61, as discussed in more detail 
in Chapter 6. This outcome measure has only recently been published and has only 
been validated within a Swedish population between the ages of 20-70 years. 
Therefore further data is required within a UK population across all age ranges 
before this may be appropriate to be used as a primary outcome measure. This 
score is therefore being collected as part of a wider validation study, outlined in 
Chapter 7, as part of this PhD thesis (Appendix E). 
 
With no validated disease specific PROMs to choose from, the next most 
appropriate currently validated patient reported measure for this population is the 
disability rating index127; again the reasons for this are discussed in greater detail 
within Chapter 6. Although not disease specific, it has been validated within an 
orthopaedic clinic setting for a range of orthopaedic presentations. It is a self-
administered form with twelve questions regarding common physical activities, to 
which patients respond using a 100mm visual analogue scale. There are two anchor 
points ‘without difficulty = 0’ and ‘not at all = 100’. The twelve questions are 
subdivided into three broad categories; common basic activities of daily life, more 
demanding daily physical activities and work-related or more vigorous activities 
(Appendix F). This was taken in conjunction with a more generic quality of life 
measure (EQ-5D questionnaire)128.  
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The EQ-5D is a standard instrument for use as a measure of health outcome. It is 
self-completed and comprises of five domains; mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression. These combined domains result in a single 
health index score; there are 243 possible health states, plus unconscious and 
death. The second part of the outcome is a visual analogue scale of 0-100 that asks 
participants to rate how good or bad their own health state is, no points being ‘worst 
imaginable health state’ and 100 being ‘best imaginable health state’. This outcome 
measure has been validated within an orthopaedic context and in a range of 
populations and languages (Appendix G). 
 
Within the study of healthy participants, outlined in Chapter 3, altering the number of 
heel wedge inserts had an effect on heel and forefoot pressures as well as the 
proportion of time spent within the terminal stance and pre-swing phase of the gait 
cycle as a proportion of the total stance phase. It was not known if these changes in 
planter pressure distribution would translate into clinical practice. Therefore 
measurement of in-shoe plantar pressures during each visit, using the same 
protocol outlined in Chapter 3 will provide important secondary observations. 
 
As discussed in Chapter 3, the interventions being assessed will allow increased 
movement and potentially increased force production within the healing tendon. 
Consequently there is a balance between subjecting a healing tendon to enough 
stress/strain to promote the healing response (discussed in Chapter 1) and 
subjecting it to too much, resulting in complications. Expected serious adverse 
events associated with TA rupture rehabilitation include re-rupture, tendon 
lengthening, adhesion, disturbed sensibility, keloid scarring and infection. These 
adverse events will be recorded and reported to the trial sponsor and ethics 
committee, in line with the trial protocol. 
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The time points at which to record these outcomes was based on knowledge 
surrounding healing time frames, as well as routine practice follow up appointments. 
Patients were reviewed every two weeks for the first twelve weeks predominantly to 
screen for the development of any complications. Two further clinic appointments 
were then made at six and nine months to review progress with return to activities of 
daily living. Therefore, complications were evaluated at each time point. Patient 
reported outcome scores were collected at 2,6,12, 24 and 36 weeks to allow 
evaluation of functional recovery during both the acute and mid-term phases.  
 
The datasets were analysed using descriptive statistics only, secondary to the small 
sample sizes between these three groups of patients.  
 
5.1.6 Adverse event management 
At each visit following initial consent procedures, each participant was asked 
whether they had experienced any adverse events since their last visit. An adverse 
event was defined as any untoward medical occurrence in a clinical trial subject, 
which does not necessarily have a causal relationship with the treatment. All 
adverse events were listed on the appropriate CRF for routine return to the central 
office. 
 
Serious adverse events were defined as any untoward and unexpected medical 
occurrence that resulted in death, was life-threatening, required hospitalisation or 
prolongation of existing hospitalisation, resulted in persistent or significant disability 
or incapacity, was a congenital anomaly or birth defect, any other important medical 
condition which although not included in the above, may require medical or surgical 
intervention to prevent one of the outcomes listed. 
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All SAEs were entered onto the SAE reporting form. Once received by the Principal 
Investigator, causality and expectedness was determined. Serious adverse events 
that were deemed to be unexpected and related to the trial were notified to the main 
Research Ethics Committee within 15 days for non-life-threatening event and within 
seven days for a life-threatening event. All participants experiencing serious 
adverse events were followed-up as per protocol until the end of the trial.  
 
5.1.7 End of trial 
The end of the trial is defined as the final visit to the clinic of the last participant. 
 
5.1.8 Data management, statistical analysis and trial organisation 
The CRFs were designed by the researcher and reviewed by the Principal 
Investigator (PhD supervisor Mr Matthew Costa) and guidance from the trial’s 
statistician. All CRFs were completed by the research team, with the participant 
present, and managed centrally. All CRFs can be found in Appendix H. 
 
All electronic patient-identifiable information was held on a secure, password-
protected database accessible only to essential personnel. Paper forms with 
patient-identifiable information were held in secure, locked filing cabinets in a 
restricted area of Warwick Medical School. Patients were identified by a code 
number only. Data was entered onto an electronic database immediately following 
each research clinic.  
 
Direct access to source data/documents was required for trial related monitoring. All 
paper and electronic data would be retained for at least five years after completion 
of the trial. As part of my on-going PhD supervision the supervisors had reviewed 
the protocol for this study and had received progress reports at their request. 
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Accumulating data was monitored at frequent intervals to identify and facilitate the 
early remedial action of certain problems such as recruitment, data collection and 
compliance. Yearly progress reports were also submitted to the funders of this 
project (Arthritis Research UK), as outlined within the terms and conditions of the 
awarded grant.  
 
The day to day management of the project was overseen by the PhD supervisors. 
There was standard NHS cover for negligent harm in place. There was no cover for 
non-negligent harm. Insurance was in place until July 2011 and renewed 
accordingly. Ethical and research and development approvals were also in place. 
Additionally, all research staff involved held a contract with the University of 
Warwick and an honorary contract for research services with the University 
Hospitals Coventry and Warwickshire. 
 
The Principal Investigator was Mr Matthew Costa, who had undertaken relevant 
mandatory training in GCP and the University of Warwick ‘Chief Investigators’ 
course. Clinically, Mr Costa is also an orthopaedic consultant and all trial 
participants were under his clinical care as per NHS practice. 
 
As a research physiotherapist, mandatory GCP training had been undertaken in 
addition to non-mandatory training to facilitate this role, including ‘how to consent 
participants for clinical research’ and an MSc in Trauma and Orthopaedic Surgery. 
Health Professions Council registration was also up to date. The principal 
investigator delegated duties as appropriate to the research team, and these were 
recorded on a delegation of authority log within the trial site file. 
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Financial support for this project had been awarded by Arthritis Research UK. 
Treatment costs associated with this study had been reviewed by the NHS research 
and development department, and they had agreed that there were no service 
support costs for this project and that the identified additional treatment costs would 
be paid via their normal commissioning arrangements as agreed with the local 
primary care trust. The project timetable and milestones are outlined in Table 5.1. 
Table 5.1: Project timetable 
 
5.2 Results 
The primary objective of this study was to measure patient reported outcomes 
between the interactions of the three different AFO/heel wedge insert combinations. 
The secondary objectives were to trial the clinical processes of using this AFO/heel 
wedge combination, measure the level of patient acceptance of randomisation to 
these interventions, and measure pre-defined gait parameters. 
 
Recruitment took place between September 2010 and April 2011, a recruitment rate 
of 2.1 per month. Twenty six patients were screened and eleven were not eligible; 
five were secondary to being ruptures at the musculotendinous junction, three were 
delayed presentations and three were unable to adhere to trial procedures as they 
were not remaining in the UK for follow up clinics. Fifteen patients were eligible and 
subsequently consented to take part in the study. There was no loss to follow-up as 
shown in Figure 5.2. 
Number of months 0 4 8 12 16 
Tasks to be completed  
Sept 
10 
Dec 
10 
Apr 
11 
Aug 
11 
Dec 
11 
Ethics, R&D, sponsorship and insurance.      
Prepare and refine materials      
Recruitment       
Finish all data collection      
Analysis      
Write-up and report      
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The baseline demographics for the three randomised groups of five participants are 
shown in Table 5.2. This table demonstrates that the one heel raise group was an 
older age group compared to the other two and, unlike the other two groups, was all 
female. However, all other baseline demographics were comparable, including 
height, weight and pre-existing pathologies. Sport was the most prevalent 
mechanism of injury (10/15).  
 
Within the three heel raise group one patient was consented and randomised to the 
intervention, but subsequently refused the intervention. This patient was still 
managed with three heel raises but within a rigid rocker bottom AFO rather than the 
carbon fibre AFO. There were two further protocol violations within this group; the 
first was a re-rupture at the six week time point, resulting in an additional four week 
period wearing the AFO. The second occurred five months post rupture, and was a 
re-rupture secondary to being involved in a physical attack, resulting in a further 
eight weeks in an AFO. 
 
There were no SAEs or protocol violations within the two heel raise group. Within 
the one heel raise group one patient sustained a re-rupture at the ten week time 
point. This was subsequently managed in an AFO for a further nine weeks. At the 
ten week time point the same patient sustained a further re-rupture which was 
managed with a further period of non-operative management within an AFO for a 
longer period of time (16 weeks). 
 
Figure 5.3 to Figure 5.5 demonstrate the functional outcome scores for the three 
AFO/heel wedge combination groups as a change from median baseline scores. 
The ranges of results around the median change from baseline are shown in the 
table underneath each figure.  
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      Assessed for 
eligibility (n=26) 
 
    
      
 
    
       
Excluded (n=11) 
 
Did not meet eligibility (n=11) 
Refused to participate (n=0.) 
 
      
      
      
          
     
Randomised to 
receive one, two or 
three heel raises. 
 
    
      
 
     
  
Allocated to three 
heel raises (n=5) 
 
Received 
intervention (n=4) 
 
Protocol Violation 
(n=2) 
 
 
Allocated to two 
heel raises (n=5) 
 
Received 
intervention (n=5) 
 
 Protocol Violation 
(n=0) 
 
Allocated to one 
heel raise (n=5) 
 
Received 
intervention (n=5) 
 
Protocol Violation 
(n=1) 
 
          
  
Loss to follow up 
(n=0)  
 
 
 
Loss to follow up 
(n=0) 
 
 
 
Loss to follow up 
(n=0) 
 
 
          
  
Analysed: 
 
2 weeks  (n=5) 
4 weeks  (n=5) 
6 weeks  (n=5) 
8 weeks  (n=5) 
10 weeks (n=5) 
12 weeks (n=5) 
6 months (n=4) 
9 months (n=5) 
 
Excluded from 
analysis (n=0) 
 
 
 
Analysed: 
 
2 weeks  (n=5) 
4 weeks  (n=5) 
6 weeks  (n=5) 
8 weeks  (n=5) 
10 weeks (n=5) 
12 weeks (n=5) 
6 months (n=5) 
9 months (n=5) 
 
Excluded from 
analysis (n=0) 
 
 
 
Analysed: 
 
2 weeks  (n=5) 
4 weeks  (n=5) 
6 weeks  (n=5) 
8 weeks  (n=5) 
10 weeks (n=5) 
12 weeks (n=5) 
6 months (n=4) 
9 months (n=5) 
 
Excluded from 
analysis (n=0) 
 
 
          
Figure 5.2: Flow chart of participants through the trial 
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Table 5.2: Baseline demographics for the three study groups 
 Three heel raises Two heel raises One heel raise 
Mean age in years (SD) 38.6 (7.3) 42.2 (13.8) 56.8 (12.0) 
Male/Female 2/3 4/1 0/5 
Left/Right 4/1 4/1 3/2 
Mean height in cm (SD) 170.0 (7.5) 171.8 (11.0) 170.8 (7.8) 
Mean weight in Kg (SD) 76.6 (12.1) 85.0 (37.7) 72.4 (6.8) 
Smokes (Y/N) 1/4 0/5 1/4 
Smoked in past (Y/N) 0/5 1/4 5/0 
Ethnic background White: 4 
Indian: 1 
White: 2 
Indian: 2 
Black Caribbean: 1 
White: 5 
 
Current medication 2 patients: No medications 
 
1 patient: anti-depressant 
 
1 patient: beta blocker 
 
1 patient: simvastatin 
4 patients: No 
medications 
 
1 patients: inhaler for 
asthma 
4 patients: No 
medications 
 
1 patient: Prozac 
Pre-existing ipsilateral 
problem  
3 patients: No problems 
 
1 patient: patella 
tendinopathy 
 
1 patient: TA  tendinopathy 
 
3 patients: No 
problems 
 
1 patient: Hip 
arthroscopy (2010) 
 
1 patient: Knee 
cartilage removal 
(1976) 
4 patients: No 
problems 
 
1 patient: TA 
tendinopathy 
 
Pre-existing contralateral 
problem 
4 patients: No problems 
 
1 patient: TA tendinopathy 
 
5 patients: No 
problems 
 
3 patients: No 
problems 
 
1 patient: Hip 
resurfacing 
 
1 patient: Ankle 
fracture (15 years 
ago) 
 
1 patient: Knee 
arthroscopy (10 
years ago) 
Any other new injuries None None None 
Mechanism of injury Sport: 4 
Dancing: 1 
Sport:4 
Pushing Car: 1 
 
 
Sport:2 
Walking: 2 
Dancing:1 
Stairs:1 
Management (Op/Non-Op) 0/5 1/4 1/4 
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Range of results at 
each time point (As 
change from median 
baseline score) 
Three heel raises Two heel raises One heel raise 
Two weeks -72 to -96 -47 to -93 -33 to -88 
Six weeks -40 to -86 -62 to -79 -27 to -60 
Three months -41 to -76 -52 to -73 -13 to -67 
Six months -28 to -71 -31 to -43 -32 to -41 
Nine months -3 to -37 -11 to -45 0 to -44 
 
Figure 5.3: Median change from baseline for ATRS scores with table demonstrating 
the range of values at each time point for the three groups 
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Range of results at 
each time point (As 
change from median 
baseline score) 
Three heel raises Two heel raises One heel raise 
Two weeks 39 to 78 7 to 84 16 to 50 
Six weeks 30 to 70 42 to 72 4 to 34 
Three months 22 to 46 21 to 68 7 to 40 
Six months 10 to 36 10 to 72 0 to 40 
Nine months 16 to 0 69 to 4 34 to 0 
 
Figure 5.4: Median change from baseline for DRI scores with table demonstrating the 
range of values at each time point for the three groups 
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Range of results at 
each time point (As 
change from median 
baseline score) 
Three heel raises Two heel raises One heel raise 
Two weeks -0.19 to -0.48 -0.19 to -0.64 0 to -0.31 
Six weeks 0 to -0.64 -0.31 to -0.48 0 to -0.31 
Three months -0.12 to -0.31 -0.12 to -0.41 0 to -0.31 
Six months 0 to -0.31 0 to -0.27 0 to -0.38 
Nine months 0 to -0.15 0 to -0.41 0 to -0.31 
 
Figure 5.5: Median change from baseline for EQ-ED scores with table demonstrating 
the range of values at each time point for the three groups 
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Alongside PROMs, gait parameters were also evaluated as a secondary objective. 
Figure 5.6 and Figure 5.7 demonstrate the mean heel and forefoot pressures (KPa) 
and standard deviations for the injured and uninjured limb at each time point for 
each group up to three months. Figure 5.8 illustrates the percentage amount of time 
spent in terminal stance and pre-swing phase as a proportion of the total stance 
phase at each time point, also up to three months. Data collection at the six and 
nine month time points was planned, however due to technical failures the gait 
analysis system was not available. 
 
The graphs clearly demonstrate the same patterns seen within the previous 
Chapter. These patterns include the injured limb displaying increased heel 
pressures, decreased forefoot pressures and a decrease in the amount of time 
spent in the terminal stance and pre-swing phase of the gait cycle, gradually 
returning to values of the uninjured limb over time. 
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Figure 5.6: Mean and SD for heel pressure measurements (KPa) for injured (blue line) and uninjured (green line) limb at each time point. From left to right: 
Three heel raise group, two heel raise group and the one heel raise group 
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Figure 5.7: Mean and SD for forefoot pressure measurements (KPa) for injured (blue line) and uninjured (green line) limb at each time point. From left to right: 
Three heel raise group, two heel raise group and the one heel raise group 
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Figure 5.8: Mean and SD for terminal stance and pre-swing (%) for injured (blue line) and uninjured (green line) limb at each time point. From left to right: Three 
heel raise group, two heel raise group and the one heel raise group 
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5.3 Discussion 
The primary objective of this study was to measure patient reported outcomes 
between the interactions of the three different AFO/heel wedge insert combinations. 
The secondary objectives were to trial the clinical processes of using this AFO/heel 
wedge combination, measure the level of patient acceptance of randomisation to 
these interventions and measure pre-defined gait parameters. 
 
Across the three reported PROMs, all three patient groups gradually returned to 
pre-injury scores over the nine month time period. There were also a wide range of 
scores within the groups at each time point, as would be expected with a small 
sample of five in each group. It was also clear to see that there was a trend in the 
one heel raise group to consistently achieve higher PROM’s outcomes when 
compared to the two and three heel raise groups, throughout the earlier time points. 
However by six months a convergence of the results occurs across the three 
groups. These trends between the groups were not observed within the secondary 
outcome gait data; however this was also limited by the missing data at the final two 
time points, secondary to irreconcilable technical faults with the gait analysis 
system. 
 
This could imply that the theoretical advantages of using one heel raise, as opposed 
to two or three, proposed in Chapter 3 may result in improved PROMs data only 
during, and immediately after the AFO wearing phase. However this is only pilot 
data and consequently does not provide definitive evidence, but can be used to 
inform the estimate of potential effect sizes and consequently the possibility of 
future clinical trials. Therefore, in relation to the first objective of this study, there is 
an indication that there is an interaction between the AFO and heel wedge insert 
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combination. How this information will be used to guide future research will be 
discussed in the final chapter. 
 
The secondary objectives of this study were to investigate the clinical processes 
and patient acceptance of randomisation to the interventions. All patients who were 
approached to take part in the study did so. However one patient decided not to 
proceed with the intervention once they had been fitted with the AFO and heel 
wedge insert combination. In this particular case the patient felt that the AFO design 
did not look robust and requested an alternative design. This raises important 
questions in relation to the importance of not just the quantitative aspects of what 
interventions work and why, but also the qualitative aspects of intervention 
development.  
 
These questions from a qualitative paradigm are as equally as important as the 
quantitative aspects, which the scenario described above exemplifies. However 
these qualitative issues surrounding attitudes and acceptability to proposed 
changes to treatment interventions to be researched in the future go beyond the 
patient.  
 
To investigate attitudes, acceptance and experiences of the proposed 
developments in TA rupture rehabilitation; future research would need to include a 
vast range of stakeholders. These would include not only patients, but also the 
health care professionals who would be responsible for delivering the interventions 
(consultants and allied health professionals), members of the public who may be 
involved with helping patients and also more broadly, charities that represent these 
patient groups and ethics committee members who would be responsible for 
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approving future research. Exactly how and when these issues could be further 
explored will be discussed in detail within the final chapter. 
 
Alongside the integration of qualitative research in future developments, there is 
also the outstanding question regarding the correct quantitative outcomes being 
measured. Throughout this and previous chapters it has been discussed that the 
authors of the ATRS PROM have advocated it as the only disease specific validated 
PROM for use with this patient population. Consequently the final key focus of this 
PhD will be on identifying what PROMs have been used by researchers previously, 
and further investigating the validity and reliability of the properties of these 
commonly used measurement tools. 
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Abstract 
 
Background  
Currently there is no consensus regarding the optimal management for patients 
following an Achilles tendon rupture. To allow comparisons across research a 
universally accepted outcome measure is required. However, there are currently a 
range of these reported within the literature. 
 
Purpose 
The first aim of this research was to identify the most frequently used patient 
reported outcomes for patients following a rupture of their Achilles tendon. The 
secondary aim was to then analyse the evidence to support their use. 
 
Methods 
The electronic databases MEDLINE, EMBASE and AMED were searched up to 
September 2010. Predefined inclusion and exclusion criteria were then applied to 
identify what outcome measures are reported in the literature. Aspects of validity 
were then defined and a checklist used to determine which aspects have been 
evaluated. 
 
Results 
Twenty one outcome measures in fifty research papers were identified. The most 
commonly used was the American Orthopaedic Foot and Ankle Society hind-foot 
score. Of these twenty one outcome measures only four cited independent 
validation data. Of these four, only the ‘Achilles tendon Total Rupture Score’ 
reported evidence to support multiple facets of validity, as defined by a 
predetermined criteria checklist. 
 
Conclusions 
The Achilles tendon Total Rupture Score is the only outcome measure which has 
demonstrated multiple facets of validity for use in this group of patients. However, 
even this tool has limitations. Researchers should be aware of the limitations of the 
available outcome measurement tools and evaluate their validity before they use 
them in clinical research.  
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6.1 Protocol 
The MRC complex intervention framework outlines a process of developing theory, 
piloting procedures and assessing effectiveness. However to assess effectiveness 
the researcher requires a valid, reliable and responsive tool to achieve this. Within 
trauma and orthopaedics, the traditional method for determining the benefits of a 
new intervention have been focused on clinical objective measures. Such measures 
for TA rupture research have included muscle strength, calf circumference and 
ROM55.  
 
More recently, the Department of Health have outlined that technical and clinical 
measures should come secondary to treatment effectiveness from the patient’s 
perspective. This is seen as an essential component for putting quality at the centre 
of NHS practice56. Consequently, there is a growing trend, across health care 
specialities, to use PROMs as primary outcome measures within clinical 
research131. 
 
Two broad types of PROMs have been developed132. The first is categorised as 
‘disease specific’ and the second as ‘quality of life’131. Both are multi item 
questionnaires, predominantly completed by the patient. They include questions that 
ask the patient about various constructs. Such construct examples include physical 
activities, pain and social functioning. These are then quantitatively scored, using a 
predefined scoring or indexing system.  
 
The key difference between these two broad categories is that disease specific 
measures have been developed within the construct of a specific pathology or 
anatomical region. Consequently they ask questions specifically directed to those 
conditions/areas. In contrast, quality of life measures are more generic in their 
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questioning and applied across disease areas and anatomical regions. Currently 
there is a range of multi-item PROMs used within the context of TA rupture 
management, as outlined in chapter 1.  
 
The purpose of this chapter is to systematically review which multi-item outcome 
measures are most frequently used within the research pertaining to acute TA 
rupture management. The secondary objective is to evaluate aspects of validity of 
these commonly used measures. It is intended that this review will provide 
structured evidence to guide the selection of an outcome measure to be used within 
a research context. 
 
6.1.1 Research questions 
To achieve these objectives the following research questions will be addressed: 
 
1. What are the most frequently used multi-item outcome instruments in studies 
reporting acute TA rupture management? 
2. Does the literature provide evidence to support the identified disease specific 
outcomes in terms of aspects of validity, reliability and responsiveness as 
defined by a quality criteria score? 
 
6.1.2 Criteria for including studies: Identifying what outcomes are currently used 
To address the first research question all interventional study designs and 
languages were included and translated where necessary. The review included all 
subjects over 18 years old with an isolated, primary acute TA rupture. An acute TA 
rupture was defined as being less than 14 days old69. Articles reporting subjects 
presenting with delayed presentation (over 14 days), re-rupture or previous TA 
surgery were excluded.  
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All articles had to document the use of a multi-item health outcome measure. 
Articles reporting single item outcomes such as strength, re-rupture or patient 
satisfaction were excluded. Additionally, multi-item scoring systems containing no 
patient reported items were also excluded. 
 
6.1.3 Criteria for including studies: Supporting validation evidence  
To address the second research question, all identified disease specific outcome 
measures identified from the first research question were included in this second 
stage of the review. Any outcome measure used within an article without 
independent validation data cited was excluded.  
 
All study designs and languages were included and translated where necessary in 
this review. All studies reporting the development and construct of the identified 
outcomes were also included. Any subsequent studies reporting validity, reliability or 
responsiveness of the specified outcome measures within a population who had 
sustained an acute TA rupture were also included. Articles not reporting aspects of 
development, validity, reliability or responsiveness were excluded. Articles reporting 
aspects of subsequent, validity, reliability or responsiveness within populations other 
than those who have sustained an acute TA rupture were also excluded. 
 
6.1.4 Search strategy: Identifying what outcomes are currently used 
This search employed the electronic databases of MEDLINE, AMED and EMBASE 
using the Ovid search engine. The following search strategies in Table 6.1 were 
used within these databases to identify which outcome instruments are used in 
practice to address the first research question. Within the MEDLINE search an 
additional MeSH heading ‘outcome assessment’ was used which is not available 
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within AMED and EMBASE. The remainder of the search terms are exact for all 
three databases. 
 
Table 6.1: Search strategies used to identify what outcome measures are used 
 
MEDLINE 
 
Search terms 
1 exp. Achilles Tendon/ 
2 exp. Rupture/ 
3 Achill$.m_titl 
4 TendoAchill$.m_titl 
5 Rupture$.m_title 
6 1 OR 3 OR 4 
7 2 OR 5 
8 6 AND 7 
9 exp Treatment Outcome/ 
10 exp. Questionnaires/ 
11 exp ‘Quality of Life’/or exp ‘Outcome Assessment (Health Care)’/or exp Health Status 
12 9 OR 10 OR 11 
13 8 AND 12 
 
AMED and EMBASE 
 
Search terms 
1 exp. Achilles Tendon/ 
2 exp. Rupture/ 
3 Achill$.m_titl 
4 TendoAchill$.m_titl 
5 Rupture$.m_title 
6 1 OR 3 OR 4 
7 2 OR 5 
8 6 AND 7 
9 exp Treatment Outcome/ 
10 exp. Questionnaires/ 
11 exp ‘Quality of Life’/or exp Health Status/ 
12 9 OR 10 OR 11 
13 8 AND 12 
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6.1.5 Search strategy: Supporting validation evidence 
To address the second research question, the reference lists of the included articles 
were checked for references pertaining to the development of the identified outcome 
measures. In addition to this a second search strategy was employed using 
MEDLINE, AMED and EMBASE, searched via Ovid. The search strategy used is 
outlined in Table 6.2. The individual search terms were based on the quality criteria 
proposed for measurement properties of health status questionnaires by Terwee et 
al133. 
 
Table 6.2: Search strategy used to identify studies to support the validity, reliability 
and responsiveness of the identified outcome measures 
 
 
Search terms 
1 Specified Outcome Measure.mp 
2 Content validity.mp 
3 Internal Consistency.mo 
4 Criterion Validity.mp 
5 Construct Validity.mp 
6 Reproducibility Agreement.mp 
7 Reproducibility Reliability.mp 
8 Responsiveness.mp 
9 Floor and Ceiling Effects.mp 
10 Interpretability.mp 
11 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 
12 1 AND 11 
 
6.1.6 Methods of review: Identifying what outcomes are currently used 
Articles produced from the search strategies were independently assessed for 
inclusion by two reviewers (RK and CP). The reviewers evaluated all identified titles 
and abstracts independently and excluded any clearly irrelevant articles at this 
point. The remaining articles were ordered in full and assessed against the eligibility 
criteria, differences were resolved by discussion. 
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Data was extracted from all included articles by a single reviewer (RK) and verified 
by a second reviewer (CP). An example of the predefined data extraction table is 
summarised in Table 6.3. It includes information regarding the title of the outcome 
measure, how many have cited it, a description of the number of items it contains, 
item content, response scale and score range. 
 
Table 6.3: Example of data extraction table for the identified outcome measures 
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6.1.7 Methods of review: Supporting validation evidence 
Articles produced from the search strategies were independently assessed for 
inclusion by two reviewers (RK and CP). The reviewers evaluated all identified titles 
and abstracts independently and excluded any clearly irrelevant articles at this 
point. The remaining articles were ordered in full and assessed against the eligibility 
criteria, differences were resolved by discussion. 
 
To investigate the evidence pertaining to the validity, reliability and responsiveness 
of the identified outcomes measures reported within the literature a checklist was 
applied. The checklist outlines nine quality criteria for questionnaires of health 
status. These quality criteria include content validity, internal consistency, criterion 
validity, construct validity, reproducibility (agreement and reliability), reliability, 
responsiveness, floor/ceiling effects and interpretability. Each quality criteria is then 
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assigned one of three outcomes, a positive rating, intermediate rating or negative 
rating as outlined by Terwee et al133 (Appendix I). 
 
An example of the data extraction table can be found below (Table 6.4). The data 
was extracted from the included articles, from the secondary search, by a single 
reviewer (RK) and verified by a second reviewer (CP). 
 
Table 6.4: Example of data extraction table 
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6.2 Results 
6.2.1 Search results: Identifying what outcomes are currently used 
The search was carried out 29/09/10. The individual search strategies for each 
database are shown in Table 6.5 through to Table 6.7; Figure 6.1 shows the overall 
results of the combined databases. Once duplicates were removed from the 
combined results, 414 records were screened for eligibility. Of these 327 were 
excluded, based on the title and abstract information. Eighty seven full text articles 
were ordered, to be assessed against the eligibility criteria. 
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550 records identified through 
database searching (MEDLINE, 
AMED and EMBASE) 
 
 
 
 
 
Unpublished literature: 0 
  
 
 
414 records after duplicates removed and subsequently screened 
   
 
 
  
327 articles excluded based on title and abstract  
(47 not interventional study design; 154 not acute 
rupture; 4 not adult; 35 not multi-item; 87 not patient 
reported) 
 
 
   
 
 
 
87 Full text articles ordered and assessed for 
eligibility. 
 
  
Excluded: 37 
 
Unable to obtain form British library: 2 
Not interventional study design: 9 
Not multi-item score: 15 
Not patient reported: 11 
 
 
 
 
Added: 0 
 
 
 
  
Included: 50 
 
 
 
Figure 6.1: Search strategy results to identify what outcomes are used 
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Table 6.5: Search strategy results: MEDLINE 
 
 
Search terms Results 
1 exp. Achilles Tendon/ 4942 
2 exp. Rupture/ 30983 
3 Achill$.m_titl 3514 
4 TendoAchill$.m_titl 124 
5 Rupture$.m_title 32396 
6 1 OR 3 OR 4 5606 
7 2 OR 5 49158 
8 6 AND 7 1532 
9 exp Treatment Outcome/ 458841 
10 exp. Questionnaires/ 223377 
11 
exp ‘Quality of Life’/or exp ‘Outcome Assessment (Health Care)’/or exp 
Health Status 
624370 
12 9 OR 10 OR 11 807821 
13 8 AND 12 208 
 
Table 6.6: Search strategy results: AMED  
 
 
Search terms Results 
1 exp. Achilles Tendon/ 421 
2 exp. Rupture/ 290 
3 Achill$.m_titl 472 
4 TendoAchill$.m_titl 32 
5 Rupture$.m_title 259 
6 1 OR 3 OR 4 505 
7 2 OR 5 383 
8 6 AND 7 148 
9 exp Treatment Outcome/ 12877 
10 exp. Questionnaires/ or ‘ Quality of Life’ 7602 
11  exp Health Status/ 2175 
12 9 OR 10 OR 11 21184 
13 8 AND 12 30 
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Table 6.7: Search strategy results: EMBASE  
 
 
Search terms Results 
1 exp. Achilles Tendon/ 4789 
2 exp. Rupture/ 58696 
3 Achill$.m_titl 4160 
4 TendoAchill$.m_titl 146 
5 Rupture$.m_title 26143 
6 1 OR 3 OR 4 6699 
7 2 OR 5 67401 
8 6 AND 7 1835 
9 exp Treatment Outcome/ 699633 
10 exp. Questionnaires/ 256675 
11 exp ‘Quality of Life’/or exp Health Status/ 249850 
12 9 OR 10 OR 11 1097462 
13 8 AND 12 312 
 
The outcome measures identified from the included articles are summarised within 
the predefined data extraction table in Table 6.8. In total 21 multi-item patient 
reported outcomes were identified. Of these four were generic quality of life 
outcome measures; two were region specific and 15 were disease specific outcome 
measures. The AOFAS was the most frequently used score (19 articles). 
 
Total items for the questionnaires ranged from 5 to 36 covering a range of content 
areas. The responses to the questions involved responding to a number of set 
categories in all 21 outcomes, these were then either summed to achieve a score or 
applied to an index which then translated to a single score. Of the 21 outcome 
measures 13 contained an objective component in addition to the subjective patient 
reported component and the remaining eight were patient reported only. 
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Table 6.8: Summary of outcome measures used in published research  
 
Name of 
outcome 
Total 
citations 
Outcome 
type 
Total items Item content Response scale Score range Subjective (A) or 
subjective and 
objective (B) 
Generic Quality of Life Outcome Measures 
EQ-5D 1 Global 5 Mobility, self-care, usual 
activities, pain, 
anxiety/depression 
Categories: Three 
responses.  
 
Combined responses 
result in one of 245 
combinations, which each 
is allocated a score 
 
Range: -1 to +1 A 
SF-12 1 Global 12 Physical and mental 
components 
Categories: Five 
responses 
 
Scored using an algorithm 
Responses applied to an 
algorithm range from 0 to 
100 
 
Profile measure that 
yields two summary 
scores (physical and 
mental health) 
 
A 
SF-36 1 Global 36 Eight domains of health: 
physical function, physical 
role, bodily pain, general 
health, vitality, social 
functioning, emotional role 
and mental health 
Categories: Five 
responses 
 
Scored using an algorithm 
Responses applied to an 
algorithm range from 0 to 
100 
 
Profile measure that 
yields two summary 
scores (physical and 
mental health) 
 
A 
Rand 36 1 Global 36 Eight domains of health: 
physical function, physical 
role, bodily pain, general 
health, vitality, social 
functioning, emotional role 
and mental health 
Categories: Five 
responses 
 
Scored using an algorithm 
Responses applied to an 
algorithm range from 0 to 
100 
 
Profile measure that 
yields two summary 
scores (physical and 
mental health) 
 
 
 
A 
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Name of 
outcome 
Total 
citations 
Outcome 
type 
Total items Item content Response scale Score range Subjective (A) or 
subjective and 
objective (B) 
Region Specific  Outcome Measures 
AOFAS 19 Region 
Specific: Ankle-
Hindfoot,  
9 Pain, function, walking 
distance, walking surface, 
ROM, foot alignment, gait 
Categories: Between 2 
and 4 responses 
 
Assigned points per 
response between 0 and 
40 
 
Range: 0 to100 B 
Olerud 
Molander 
Ankle Score 
1 Region 
Specific: Ankle 
9 Pain, stiffness, swelling, 
stair climbing, running, 
jumping, squatting, 
supports, work activities. 
Categories: Between  2 
and 5 responses 
 
Assigned points per 
response between 0 and 
2 
 
Range: 0 to100 
 
Excellent: 91-100 
Good: 61-90 
Fair: 60-31 
Poor: 0-30 
A 
Achilles Tendon Specific Outcome Measures 
Holz Score 4 Disease 
Specific (TA) 
5 ROM, gait, strength, pain, 
return to sports 
Categories: Three 
responses assigned 1,2 
or 3 points 
Range: 5 to 5 
 
Good: 12-15 
Fair: 8-11 
Poor: <7 
 
B 
Hannover 
Achilles Score 
1 Disease 
Specific (TA) 
11 ROM, calf circumference, 
Thompson test, strength, 
pain, return to sport, 
weather related problems, 
satisfaction. 
Categories: Between 2 
and 4 response. 
 
Assigned points per 
response between 0 to 10 
Range: 0 to100 
 
Excellent: 9-1000 
Very good: 8-890 
Good: 70-79 
Sufficient: 6-690 
Poor: <60 
 
 B 
Thermann 
Score 
8 Disease 
Specific: (TA) 
11 ROM. Calf circumference, 
strength, pain, return to 
sport, sensitivity to 
weather, patient 
satisfaction, Thompson 
test 
Categories: Between 2 
and 4 responses 
 
Assigned points per 
response between 0 and 
10 
Range: 0 to100 
 
Excellent: 90-100 
Good: 80-89 
Fair: 70-79 
Poor: 60-69 
 
 
 
 
 
 
B 
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Name of 
outcome 
Total 
citations 
Outcome 
type 
Total items Item content Response scale Score range Subjective (A) or 
subjective and 
objective (B) 
Modified 
Thermann 
Score 
2  Disease 
Specific (TA) 
11 ROM, calf circumference, 
strength, pain, return to 
sports, sensitivity to 
weather, patient 
satisfaction 
Categories: Between 2 
and 5 responses 
 
Assigned points per 
response between 0 and 
10 
Range: 0 to 100 
 
Very good: 100-90 
Good: 89-80 
Moderate: 79-70 
Fair: 69-60 
Poor: <60 
 
B 
Modified 
Thermann 
Score  
1 Disease 
Specific (TA) 
10 ROM, calf circumference, 
return to sports, patient 
satisfaction 
Categories: Between 3 
and 4 responses 
 
Assigned points per 
response between 0 and 
10 points 
 
Range: 0 to 100 B 
Modified 
Thermann 
Score  
1 Disease 
Specific (TA)  
8 ROM, strength, pain, 
return to sport, patient 
satisfaction 
Categories: Four 
responses 
 
Assigned points per 
response between 0 and 
10 
Range: 0 to 80 
 
Very Good: 70-80 
Good: 60-69 
Fair: 50-59 
Poor: <50 
 
B 
Leppilahti 
Score 
5 Disease 
Specific (TA) 
7 Pain, stiffness, subjective 
strength, ROM, footwear 
restrictions, isokinetic 
muscle strength, 
satisfaction 
Categories: Between 3 
and 4 responses 
 
Assigned points per 
response between 0 and 
15 
Range: 0 to100 
 
Excellent: 90-100 
Good: 75-85 
Fair: 60-70 
Poor: <55 
 
B 
Modified 
Leppilahti 
Score 
2 Disease 
Specific (TA) 
5 Pain, Stiffness, subjective 
strength, footwear 
restrictions, patient 
satisfaction 
Categories: Between 3 
and 4 responses 
 
Assigned points per 
response between 0 and 
15. 
 
 
 
 
 
 
Range: 0 to70 A 
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Name of 
outcome 
Total 
citations 
Outcome 
type 
Total items Item content Response scale Score range Subjective (A) or 
subjective and 
objective (B) 
Rupp Achilles 
tendon score  
1 Disease 
Specific (TA) 
13 Strength, ROM, calf 
circumference, activities of 
daily living, pain, patient 
satisfaction 
Categories: Between 4 
and 5 responses  
 
Assigned points per 
response, between -5 and 
+5 
Range: -53 to 58 
 
Excellent: 40-60 
Good: 20-39 
Satisfactory: 0-19 
Poor: <0 
 
B 
Modified Rupp 
Score 
1 Disease 
Specific (TA) 
7 Pain, patient satisfaction, 
function, return to work 
and sport. 
Categories: Between two 
and four responses 
 
Assigned  points per 
response between -5 and 
5 
Range: -24 to 28 
 
Excellent: Over 30 
Good: 15-30 
Fair: 5-15 
Poor: <5 
 
A 
ATRS 3 
 
Disease 
Specific (TA) 
10 Patient reported strength, 
fatigue, stiffness, pain, 
activities of daily living, 
walking on even surfaces, 
walking uphill, running, 
jumping physical labour 
Categories: Eleven 
responses 
 
Assigned points per 
response between 0 and 
10 
 
Range: 0 to 100 A 
Modified 
Mandelbaum 
and Pavanini 
Scale  
1 Disease 
Specific 
5 ROM, patient satisfaction, 
strength, pain, return to 
sports 
Categories: Between 2 
and 3 responses 
 
Assigned points per 
response between 0 and 
10 
 
Range: 5 to 50 B 
Objective and 
Subjective 
Outcome 
Score  
1 Disease 
Specific 
8 ROM, calf circumference, 
strength, pain, 
complications, satisfaction 
Categories: Between 3 
and 4 responses  
 
Assigned points per 
response between 0 and 
15 
 
Range: 0 to 100 B 
Achilles 
Tendon 
Evaluation 
Score  
1 Disease 
Specific (TA) 
11 Gait, strength, Thompson 
test, patient satisfaction 
Categories: Three 
responses 
 
Assigned points per 
response between 0 and 
10 
Range: 0 to 100 
 
Excellent: 90-100 
Good: 80-89 
Fair: 70-79 
Poor: <70 
 
B 
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Name of 
outcome 
Total 
citations 
Outcome 
type 
Total items Item content Response scale Score range Subjective (A) or 
subjective and 
objective (B) 
Post-operative 
Rating Scale  
1 Disease 
Specific (TA) 
7 Pain, ROM, jumping 
capacity, calf atrophy, 
VAS, wound healing, gait 
Categories: Between 3 
and 4 responses 
Assigned points per 
response between 0 and 
15 
 
Range:0 to 100 
 
Excellent: 90-100 
Good: 90-80 
Fair: 80-70 
Poor: <70 
 
B 
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6.2.2 Search results: Supporting validation evidence 
Twenty one multi-item outcome measures were reported within the literature 
pertaining to acute TA rupture management. Of these 21 articles, four were 
excluded from this second stage of the review because they were not disease 
specific and a further 13 were excluded for not citing independent validation data 
within the article. This resulted in four included outcome measures in this second 
stage of the review. These outcomes were the AOFAS, Olerud Molander Ankle 
Score, Leppilahti Score and ATRS. 
 
The second literature search was carried out on 30/11/10 for the above outcome 
measures. The individual search results for each database can be found in Table 
6.9 through to Table 6.11. The combined results for each outcome measure are 
demonstrated in Figure 6.2 through to Figure 6.5.  
 
The first literature search was in regard to the AOFAS. A total of three articles were 
identified from the search, of which three were excluded because they did not report 
either the development of the outcome measure or any independent validation data 
that included patients who had sustained a TA rupture. On searching the reference 
lists of articles that had cited the AOFAS, all referred to one article from 1994 
outlining the development of the score, which was included. 
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 6 records identified 
through database 
searching 
(MEDLINE, AMED 
and EMBASE) 
 
 
 
 
 
Unpublished 
literature: 0 
  
 
 
 3 records after duplicates removed and 
subsequently screened 
   
 
 
  
3 articles excluded based on 
title and abstract:  
3 Not about validity of score 
 
 
   
 
 
 
 0 Full text articles ordered 
and assessed for eligibility:0 
 
  
Excluded: 0 
 
 
 
 
 
 
 
 
 
Added from 
reference 
list of 
papers: 1 
 
 
  
Included:1 
 
 
 
 
   
   
 
    
   
    
 
 
 
 
 
  
   
 
  
 2 records identified 
through database 
searching 
(MEDLINE, AMED 
and EMBASE) 
 
 
 
 
 
Unpublished 
literature: 0 
  
 
 
 1 record after duplicates removed and 
subsequently screened 
   
 
 
  
 1 article excluded based on 
title and abstract: 
1 Not about validity of score 
 
 
   
 
 
 
 0 Full text articles ordered 
and assessed for eligibility. 
 
  
Excluded: 0 
 
 
 
 
 
 
 
 
 
Added  
from 
reference 
list of 
papers: 1 
 
 
 
  
Included: 1 
 
 
 
 
 
Figure 6.2: Search strategy results for 
AOFAS 
 
 
 
  
Figure 6.3: Search strategy results for 
Olerud and Molander ankle score 
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 0 records identified 
through database 
searching 
(MEDLINE, AMED 
and EMBASE) 
 
 
 
 
 
Unpublished 
literature: 0 
  
 
 
  0 records after duplicates removed and 
subsequently screened 
   
 
 
  
 0 articles excluded based 
on title and abstract  
 
 
 
   
 
 
 
  0 Full text articles ordered 
and assessed for eligibility. 
 
  
Excluded: 0 
 
 
 
 
 
 
 
 
 
Added: 1 
 
 
 
 
  
Included: 1 
 
 
 
 
 
 
 
 
 
 
 
 
  
 0 records identified 
through database 
searching 
(MEDLINE, AMED 
and EMBASE) 
 
 
 
 
 
Unpublished 
literature: 0 
  
 
 
 0 records after duplicates removed and 
subsequently screened 
   
 
 
  
 0 articles excluded based 
on title and abstract  
 
 
 
   
 
 
 
 0 Full text articles ordered 
and assessed for eligibility. 
 
  
Excluded: 0 
 
 
 
 
 
 
 
 
 
Added: 1 
 
 
 
  
Included:1 
 
 
 
 
Figure 6.4: Search strategy results for Leppilahti Score  Figure 6.5: Search strategy results for ATRS 
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Table 6.9: Search strategy results: MEDLINE 
 
Search terms Results 
1 American Orthopaedic Foot and Ankle Society Hindfoot Score.mp 30 
2 Leppilahti score.mp 2 
3 Achilles tendon total rupture score.mp 2 
4 Olerud and molander ankle score.mp 18 
5 Content validity.mp 2092 
6 Internal Consistency.mp 10302 
7 Criterion Validity.mp 1254 
8 Construct Validity.mp 7052 
9 Reproducibility Agreement.mp 16 
10 Reproducibility Reliability.mp 42 
11 Responsiveness.mp 69424 
12 Floor and Ceiling Effects.mp 365 
13 Interpretability.mp 676 
14 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 85889 
15 1 AND 14 3 
16 2 AND 14 0 
17 3 AND 14 0 
18 4 AND 14 1 
 
Table 6.10: Search strategy results: AMED 
 
Search terms Results 
1 American Orthopaedic Foot and Ankle Society Hindfoot Score.mp 24 
2 Leppilahti score.mp 0 
3 Achilles tendon total rupture score.mp 1 
4 Olerud and molander ankle score.mp 4 
5 Content validity.mp 239 
6 Internal Consistency.mp 976 
7 Criterion Validity.mp 146 
8 Construct Validity.mp 818 
9 Reproducibility Agreement.mp 1 
10 Reproducibility Reliability.mp 7 
11 Responsiveness.mp 884 
12 Floor and Ceiling Effects.mp 69 
13 Interpretability.mp 29 
14 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 2430 
15 1 AND 14 0 
16 2 AND 14 0 
17 3 AND 14 0 
18 4 AND 14 0 
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Table 6.11: Search strategy results: EMBASE 
 
 
Search terms Results 
1 American Orthopaedic Foot and Ankle Society Hindfoot Score.mp 29 
2 Leppilahti score.mp 4 
3 Achilles tendon total rupture score.mp 6 
4 Olerud and molander ankle score.mp 22 
5 Content validity.mp 2998 
6 Internal Consistency.mp 12731 
7 Criterion Validity.mp 1484 
8 Construct Validity.mp 8866 
9 Reproducibility Agreement.mp 21 
10 Reproducibility Reliability.mp 51 
11 Responsiveness.mp 80497 
12 Floor and Ceiling Effects.mp 416 
13 Interpretability.mp 862 
14 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 101260 
15 1 AND 14 3 
16 2 AND 14 0 
17 3 AND 14 0 
18 4 AND 14 1 
 
The second search was focused on the Olerud and Molander ankle fracture scoring 
system. A total of one article was identified from the search, this article was 
excluded because it did not report either the development of the outcome measure 
or any independent validation data that included patients who had sustained a TA 
rupture. On searching the reference lists of articles that had cited the Olerud and 
Molander ankle fracture scoring system, all referred to one article from 1984 
outlining the development of the score, which was included. 
 
The final two searches, encompassing the Leppilahti score and ATRS score 
identified no articles from the searches. One article reporting the development of the 
outcome measures was identified from the reference lists of citing articles for each 
outcome measure. 
Page | 260  
 
Consequently each outcome measure identified did not have any published 
independent validation data, within a population of patients who had sustained an 
acute Achilles tendon rupture, outside of the original development article. Each of 
these articles were subsequently assessed against the checklist proposed for 
measurement properties of health status questionnaires by Terwee et al133. The 
criteria definitions for this checklist can be found in Appendix I. 
 
Table 6.12 summarises the results obtained from applying the checklist to the four 
articles outlining the development of the individual outcome measures. For the 
Leppilahti score and AOFAS no information was available beyond a description of 
the target population. The Olerud and Molander ankle score provided some 
additional information regarding criterion validity and interpretability; however this 
was not within the context of patients who had sustained a TA rupture. 
 
In contrast to the other scores, the ATRS score did fulfil a higher proportion of the 
quality criteria. The ATRS scored six positive ratings across content validity, 
criterion validity, construct validity, reproducibility (agreement and reliability) and 
responsiveness; with two further scores of an intermediate rating within internal 
consistency and interpretability. There was no information regarding floor and 
ceiling effects. 
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Table 6.12: Quality criteria checklist
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ATRS 
 
+ Clear description 
of measurement 
aim, both target 
population and 
experts were 
involved in item 
selection and 
development 
+ Factor 
analysis and 
Chronbach’s 
alpha 
calculated  
? Correlation 
analysis 
demonstrated 
with another 
outcome 
measure. Doubt 
regarding 
appropriate ‘gold 
standard’ 
+ Presented 
hypothesis and 
results for the 
extent to which 
the new 
outcome was 
consistent with 
another outcome 
+ Data presented 
and discussed 
regarding 
measurement 
error and 
minimally 
important 
change 
+ Evaluated the 
extent to which 
patients could be 
distinguished 
from each other 
+ Effect sizes 
were 
presented 
0 No 
Information 
available 
? Mean and 
standard 
deviation of 
scores 
presented, but 
not for different 
sub-groups 
Leppilahti Score 
 
 
- Item selection 
developed by 
experts only 
0 No 
Information 
available 
0 No Information 
available 
0 No Information 
available 
0 No Information 
available 
0 No Information 
available 
0 No 
Information 
available 
0 No 
Information 
available 
0 No Information 
available 
AOFAS 
 
 
 
- Item selection  
developed by 
experts only 
0 No 
Information 
available 
0 No Information 
available 
0 No Information 
available 
0 No Information 
available 
0 No Information 
available 
0 No 
Information 
available 
0 No 
Information 
available 
0 No Information 
available 
Olerud Molander 
Ankle Score 
- Target 
population, ankle 
fractures, items 
developed by 
experts only 
0 No 
Information 
available 
? Insufficient 
information 
regarding 
method of 
correlation 
analysis 
presented and 
‘gold standard’ 
0 No Information 
available 
0 No Information 
available 
0 No Information 
available 
0 No 
Information 
available 
0 No 
Information 
available 
+ Different patient 
sub-groups 
presented 
+ = Positive rating                                                 ? = Intermediate rating                                           - = Negative rating                                                        0 = No information available 
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6.3 Discussion 
A universal choice of outcome measure used within clinical and research practice is 
imperative to allow comparisons across different treatment modalities to determine 
optimum management strategies. Therefore this chapter aimed to address two 
questions. Firstly, what is currently used, as defined by what is reported within the 
literature, and secondly are these outcome measures appropriate, as defined by the 
quality criteria outlined by Terwee et al133. 
 
Twenty one different multi-item outcome measures were identified from the first 
search strategies. This large range highlights the lack of agreement amongst 
researchers and clinicians regarding what should be reported. Furthermore this also 
makes comparisons across studies problematic. However, the most reported 
outcome was the AOFAS hind-foot score, being cited by 38% of all included articles. 
 
Of the 21 identified outcome measures, only four cited independent validation data. 
Of these four outcome measures two contained both subjective and objective 
components (AOFAS and Leppilahti score). This split has been criticised because 
the clinical component could introduce bias due to differences between clinical 
examiners and secondly does not provide any additional information regarding 
treatment benefit from the patient’s perspective134. 
 
Three of the four outcome measures also lacked methodology regarding their 
development, consisting of expert discussion only. This is in contrast to the 
development of the ATRS which utilised a systematic method of item generation, 
test construction and item reduction, using a range of health care professionals and 
comments from patients. Furthermore the ATRS was the only score to present 
validation data across a range of quality criteria. 
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Consequently although the AOFAS is the most widely cited outcome measure within 
the literature regarding TA rupture management, it has no independent validation 
data to support its use. There have been further validation papers published within 
different patient populations to provide aspects of validity for the AOFAS. These 
have included investigating correlations with the SF-36 and other generic measures 
such as EQ-5D. However these have shown only weak correlations and have raised 
concern regarding the use of AOFAS in these other patient populations that are 
included in this region specific outcome measure58,135. 
 
In contrast, the ATRS was only cited in 6% of the included articles, which may be a 
reflection of its recent development (first published 2007). However the 
development article presents data on many important aspects of validity, including 
content, internal consistency, criterion validity, construct validity, reliability, 
responsiveness and interpretability. This is the only disease specific PROM with 
accompanying exploration of aspects of validity presented in this review. 
 
It is important for the development of clinical research that both a practical and 
appropriate PROM is universally accepted. This will allow comparisons and meta-
analysis of high quality RCTs possible into this increasingly common injury. At 
present the best available evidence suggests that the ATRS could be the most 
appropriate outcome measure for evaluating the management of acute TA ruptures. 
 
However, the ATRS is a new patient reported outcome measure that has been 
evaluated within a single sample, three months post injury. Consequently further 
studies evaluating the validity, reliability and responsiveness of this outcome 
measure are required outside the developing research group. This is needed across 
a range of patients, at differing points in their rehabilitation.  
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7 Validation: The Achilles tendon Total Rupture Score (ATRS) 
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Abstract 
 
Background 
The Achilles tendon Total Rupture Score was first developed in 2007 in response to 
the need for a disease specific patient reported outcome measure for this 
population. Beyond this original development paper, no further validation studies 
have been published. 
 
Objectives 
The purpose of this study was to evaluate internal consistency, criterion validity, 
construct validity and responsiveness of the Achilles tendon Total Rupture Score 
within a UK population. 
 
Methods 
Between August 2007 and June 2009, 70 consecutive patients were screened and 
64 eligible patients with an acute rupture of their Achilles tendon completed the 
Achilles tendon Total Rupture Score alongside two further patient reported outcome 
measures, the Disability Rating Index and EQ-5D. These were completed at 
baseline, six weeks, three months, six months and nine months post injury.  
 
The Achilles tendon Total Rupture Score was evaluated for internal consistency 
using Cronbach’s alpha, in addition to criterion and construct validity through 
correlation analysis. Finally responsiveness of the score was evaluated by analysing 
floor and ceiling effects and calculating its relative efficiency in comparison to the 
Disability Rating Index and EQ-5D scores at defined time points. 
 
Results 
At each time point the Achilles tendon Total Rupture Score demonstrated high 
internal consistency (Cronbachs alpha > 0.8) and correlated significantly (p<0.001) 
with the Disability Rating Index. Furthermore, the ability of the new score to detect 
clinically important changes over time (responsiveness) was shown to be greater 
than both the Disability Rating Index and EQ-5D. 
 
Conclusions 
The Achilles tendon Total Rupture Score has been advocated as the only validated 
PROM available for use with patients following an Achilles tendon rupture. However 
beyond the original development paper, no further validation studies have been 
published. 
 
This is the first study to evaluate aspects of validity of this newly developed outcome 
measure, outside of the developing centre. This research supports further aspects 
of validity of the newly developed patient reported outcome measure for patients 
who have sustained a rupture of their Achilles tendon. 
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7.1 Protocol  
Chapter 6 outlined that there are a range of region specific and disease specific 
outcome measures used to evaluate TA rupture management57-60. The region 
specific outcomes have been criticised for lacking discriminatory validity, and being 
validated against a sample of patients with a range of foot and ankle pathologies 
that do not specifically include patients with TA ruptures61. Of the identified disease 
specific outcome measures, only the newly developed ATRS presented validation 
data across a range of quality criteria as defined by Terwee et al61. 
 
The ATRS contains 10 items, for which patients are asked to respond using an 11 
point Likert scale. The authors of the ATRS detailed the methods used to generate 
the final measure, through a panel of wide ranging experts and patients. This 
process addressed the content and face validity of the new outcome score. 
Following the agreed content of the final measure, further facets of validity were 
evaluated including test-re-test reliability, internal consistency and responsiveness. 
Finally, elements of construct validity between the overall ATRS score and 
subscales of the FAOS and VISA-A measures were evaluated, alongside factor 
analysis to determine how many dimensions the new ATRS measured. 
 
However, a newly developed PROM cannot be deemed ‘valid’ based on a single 
sample, within a single country alone. The processes involved in developing a 
PROM have been widely discussed and have resulted in published quality criteria 
checklists, to quantify the extent to which the developed measures have been 
investigated. The checklist published by Terwee et al133 is one such example. The 
checklist comprises of quality criteria including content validity, internal consistency, 
criterion validity, reproducibility (agreement and reliability), responsiveness, 
floor/ceiling effects and interpretability. These elements of outcome measure 
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construction are also consistent with those reported by the HTA, within their 
document entitled ‘Evaluating patient-based outcome measures for use in clinical 
trials’131. 
 
Chapter 6 highlighted which of these quality criteria had been investigated within the 
original ATRS development paper. The aim of this study was to evaluate further 
components of validity within a UK sample across all age ranges at immediate, as 
well as longer term outcome points. This will address the following specific aspects 
of validity: 
 
1. Internal consistency 
2. Criterion (concurrent) validity 
3. Construct (divergent and convergent)validity 
4. Responsiveness at six weeks, three, six and nine months post injury. 
 
7.1.1 Objectives and null Hypotheses 
The primary objectives of this chapter are to evaluate further aspects of validity of 
the ATRS to address the following null hypotheses: 
1. Internal Consistency: There are no inter-correlations between individual items of 
the ATRS, as defined by a Cronbach alpha of less than 0.7. 
2. Criterion Validity: There is no correlation between the overall score of the ATRS 
and the DRI questionnaire as defined by a correlation coefficient of less than 0.7.  
3. Construct Validity: There is no correlation between the overall ATRS score when 
compared to measures of similar constructs of symptoms and physical activity as 
defined by a correlation coefficient of less than 0.7. 
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4. Responsiveness: There are no floor or ceiling effects, as defined by <15% of 
respondents achieving the highest/lowest scores and the relative efficiency will 
be less than one when compared to the DRI and EQ-5D measures. 
7.1.2 Trial summary and trial flow diagram 
All patients who presented to the University Hospitals Coventry and Warwickshire 
NHS Trust fracture clinic with an acute rupture of their TA were screened. The only 
eligibility criteria were that they had no other serious injuries to either lower limb, 
previous history of tendon rupture, or inability to read English. These broad eligibility 
criteria were used to ensure that the results of the study could be readily 
generalised to the wider population, whom this outcome measure would be used 
for. 
 
Following ethical approval, a consecutive series of 64 patients, whether treated 
operatively or non-operatively, were placed in an IWB AFO for eight weeks and 
attended clinic for routine clinical follow up every two weeks, for twelve weeks, then 
at six and nine months. Initially patients were asked to complete three 
questionnaires (ATRS, DRI and EQ-5D) based on pre-injury status. This was then 
followed by the same questionnaires at the defined follow up time points (Figure 
7.1). 
 
Following recruitment and follow up of the consecutive series of patient’s, 
descriptive and inferential statistical methods were carried out using SPSS v.17 and 
Microsoft Excel 2007. Internal consistency was evaluated using Cronbachs alpha. 
Criterion validity was assessed by correlation coefficients between the overall DRI 
and ATRS scores. Construct validity was evaluated by correlation coefficients 
between the overall ATRS score and subscales of DRI (1: common basic activities, 
2: more demanding physical activities, 3: work related or more vigorous activities) 
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and EQ-5D scores. Finally, responsiveness was evaluated by evaluating floor and 
ceiling effects alongside the relative efficiency of the ATRS in comparison to the DRI 
and EQ-5D. 
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Figure 7.1: Expected flow of participants through the trial 
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7.1.3 Eligibility and recruitment 
All patients over 18 years presenting at the University Hospitals of Coventry and 
Warwickshire fracture clinic with a primary acute rupture of their TA (less than ten 
days) were eligible. A TA rupture was diagnosed by the consultant within the 
fracture clinic by subjective history and physical examination confirming a palpable 
gap and a positive Thompson test126. 
 
Patients presenting after ten days from injury, or with a history of previous tendon 
rupture, were excluded. Patients who had other serious injuries to either lower limb 
at the time of rupture that would alter the intervention and subsequent rehabilitation 
were also excluded. In addition to these, patients who were unable to read English 
and were therefore unable to complete the questionnaires were excluded also. 
 
Once eligible patients had consented to complete the questionnaires, they attended 
routine clinical follow up every two weeks for twelve weeks and finally six and nine 
months. At these routine clinics they were reviewed by the orthopaedic consultant, 
as necessary. In the event of a patient not attending fracture clinic a letter outlining 
a rescheduled appointment was sent, as per routine practice. If there was no 
contact within four weeks from the participant they were discharged and recorded 
as lost to follow up. 
 
7.1.4 Sample size  
The department’s statistician was consulted regarding appropriate sample sizes for 
the five null hypotheses, in addition to the review of appropriate literature. There 
was a consensus amongst the literature that there are no standards for determining 
sample sizes for validation research of patient reported outcome measures133. This 
is secondary to the descriptive nature of the interpretation. However a sample size 
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of over 50 patients has been advocated as the minimum requirement134. The 
sample was subsequently collected as part of a previously published 
comprehensive cohort study66. 
 
7.1.5  Evaluation and analysis 
As outlined in the introduction to this chapter, there is some consensus regarding 
terminology used in reference to aspects of validity. However, these can vary 
between publications. Therefore, for the purposes of this study the definitions of 
each term evaluated are outlined below. These definitions are consistent with an 
article published in 1998 entitled ‘Evaluating patient-based outcome measures for 
use in clinical trials’131 and the quality criteria for measurement properties by Terwee 
et al133. 
 
Internal Consistency: The ATRS evaluates a single construct of symptoms and 
physical activity measured through a patient’s response to ten individual questions. 
The reason for multiple items that assess the same construct is based on the 
principle that multiple measurements of the same construct will provide a more 
reliable measure than if one question were asked136. Consequently, we assume that 
items on a scale are positively correlated with each other because they are all 
evaluating the same construct. Internal consistency was evaluated using 
Cronbach’s alpha at each time point within SPSS (v.17.0). Values between 0.7 and 
0.9 were regarded as satisfactory136.  
 
Criterion Validity: Criterion validity can be split into predictive and concurrent 
validity. This study evaluated concurrent validity. This is defined as how a new 
measure correlates with a current ‘gold standard’. This was evaluated using 
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Spearman’s rank correlation coefficients for non-parametric data and Pearson’s 
correlation coefficient for parametric data at each time point. 
 
As there are no previous PROMs specific to acute TA ruptures, the ‘gold standard’ 
used within our practice was the DRI127. Although not disease specific, it has been 
validated within an orthopaedic clinic setting for a range of orthopaedic 
presentations. The DRI is a self-administered form with twelve questions regarding 
common physical activities, to which patients respond using a 100mm visual 
analogue scale. There are two anchor points ‘without difficulty = 0’ and ‘not at all = 
100’. The twelve questions are subdivided into three broad categories; common 
basic activities of daily life, more demanding daily physical activities and work 
related or more vigorous activities (Appendix F). The expected size of the 
correlation when a measure is correlated against a ‘gold standard’ has been defined 
as being of at least 0.7133. 
 
Construct Validity: The ATRS has been shown to measure one construct defined as 
‘symptoms and physical activity’, as determined by factor analysis. To further 
evaluate construct validity, the overall ATRS scores will be evaluated to determine 
how strongly it correlates with measures of the same construct and measures 
evaluating different constructs. This will be achieved by firstly evaluating correlation 
coefficients between the overall ATRS score and subscales of the DRI, which 
measure three constructs of differing levels of physical activity. Secondly correlation 
coefficients will also be analysed between the ATRS and EQ-5D, which is a generic 
quality of life measure (Appendix G). This was achieved using Spearman’s rank 
correlation coefficient for non-parametric data and Pearson’s correlation coefficient 
for parametric data within SPSS (v 17.0) at each time point. The expected size of 
the correlation was again defined as being of at least 0.7133. 
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Responsiveness: This is defined as the ability of the measurement to detect change 
across time. There are many methods associated with measuring this facet, as 
outlined by the HTA report131. For the ATRS to be responsive it needs to 
demonstrate a lack of floor and ceiling effects, subsequently demonstrating a 
distribution of scores around the middle score. Therefore to evaluate 
responsiveness of the ATRS, the floor and ceiling effects were firstly evaluated and 
defined as being present if more than 15% of respondents achieved the lowest or 
highest possible scores133. This was followed by a relative efficiency calculation to 
analyse responsiveness of the ATRS versus the EQ-5D and DRI, according to Barr 
et al137. Using this method a score of greater than one would indicate the ATRS was 
more responsive than the EQ-5D and DRI, conversely a score less than one would 
indicate the ATRS to be less responsive than the EQ-5D and DRI. 
 
7.1.6 End of study 
The end of the study was defined as the final visit to the clinic of the last participant. 
 
7.1.7 Data management  
The questionnaires were compiled by the researcher in conjunction with the lead 
PhD Supervisor (Mr Matthew Costa) who is also the clinical lead for this service.  
 
All electronic patient-identifiable information was held on a secure, password-
protected database accessible only to essential personnel, as per standard 
operating procedures for Warwick University. Patients were identified by a code 
number only. Data was entered by the research physiotherapist onto the electronic 
database immediately following each research clinic.  
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Direct access to source data/documents was required for clinical governance and 
by the research team for data entry and analysis only. All paper and electronic data 
would to be retained for at least five years after completion of the study. 
Additionally, as part of ongoing PhD supervision, the supervisors had reviewed this 
protocol for this study and have received progress reports at their request.  
 
Accumulating data was monitored at frequent intervals to identify and facilitate the 
early remedial action of certain problems that may include data collection and 
compliance. Yearly progress reports were also submitted to the funders of this 
project (Arthritis Research UK), as outlined within the terms and conditions of the 
awarded grant.  
 
The day to day management of the project was carried out by the researcher and 
overseen by the PhD supervisors. Financial support for this project had been 
awarded by Arthritis Research UK. Treatment costs associated with this study had 
been reviewed by the NHS research and development department. The project 
timetable and milestones are outlined in Table 7.1. 
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Table 7.1: Project timetable 
 
 
7.2 Results 
Recruitment took place between August 2007 and June 2009. During this time 70 
midsubstance TA ruptures presented to the fracture clinic. Of these 70 patients, 
three did not meet the eligibility criteria because they were unable to complete the 
questionnaires. A further three patients were eligible and refused to complete the 
questionnaires.  
 
The remaining 64 patients completed the ATRS, DRI and EQ-5D questionnaires at 
six weeks, three months, six months and nine months. At the six week time point 
one patient was lost to follow up, therefore 63 (98%) patients were followed up, 
followed by 60 (94%) patients at three months, 58 (91%) at six months and 56 
(88%) at nine months.  
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Figure 7.2: Flow of participants throughout the trial period 
 
The baseline demographics of the included patients are presented in Table 7.2. 
These demographics illustrate that this sample is consistent with the current 
literature, identifying the male, 30-40 year age group the most likely to sustain this 
injury. There was an even distribution of left and right feet affected and the majority 
received non-operative management. 
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Table 7.2: Patient demographics 
 Baseline demographics 
Mean age in years (SD) 44 years (12) 
Male/Female 48/16 
Left/Right 34/30 
Mean height in cm (SD) 172cm (10) 
Mean weight in Kg (SD) 80Kg (17) 
Management (Op/Non-Op) 19/45 
 
7.2.1 Analysis: Descriptive 
Table 7.3 through to Table 7.7 illustrate the minimum, maximum, mean, standard 
deviation, median and inter-quartile ranges for the overall scores of the ATRS, DRI 
and EQ-5D, and for the individual items within each questionnaire that together form 
the overall score. 
 
The tables illustrate how the three overall outcome measures demonstrate a 
gradual return to pre-injury scores over the nine month time period. Over this nine 
month period overall scores from the ATRS ranged from 2 to 100, DRI ranged from 
0 to 81 and EQ-5D ranged from 0.12 to 1. The standard deviations across all time 
points of the overall ATRS scores ranged from 16 to 23, DRI ranged from 12 to 17 
and EQ-5D from 0.09 to 0.19. The standard deviation amongst the individual items 
that formed each score ranged from 1 to 4 within the ATRS and DRI, which are both 
measured on a ten point scale. The items with the larger standard deviations were 
those asked at the six and nine month time points within the items regarding 
heavier/higher impact activities such as heavy work, return to sports, jumping and 
running. 
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Table 7.3: Descriptive statistics for ATRS, DRI and EQ-5D pre-injury scores 
Q. Item n = Min Max Mean SD Med IQR 
 Overall ATRS Score 64 7 100 91 21 100 5 
1 Are you limited because of decreased 
strength in the calf/Achilles tendon/foot? 
64 1 10 9 2 10 0 
2 Are you limited because of fatigue in the 
calf/Achilles tendon/foot? 
64 1 10 9 2 10 0 
3 Are you limited due to stiffness in the 
calf/Achilles tendon/foot? 
64 1 10 9 2 10 0 
4 Are you limited because of pain in the 
calf/Achilles tendon/foot? 
64 1 10 9 2 10 0 
5 Are you limited during activities of daily 
living? 
64 1 10 9 2 10 0 
6 Are you limited when walking on uneven 
surfaces? 
64 1 10 9 2 10 0 
7 Are you limited when walking quickly 
upstairs or uphill? 
64 1 10 9 2 10 0 
8 Are you limited during activities that 
include running? 
64 0 10 9 3 10 1 
9 Are you limited during activities that 
include jumping 
64 0 10 9 3 10 1 
10  Are you limited in performing hard 
physical labour 
64 0 10 9 3 10 0 
 Overall DRI Score 64 0 65 6 13 1 5 
1 Dressing (without help) 64 0 5 0 1 0 0 
2 Out-door walks 64 0 8 0 1 0 0 
3 Climbing Stairs 64 0 7 0 1 0 0 
4 Sitting longer time 64 0 5 0 1 0 0 
5 Standing bent over a sink 64 0 9 1 2 0 0 
6 Carrying a bag 64 0 6 0 1 0 0 
7 Making a bed 64 0 6 0 1 0 0 
8 Running 64 0 10 1 3 0 1 
9 Light work 64 0 6 0 1 0 0 
10 Heavy work 64 0 10 1 2 0 0 
11 Lifting heavy objects 64 0 10 1 3 0 0 
12 Participating in exercise/sports 64 0 10 1 2 0 0 
 Overall EQ-5D 64 0.64 1 0.96 0.09 1.00 0.00 
1 Mobility 64 1 2 1 0 1 0 
2 Self-care 64 1 2 1 0 1 0 
3 Usual activities 64 1 2 1 0 1 0 
4 Pain and Discomfort 64 1 2 1 0 1 0 
5  Anxiety and Depression 64 1 2 1 0 1 0 
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Table 7.4: Descriptive statistics for ATRS, DRI and EQ-5D recorded at six weeks   
Q. Item n = Min Max Mean SD Med IQR 
 Overall ATRS Score 63 5 88 35 19 35 25 
1 Are you limited because of decreased 
strength in the calf/Achilles tendon/foot? 
63 0 10 4 3 3 5 
2 Are you limited because of fatigue in the 
calf/Achilles tendon/foot? 
63 0 10 4 3 5 5 
3 Are you limited due to stiffness in the 
calf/Achilles tendon/foot? 
63 0 10 5 3 4 5 
4 Are you limited because of pain in the 
calf/Achilles tendon/foot? 
63 0 10 6 3 7 5 
5 Are you limited during activities of daily 
living? 
63 1 10 5 3 5 5 
6 Are you limited when walking on uneven 
surfaces? 
63 0 10 4 3 3 4 
7 Are you limited when walking quickly 
upstairs or uphill? 
63 0 10 3 3 3 4 
8 Are you limited during activities that 
include running? 
63 0 10 1 2 0 1 
9 Are you limited during activities that 
include jumping 
63 0 10 1 2 0 1 
10  Are you limited in performing hard 
physical labour 
63 0 10 2 2 1 2 
 Overall DRI Score 63 0 81 41 17 39 23 
1 Dressing (without help) 63 0 7 1 1 1 1 
2 Out-door walks 63 0 10 4 3 4 4 
3 Climbing Stairs 63 0 9 3 2 2 4 
4 Sitting longer time 63 0 8 1 2 0 3 
5 Standing bent over a sink 63 0 9 2 2 1 3 
6 Carrying a bag 63 0 10 2 3 1 4 
7 Making a bed 63 0 9 2 2 1 3 
8 Running 63 0 10 9 2 10 0 
9 Light work 63 0 10 3 3 2 5 
10 Heavy work 63 0 10 7 3 8 5 
11 Lifting heavy objects 63 0 10 7 4 9 7 
12 Participating in exercise/sports 63 0 10 9 3 10 1 
 Overall EQ-5D 63 0.12 1.00 0.70 0.19 0.69 0.23 
1 Mobility 63 1 2 2 0 2 1 
2 Self-care 63 1 2 1 0 1 1 
3 Usual activities 63 1 3 2 1 2 0 
4 Pain and Discomfort 63 1 3 2 1 1 1 
5  Anxiety and Depression 63 1 2 1 0 1 0 
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Table 7.5: Descriptive statistics for ATRS, DRI and EQ-5D recorded at three months 
Q. Item n = Min Max Mean SD Med IQR 
 Overall ATRS Score 60 2 71 40 16  38 24 
1 Are you limited because of decreased 
strength in the calf/Achilles tendon/foot? 
60 1 9 4 2 5 4 
2 Are you limited because of fatigue in the 
calf/Achilles tendon/foot? 
60 0 10 5 3 5 4 
3 Are you limited due to stiffness in the 
calf/Achilles tendon/foot? 
60 0 10 5 2 5 4 
4 Are you limited because of pain in the 
calf/Achilles tendon/foot? 
60 0 10 6 3 7 4 
5 Are you limited during activities of daily 
living? 
60 0 10 6 2 6 4 
6 Are you limited when walking on uneven 
surfaces? 
60 0 10 5 3 5 4 
7 Are you limited when walking quickly 
upstairs or uphill? 
60 0 10 4 2 4 4 
8 Are you limited during activities that 
include running? 
60 0 5 1 1 0 1 
9 Are you limited during activities that 
include jumping 
60 0 4 0 1 0 1 
10  Are you limited in performing hard 
physical labour 
60 0 7 2 2 2 2 
 Overall DRI Score 60 0 79 33 15 33 20 
1 Dressing (without help) 60 0 5 0 1 0 0 
2 Out-door walks 60 0 10 3 2 2 5 
3 Climbing Stairs 60 0 8 2 2 2 4 
4 Sitting longer time 60 0 8 1 2 0 0 
5 Standing bent over a sink 60 0 8 1 2 0 1 
6 Carrying a bag 60 0 8 1 2 0 1 
7 Making a bed 60 0 8 1 2 0 2 
8 Running 60 0 10 9 2 10 0 
9 Light work 60 0 8 2 2 1 3 
10 Heavy work 60 0 10 6 3 6 6 
11 Lifting heavy objects 60 0 10 6 3 5 6 
12 Participating in exercise/sports 60 0 10 8 3 10 4 
 Overall EQ-5D 60 0.52 1.00 0.76 0.11 0.69 0.12 
1 Mobility 60 1 2 2 0 2 1 
2 Self-care 60 1 2 1 0 1 0 
3 Usual activities 60 1 3 2 1 2 0 
4 Pain and Discomfort 60 1 2 2 1 2 1 
5  Anxiety and Depression 60 1 2 1 0 1 0 
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Table 7.6: Descriptive statistics for ATRS, DRI and EQ-5D recorded at six months 
Q. Item n = Min Max Mean SD Med IQR 
 Overall ATRS Score 58 15 100 66 23 72 41 
1 Are you limited because of decreased 
strength in the calf/Achilles tendon/foot? 
58 1 10 7 2 7 4 
2 Are you limited because of fatigue in the 
calf/Achilles tendon/foot? 
58 2 10 7 3 8 4 
3 Are you limited due to stiffness in the 
calf/Achilles tendon/foot? 
58 1 10 7 2 8 3 
4 Are you limited because of pain in the 
calf/Achilles tendon/foot? 
58 1 10 8 3 9 4 
5 Are you limited during activities of daily 
living? 
58 1 10 8 2 9 3 
6 Are you limited when walking on uneven 
surfaces? 
58 1 10 8 3 9 4 
7 Are you limited when walking quickly 
upstairs or uphill? 
58 1 10 7 3 8 5 
8 Are you limited during activities that 
include running? 
58 0 10 4 4 5 7 
9 Are you limited during activities that 
include jumping 
58 0 10 4 3 4 6 
10  Are you limited in performing hard 
physical labour 
58 0 10 6 3 7 5 
 Overall DRI Score 58 0 72 16 14 15 17 
1 Dressing (without help) 58 0 1 0 0 0 0 
2 Out-door walks 58 0 7 1 2 0 1 
3 Climbing Stairs 58 0 7 1 1 0 1 
4 Sitting longer time 58 0 9 0 2 0 0 
5 Standing bent over a sink 58 0 5 0 1 0 0 
6 Carrying a bag 58 0 7 1 1 0 0 
7 Making a bed 58 0 10 1 2 0 0 
8 Running 58 0 10 5 4 5 8 
9 Light work 58 0 7 1 1 0 0 
10 Heavy work 58 0 10 2 3 1 5 
11 Lifting heavy objects 58 0 10 2 3 1 3 
12 Participating in exercise/sports 58 0 10 4 4 4 7 
 Overall EQ-5D 58 0.43 1.00 0.87 0.14 0.88 0.25 
1 Mobility 58 1 2 1 0 1 1 
2 Self-care 58 1 1 1 0 1 0 
3 Usual activities 58 1 3 1 1 1 1 
4 Pain and Discomfort 58 1 2 1 1 1 1 
5  Anxiety and Depression 58 1 2 1 0 1 0 
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Table 7.7: Descriptive statistics for ATRS, DRI and EQ-5D recorded at nine months 
Q. Item n = Min Max Mean SD Med IQR 
 Overall ATRS Score 56 25 100 79 20 86 32 
1 Are you limited because of decreased 
strength in the calf/Achilles tendon/foot? 
56 2 10 8 2 8 2 
2 Are you limited because of fatigue in the 
calf/Achilles tendon/foot? 
56 2 10 8 2 9 3 
3 Are you limited due to stiffness in the 
calf/Achilles tendon/foot? 
56 2 10 8 2 9 3 
4 Are you limited because of pain in the 
calf/Achilles tendon/foot? 
56 0 10 9 2 9 2 
5 Are you limited during activities of daily 
living? 
56 1 10 9 2 10 1 
6 Are you limited when walking on uneven 
surfaces? 
56 0 10 9 2 9 2 
7 Are you limited when walking quickly 
upstairs or uphill? 
56 0 10 8 2 9 2 
8 Are you limited during activities that 
include running? 
56 0 10 6 4 8 6 
9 Are you limited during activities that 
include jumping 
56 0 10 6 4 7 7 
10  Are you limited in performing hard 
physical labour 
56 0 10 8 3 9 3 
 Overall DRI Score 56 0 64 10 12 7 15 
1 Dressing (without help) 56 0 3 0 0 0 0 
2 Out-door walks 56 0 4 1 1 0 0 
3 Climbing Stairs 56 0 6 0 1 0 0 
4 Sitting longer time 56 0 8 0 1 0 0 
5 Standing bent over a sink 56 0 5 0 1 0 0 
6 Carrying a bag 56 0 4 0 1 0 0 
7 Making a bed 56 0 5 0 1 0 0 
8 Running 56 0 10 4 4 2 8 
9 Light work 56 0 5 0 1 0 0 
10 Heavy work 56 0 9 1 2 0 2 
11 Lifting heavy objects 56 0 10 2 3 0 1 
12 Participating in exercise/sports 56 0 10 3 4 2 6 
 Overall EQ-5D 56 0.69 1.00 0.93 0.11 1.00 0.20 
1 Mobility 56 1 2 1 0 1 0 
2 Self-care 56 1 1 1 0 1 0 
3 Usual activities 56 1 2 1 0 1 0 
4 Pain and Discomfort 56 1 2 1 0 1 0 
5  Anxiety and Depression 56 1 2 1 0 1 0 
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7.2.2 Analysis: Internal consistency 
The ATRS comprises of ten items that measure a single construct, ‘symptoms and 
physical activity’. Consequently, we assume that all the items on a scale are 
positively correlated with each other because they are all evaluating the same 
construct. This concept can be evaluated using Cronbach’s alpha at each time 
point, within SPSS (v.17.0). This is a reliability coefficient based on the average 
inter-item correlations. It is calculated using the following equation: 
 
 
 
Where N equals the number of items within the questionnaire and  is equal to the 
mean inter-item correlation. Based on this equation it is clear to see that the 
Cronbach’s alpha will increase if either the number of items within the score is 
increased or the inter-item correlation increases. 
 
The Cronbach’s alpha results for the ATRS at each time point are shown in Table 
7.8. It demonstrates that the ATRS outcome measure displays an acceptable level 
of internal consistency, as defined as a value above 0.7136.  
 
Table 7.9 through to Table 7.13 show the inter-item correlation matrix’s for each 
time point. They illustrate how each item correlates with each other. For example, 
item one compared to item one has a correlation coefficient of one, as expected. 
These tables also show how the Cronbach’s alpha would alter if a single item were 
deleted from the ATRS measurement tool. 
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Table 7.8: Cronbach’s alpha for ATRS at each time point 
Time point Cronbach’s alpha 
Pre-injury 0.98 
Six weeks 0.89 
Three months 0.89 
Six months 0.95 
Nine months 0.94 
 
The results of these tables consistently show, across all time points, that deletion of 
any single item only changes the internal consistency by a maximum of 0.03. 
Evaluating the inter-item correlation matrix’s it is clear that items eight, nine and ten 
at the six week and three month time points correlate less with items one to seven. 
This would be expected at these time points, because these items measure 
jumping, running and hard physical labour that patients would not be expected to be 
doing at these time points. The inter-item correlations of items eight, nine and ten 
are more highly correlated with the remaining ten items at the six and nine month 
time points. At these time points the assessed patients would be expected to be 
performing these activities.  
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Table 7.9: Pre-injury inter-item correlation matrix and example of Cronbach’s alpha 
result if a single item were deleted 
 1 2 3 4 5 6 7 8 9 10 If deleted 
1 1.00 0.96 0.89 0.93 0.90 0.94 0.95 0.80 0.81 0.87 0.98 
2 0.96 1.00 0.92 0.93 0.90 0.95 0.94 0.79 0.75 0.80 0.98 
3 0.89 0.92 1.00 0.92 0.85 0.91 0.85 0.70 0.68 0.79 0.98 
4 0.93 0.93 0.92 1.00 0.81 0.89 0.86 0.70 0.70 0.75 0.98 
5 0.90 0.90 0.85 0.81 1.00 0.91 0.95 0.82 0.79 0.88 0.98 
6 0.94 0.95 0.91 0.89 0.91 1.00 0.95 0.81 0.81 0.85 0.98 
7 0.95 0.94 0.85 0.86 0.95 0.95 1.00 0.86 0.85 0.89 0.98 
8 0.80 0.79 0.70 0.70 0.82 0.81 0.86 1.00 0.94 0.83 0.98 
9 0.81 0.75 0.68 0.70 0.79 0.81 0.85 0.94 1.00 0.88 0.98 
10 0.87 0.80 0.79 0.75 0.88 0.85 0.89 0.83 0.88 1.00 0.98 
 
Table 7.10: Six week inter-item correlation matrix and example of Cronbach’s alpha 
result if a single item were deleted 
 1 2 3 4 5 6 7 8 9 10 If deleted 
1 1.00 0.80 0.61 0.47 0.59 0.57 0.60 0.27 0.24 0.24 0.87 
2 0.80 1.00 0.84 0.62 0.58 0.58 0.57 0.30 0.25 0.23 0.87 
3 0.61 0.84 1.00 0.63 0.48 0.49 0.39 0.21 0.14 0.10 0.88 
4 0.47 0.62 0.63 1.00 0.65 0.49 0.43 0.20 0.13 0.31 0.88 
5 0.59 0.58 0.48 0.65 1.00 0.47 0.60 0.07 0.06 0.40 0.88 
6 0.57 0.58 0.49 0.49 0.47 1.00 0.81 0.25 0.26 0.37 0.87 
7 0.60 0.57 0.39 0.43 0.60 0.81 1.00 0.44 0.45 0.55 0.87 
8 0.27 0.30 0.21 0.20 0.07 0.25 0.44 1.00 0.84 0.63 0.89 
9 0.24 0.25 0.14 0.13 0.06 0.26 0.45 0.84 1.00 0.68 0.89 
10 0.24 0.23 0.10 0.31 0.40 0.37 0.55 0.63 0.68 1.00 0.89 
 
Table 7.11: Three month inter-item correlation matrix and example of Cronbach’s 
alpha result if a single item were deleted 
 1 2 3 4 5 6 7 8 9 10 If deleted 
1 1.00 0.79 0.64 0.33 0.50 0.58 0.55 0.30 0.30 0.30 0.87 
2 0.79 1.00 0.73 0.55 0.53 0.63 0.58 0.13 0.15 0.31 0.86 
3 0.64 0.73 1.00 0.49 0.54 0.65 0.65 0.18 0.13 0.24 0.87 
4 0.33 0.55 0.49 1.00 0.66 0.58 0.47 0.02 0.03 0.39 0.88 
5 0.50 0.53 0.54 0.66 1.00 0.70 0.48 0.10 0.10 0.39 0.87 
6 0.58 0.63 0.65 0.58 0.70 1.00 0.80 0.15 0.12 0.49 0.86 
7 0.55 0.58 0.65 0.47 0.48 0.80 1.00 0.32 0.29 0.54 0.86 
8 0.30 0.13 0.18 0.02 0.10 0.15 0.32 1.00 0.92 0.31 0.89 
9 0.30 0.15 0.13 0.03 0.10 0.12 0.29 0.92 1.00 0.34 0.89 
10 0.30 0.31 0.24 0.39 0.39 0.49 0.54 0.31 0.34 1.00 0.88 
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Table 7.12: Six month inter-item correlation matrix and example of Cronbach’s alpha 
result if a single item were deleted 
 1 2 3 4 5 6 7 8 9 10 If deleted 
1 1.00 0.79 0.73 0.61 0.63 0.56 0.65 0.66 0.66 0.65 0.94 
2 0.79 1.00 0.79 0.69 0.67 0.57 0.69 0.60 0.57 0.81 0.94 
3 0.73 0.79 1.00 0.72 0.79 0.62 0.69 0.49 0.42 0.65 0.94 
4 0.61 0.69 0.72 1.00 0.82 0.73 0.73 0.49 0.40 0.72 0.94 
5 0.63 0.67 0.79 0.82 1.00 0.82 0.86 0.56 0.46 0.72 0.94 
6 0.56 0.57 0.62 0.73 0.82 1.00 0.85 0.58 0.47 0.74 0.94 
7 0.65 0.69 0.69 0.73 0.86 0.85 1.00 0.68 0.57 0.74 0.94 
8 0.66 0.60 0.49 0.49 0.56 0.58 0.68 1.00 0.93 0.65 0.94 
9 0.66 0.57 0.42 0.40 0.46 0.47 0.57 0.93 1.00 0.59 0.95 
10 0.65 0.81 0.65 0.72 0.72 0.74 0.74 0.65 0.59 1.00 0.94 
 
Table 7.13: Nine month inter-item correlation matrix and example of Cronbach’s alpha 
result if a single item were deleted 
 1 2 3 4 5 6 7 8 9 10 If deleted 
1 1.00 0.86 0.81 0.57 0.69 0.69 0.73 0.71 0.70 0.73 0.92 
2 0.86 1.00 0.92 0.65 0.69 0.68 0.73 0.60 0.56 0.79 0.92 
3 0.81 0.92 1.00 0.60 0.71 0.64 0.74 0.61 0.54 0.74 0.92 
4 0.57 0.65 0.60 1.00 0.70 0.44 0.57 0.28 0.32 0.50 0.94 
5 0.69 0.69 0.71 0.70 1.00 0.70 0.82 0.34 0.32 0.57 0.93 
6 0.69 0.68 0.64 0.44 0.70 1.00 0.79 0.52 0.51 0.69 0.93 
7 0.73 0.73 0.74 0.57 0.82 0.79 1.00 0.53 0.51 0.65 0.93 
8 0.71 0.60 0.61 0.28 0.34 0.52 0.53 1.00 0.94 0.71 0.94 
9 0.70 0.56 0.54 0.32 0.32 0.51 0.51 0.94 1.00 0.63 0.93 
10 0.73 0.79 0.74 0.50 0.57 0.69 0.65 0.71 0.63 1.00 0.92 
 
7.2.3 Analysis: Criterion (concurrent) validity 
As outlined within the protocol, concurrent validity was to be evaluated through 
assessing correlation coefficients alongside scatter plots of the data for overall DRI 
scores compared with overall ATRS scores. Before the appropriate statistical 
evaluation could be undertaken (Pearson correlation coefficient for parametric data 
and Spearman’s rank correlation coefficient for non-parametric data) exploratory 
data analysis was carried out. 
 
Probability plots were used to assess whether or not the data sets for ATRS scores 
at each time point were normally distributed. The probability plots are graphs with 
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observed cumulative percentage on X axis and expected cumulative percentage on 
Y axis. If the selected variable matches the test distribution, the points cluster 
around a straight line. These were evaluated alongside histograms, plotting ATRS 
scores against frequency, with imposed distribution curves. These are shown in 
Figure 7.3 through to Figure 7.7. 
 
Graphically it can be seen that the ATRS data at pre-injury, six months and nine 
months are not normally distributed. The data at six weeks and three months are 
normally distributed. To further analyse these data sets a shapiro-wilk analysis was 
carried out. This analysis is based upon the null hypothesis that the samples are 
taken from a normal distribution. This null hypothesis was shown to be true for the 
six week and three month data sets (p=0.102 and 0.449). However it was rejected 
for baseline (p<0.001), six month (p=0.016) and nine month (p<0.001) data points. 
Therefore Spearman’s rank correlation coefficient, which can be used in both 
parametric and non-parametric situations, was used to evaluate concurrent validity 
of the ATRS when compared to the DRI at each time point.  
 
As Table 7.14 demonstrates the ATRS scores are significantly correlated with the 
overall DRI scores at each time point. The correlations are stronger at the six and 
nine month time points (-0.7 and -0.9) when compared to pre-injury, six weeks and 
three months (-0.6, -0.5 and -0.5). Accompanying scatter plots are illustrated in 
Figure 7.8 to Figure 7.12, graphically representing these statistically significant 
correlations (p<0.001). 
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Figure 7.3: P-P plot and histogram with distribution curve for baseline ATRS scores 
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Figure 7.4: P-P plot and histogram with distribution curve for six week ATRS scores 
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Figure 7.5: P-P plot and histogram with distribution curve for three month ATRS scores 
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Figure 7.6: P-P plot and histogram with distribution curve for six month ATRS scores 
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Figure 7.7: P-P plot and histogram with distribution curve for nine month ATRS scores 
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Table 7.14: Correlation coefficients (95% confidence intervals) for ATRS and DRI 
 
 Correlation coefficient Significance 
Pre-injury -0.6 (-0.78 to -0.30) <0.001 
6 Weeks -0.5 (-0.68 to -0.28) <0.001 
3 Months -0.5 (-0.76 to -0.37) <0.001 
6 Months -0.7 (-0.80 to -0.36) <0.001 
9 Months -0.9 (-0.94 to -0.83) <0.001 
 
Figure 7.8: Scatter plot of ATRS and DRI baseline scores 
 
Figure 7.9: Scatter plot of ATRS and DRI six week scores 
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Figure 7.10: Scatter plot of ATRS and DRI three month scores 
 
Figure 7.11: Scatter plot of ATRS and DRI six month scores 
 
Figure 7.12: Scatter plot of ATRS and DRI nine month scores 
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7.2.4 Analysis: Construct validity 
To evaluate construct validity the overall ATRS scores were compared to the three 
subscales of the DRI. ATRS scores were also compared to overall EQ-5D scores, 
which is a quality of life measure. This was achieved through Spearman’s rank 
correlation coefficient analysis, with accompanying scatter plots at each time point. 
 
The correlation coefficient results for the overall ATRS compared to EQ-5D and the 
sub-scales of DRI at each time point can be found in Table 7.15. In relation to the 
overall EQ-5D score the expected size of the correlations did not reach the 0.7 
value. Regarding the three DRI sub-divisions, this was also not met by the first sub-
division of ‘common basic activities of daily life’. This criteria was only met within the 
last time point of the second and third sub-divisions. 
Table 7.15: Correlation coefficients (95% confidence intervals) for overall ATRS 
scores when compared to the three sub-scales of the DRI and EQ-5D scores. 
Time 
point 
 
EQ-5D DRI (1) DRI (2) DRI (3) 
Pre-injury Correlation 
coefficient 
0.4 
(0.65 to 0.20) 
-0.5 
(-0.74 to -0.25) 
-0.5 
(-0.71 to -0.21) 
-0.6 
(-0.80 to -0.40) 
 Significance <0.001 <0.001 <0.001 <0.001 
6 Week Correlation 
coefficient 
0.5 
(0.69 to 0.33) 
-0.5 
(-0.68 to -0.33) 
-0.3 
(-0.50 to -0.04) 
-0.3 
(-0.59 to -0.13) 
 Significance <0.001 <0.001 0.009 0.007 
3 Month Correlation 
coefficient 
0.6 
(0.75 to 0.32) 
-0.5 
(-0.74 to -0.28) 
-0.5 
(-0.72 to -0.24) 
-0.3 
(-0.55 to 0.20) 
 Significance <0.001 <0.001 <0.001 0.020 
6 Month Correlation 
coefficient 
0.5 
(0.70 to 0.21) 
-0.5 
(-0.73 to -0.24) 
-0.7 
(-0.85 to -0.45) 
-0.6 
(-0.78 to -0.41) 
 Significance <0.001 <0.001 <0.001 <0.001 
9 Month Correlation 
coefficient 
0.3 
(0.51 to 0.01) 
-0.4 
(-0.64 to -0.40) 
-0.9 
(-0.92 to -0.80) 
-0.8 
(-0.90 to -0.68) 
 Significance 0.020 0.0010 <0.001 <0.001 
 
Scatter plots graphically presenting the relationships between the overall ATRS and 
EQ-5D scores at each time point can be found in Figure 7.13 through to Figure 
7.17.  
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Figure 7.13:Scatter plot of pre-injury ATRS scores and  EQ-5D scores 
 
Figure 7.14: Scatter plot of six week ATRS scores and six week EQ-5D scores 
 
Figure 7.15: Scatter plot of three month ATRS scores and three month EQ-5D scores 
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Figure 7.18 through to Figure 7.25 graphically represent the relationship between 
the overall ATRS scores compared to the three sub-scales of the DRI at each time 
point. 
 
  
 
Figure 7.16: Scatter plot of six month ATRS scores and six month EQ-5D scores  
 
 
Figure 7.17: Scatter plot of nine month ATRS scores and nine month EQ-5D scores 
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Figure 7.18: Scatter plot of pre-injury ATRS and DRI scores for domain one 
 
Figure 7.19:  Scatter plot of pre-injury ATRS and DRI scores for domain two 
 
Figure 7.20:  Scatter plot of pre-injury ATRS and DRI scores for domain three 
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Figure 7.21:  Scatter plot of six week ATRS and DRI six week scores for domain one 
 
Figure 7.22:  Scatter plot of six week ATRS and DRI six week scores for domain two 
 
Figure 7.23:  Scatter plot of six week ATRS and DRI six week scores for domain three 
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Figure 7.24: Scatter plot of three month ATRS and DRI three month scores for domain one 
 
Figure 7.25: Scatter plot of three month ATRS and DRI three month scores for domain two 
 
Figure 7.26: Scatter plot of three month ATRS and DRI three month scores for domain three 
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Figure 7.27: Scatter plot of six month ATRS and DRI six month scores for domain one 
 
Figure 7.28: Scatter plot of six month ATRS and DRI six month scores for domain two 
 
Figure 7.29: Scatter plot of six month ATRS and DRI six month scores for domain three 
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Figure 7.30: Scatter plot of nine month ATRS and DRI nine moth scores for domain one 
 
Figure 7.31: Scatter plot of nine month ATRS and DRI nine month scores for domain two 
 
Figure 7.32: Scatter plot of nine month ATRS and DRI nine month scores for domain three 
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7.2.5 Analysis: Responsiveness 
Floor and ceiling effects were the first aspect of responsiveness evaluated. Floor 
and ceiling effects were defined as being present if more than 15% of respondents 
achieved the highest or lowest scores. Table 7.16 illustrates the percentage of 
reported responses at the top (ceiling) of the total possible scores for the ATRS, 
DRI and EQ-5D and the percentage of reported responses at the bottom (floor) of 
the possible score for the ATRS, DRI and EQ-5D.  
 
Table 7.16: Percentage of ATRS, EQ-5D and DRI respondents at either the floor or 
ceiling of the score. 
Time point % Ceiling % Floor 
 ATRS EQ-5D DRI ATRS EQ-5D DRI 
Pre-injury 58% 81% 47% 0% 0% 0% 
6 Weeks 0% 6% 3% 0% 0% 0% 
3 Months 0% 8% 0% 0% 0% 0% 
6 Months 4% 58% 9% 0% 0% 0% 
9 Months 11% 66% 14% 0% 0% 0% 
 
 
All three scores demonstrate a ceiling effect (defined as >15% respondents) for 
reported pre-injury scores, which was highest for the more generic quality of life 
measure, EQ-5D. The ATRS and DRI scores did not demonstrate a ceiling effect at 
any other time point. This was in contrast to the EQ-5D, which demonstrated further 
ceiling effects at the six and nine moth time points. None of the three outcome 
measures demonstrated any floor effects. 
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Table 7.17 shows the relative efficiency of the ATRS in relation to the EQ-5D and 
DRI at each time point. This method of evaluating responsiveness was chosen 
because it does not require parametric assumptions. The non-parametric relative 
efficiency is calculated using the z statistic derived from the Wicoxon sign rank test 
and the following equation: 
 
Table 7.17: Relative efficiency of the ATRS across all time points 
Time point 
ATRS: Z 
statistic  
EQ-5D: Z 
statistic 
DRI Z 
statistic 
Relative efficiency 
ATRS versus EQ-5D 
Relative efficiency 
ATRS versus DRI 
Pre-injury/6week -6.8 -6.5 -6.7 (-6.8/-6.5)
2 
= 1.1 (-6.8/-6.7)
2 
= 1.0 
Pre-injury/3 month -6.7 -6.3 -6.2 (-6.7/-6.3)
2 
= 1.1 (-6.7/-6.2)
2 
= 1.2 
Pre-injury/6 month -5.5 -4.3 -4.8 (-5.5/-4.3)
2 
= 2.1 (-5.5/-4.8)
2 
= 1.3 
Pre-injury/9 month -4.6 -2.3 -2.8 (-4.6/-2.3)
2 
= 4 (-4.6/-2.8)
2 
= 2.7 
 
 
On all occasions the ATRS demonstrated greater responsiveness when compared 
to the DRI and EQ-5D. At the six month time point the ATRS was 2.1 times more 
responsive than the EQ-5D, and at nine months it was four times more responsive. 
The same trends were evident when compared to the DRI, but to a lesser extent, 
with the ATRS being 1.3 times more responsive at six months and 2.7 times more 
responsive at nine months. 
 
7.3 Discussion 
The ATRS was published in 2007, and advocated by the authors as the only 
validated PROM available to evaluate patients following a TA rupture61. However, 
there has been no subsequent validation studies published. Therefore the objective 
of this chapter was to investigate aspects of validity of this newly developed PROM. 
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The original development of the ATRS was in Swedish, using a sample of patients 
aged 20-70 years, with acute TA ruptures. The questionnaires were administered at 
one time point to 115 patients, a minimum of three months post injury to a maximum 
of 3 years. Subsequently, it was considered important to further investigate data to 
support the English translation of this outcome measure. Secondly, it was 
considered that the original paper was not representative of the bi-modal distribution 
of this injury (affecting patients post 70 years of age) and therefore should also be 
evaluated in a sample with no upper age limit10. Finally the original paper did not 
evaluate the outcome measure, both, in the acute phases of this injury (pre-3 
months) and across time within the same patient.  
 
Within the context of the above, the specific aspects of validity addressed by this 
chapter were internal consistency, criterion validity, construct validity and 
responsiveness. The results demonstrated at each time point that the ATRS had 
high internal consistency (Cronbach’s alpha between 0.89 and 0.95). However a 
result above 0.90 has been debated within the literature as being an indication that 
the outcome is too homogeneous138-139, the implication of this is that further item 
reduction may be appropriate131. This finding is consistent with the original 
development article, which also reported a high internal consistency, with a 
Cronbachs alpha of 0.96, however no suggestion for item reduction was made by 
the authors in light of this result. 
 
Criterion validity of the score was not evaluated within the original article. The 
authors stated that there was no gold standard with which to compare to. Within this 
study the DRI score was used as a ‘gold standard’ to evaluate criterion validity. It is 
acknowledged that this is not a disease specific outcome measure, but has 
validation studies to support its use in an orthopaedic outpatient setting. On this 
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basis the DRI score was used as a gold standard, however the limitations of this are 
acknowledged.  
 
Spearman’s rank correlation coefficients between the DRI and ATRS demonstrated 
stronger correlations at the six and nine month time points (-0.67 and -0.91) when 
compared to baseline, six weeks and three months (-0.59, -0.52 and -0.46).These 
correlation coefficients indicate a moderate correlation, this may be expected as 
opposed to an exact/strong correlation on the basis that the DRI is not a disease 
specific measure. Also of note is that the confidence intervals around the correlation 
coefficients were wide. These wide confidence intervals may be an indication that a 
larger sample size was required for this study.  
 
Referring to the scatter plots for these correlations it is evident that the lower 
correlation coefficients at baseline, six weeks and three months are likely to be the 
result of higher scores being attained on the DRI compared to the ATRS. This could 
be secondary to none disease specific questions within the DRI pertaining to 
problems with sitting, washing-up and standing, which patients with Achilles tendon 
ruptures would not have any problems with at any stage of their recovery. This is 
also reflected within the descriptive data tables, which demonstrate the mean values 
for each score item at each time point. 
 
Construct validity and responsiveness were also addressed within this chapter. As 
would be expected, the ATRS correlated more strongly towards the third subscale 
of the DRI, which evaluates more demanding physical activities. This is in contrast 
to the first two subscales which address normal and light activities and the EQ-5D 
which evaluates a quality of life construct. Again the key limitation of these 
correlations is that the scores are measuring only similar constructs as opposed to 
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exact constructs. Again there were also large confidence intervals reported, 
indicating a larger sample may have been required. 
 
The more specific ATRS outcome measure demonstrated greater responsiveness 
than the more generic DRI and EQ-5D scores at each time point. These results 
were in keeping with the original development article. The level of responsiveness 
was only marginal in comparison to the DRI and EQ-5D up until the three month 
time point, with greater levels of responsiveness evident at the six month and nine 
month time points. This may by representative of the greater ceiling effects seen 
within the EQ-5D and DRI scores. There are many methods available to determine 
responsiveness140. This method was used as opposed to more routinely reported 
effect sizes because it does not require parametric assumptions. 
 
Investigating aspects of validity within the area of ‘PROM’s’ has been recognised as 
being a ‘grey’ area, where there is no consensus on the exact methodology to be 
used140. However there is agreement that validating a newly developed outcome 
measure is an ongoing process. This process involves the outcome measure being 
investigated in different countries, in different languages, across varying patient sub-
groups, within a range of clinical contexts. In relation to the TA, this would involve 
further research including patients with a delayed presentation or following tendon 
shortening/reconstruction procedures as an example.  
 
This chapter does not answer the question pertaining to whether or not the ATRS is 
a valid measure, but it does contribute further to the ongoing process of validating a 
newly developed outcome. Furthermore, despite the highlighted limitations, this is 
the only disease specific PROM available with any validation data to support its use, 
as discussed in the previous chapter. So whilst there is scope to further explore 
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aspects of validity of this new score, with larger samples, this study is a positive 
step towards the use of a universal measure of outcome for patients with a rupture 
of the Achilles tendon. 
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8.1 Review of thesis aims 
Within trauma and orthopaedics there has been an ever increasing trend towards 
the implementation of controlled trials to determine the clinical and cost 
effectiveness of interventions141. However, prior to the planning and implementation 
of such cost and time intensive endeavours, it is imperative that the researcher has 
fully investigated the components of the interventions to be trialled64.  
 
Clearly defining the components and the importance of underpinning them with 
relevant theory and context is pivotal to ensuring that the interventions to be later 
trialled are appropriate in design67. It is acknowledged that this in itself is not a 
simple task, and is reflected in the range of methodologies used to achieve these 
goals within different clinical contexts142-143. However in each case it is imperative to 
outline the literature to date, leading to the specific questions to be addressed. The 
first chapters of this thesis served this purpose. 
 
The introduction to this thesis summarised the clinical development of TA rupture 
management from the first documented report on the topic in 157525, through to the 
first RCT of operative versus non-operative repair in 198127. Numerous RCTs on the 
same topic followed, which were meta-analysed by the Cochrane group in 200439.  
 
This review group concluded that higher re-rupture rates were present amongst 
non-operatively managed patients. However, the key finding within this review lay 
within their comparison of NWB cast immobilisation to WB protocols. These 
comparisons demonstrated a reduction in re-rupture incidence from 12% to 2% 
within non-operatively managed patients which is equivalent to results seen in 
patients managed operatively. Therefore, with an already low incidence of other 
complications (3%), the authors discussed the need to investigate rehabilitation 
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strategies further, acknowledging that currently a wide range of protocols exists. 
Subsequently, before further research comparing rehabilitation protocols could 
proceed, this issue of the variation amongst protocols needed to be addressed. 
 
Weight bearing protocols contain a number of interacting components, and as such 
are defined as complex interventions. The problems and challenges associated with 
developing and defining complex interventions have been outlined by the MRC in a 
framework for researchers. Subsequently this framework has informed the basis for 
the overall aim of this thesis, which was to develop IWB interventions for patients 
who have sustained an acute rupture of their TA to inform a definitive evaluation of 
their effectiveness. To achieve this overall aim, four specific objectives were set, as 
follows: 
 
1) Systematically identify and summarise, from clinical studies, the components 
that define IWB interventions currently documented for the treatment of 
acute TA ruptures. 
2) Evaluate how these identified IWB components affect gait parameters within 
healthy participants, to provide a theoretical basis on which to develop 
interventions within a patient population. 
3) Pilot the IWB interventions in a patient population to enable evaluation of 
patient recruitment rates, follow up, PROM variability and CRF design. 
4) Systematically identify and critically evaluate the PROMS used within the 
published literature, and further evaluate elements of measurement 
properties of an appropriate disease specific PROM, to be used as a primary 
outcome measure within the evaluation phase. 
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In relation to the MRC framework, objectives one and two relate to the development 
phase and objectives three and four relate to feasibility and piloting. These phases 
subsequently inform the evaluation and implementation phases of the MRC 
framework. Consequently, the remaining sections of this thesis will firstly summarise 
the findings of the four objectives and then discuss the implications of these findings 
in relation to the subsequent phases of the MRC complex intervention framework. 
 
8.2 Limitations 
In relation to the methods used in this thesis, a number of important limitations need 
to be considered when drawing on the final conclusions. Firstly within the two 
chapters systematically reviewing data, the key limitations were related to the 
heterogeneity of the included studies. This had the subsequent implication that it 
was not appropriate to combine the outcome data sets. Furthermore, steps could 
have been taken by the researcher to pre-publish search strategies to increase the 
reliability of the findings.  
 
Within the experimental chapter (Gait analysis of healthy participant’s) the key 
limitation was the use of healthy participant’s. Consequently the results of this 
research could not be applied directly to a clinical context (limited external validity). 
Furthermore, this study had only evaluated a limited number of gait parameters. It is 
acknowledged that a variety of methods exist to evaluate gait parameters, of which 
pressure measurements and range of movement form only part. In relation to the 
specific conduct of the study, the main issues of reliability centred around the lack of 
independent intra tester data and lack of blinding of test conditions/analysis, which 
could introduce researcher bias. 
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In the later clinical studies, the sample size was the main concern and area for 
discussion. There are no formal methods for determining sample size calculations 
for pilot data, limiting the definitive conclusions that can be drawn from the data. 
However, this data was important for testing the interventions in practice and 
gaining data to inform future clinical studies in this area. These piloting phases also 
highlighted the potential confounding of including both operatively and non-
operatively managed patient’s, which is a further limitation of these studies. 
 
Within the exploration of PROM validity the main limitations of this research were 
centred on the lack of a defined ‘gold standard’ on which to base criterion validity 
and a lack of validated foot and ankle scores in related areas to compare aspects of 
construct validity. There was also the same issue of determining a sample size for 
this research, as again there are no established methods in this research context. 
 
Each study design was based around the MRC framework. However, this 
framework has also been subject to criticisms for not providing sufficient guidance to 
researchers regarding exactly how to achieve the aims of each phase. For example, 
although each of these chapters is based on the framework, other methodologies 
could have been implemented such as qualitative interviews with patients and staff, 
either prior to the piloting phase and/or after this phase. Such methods have been 
implemented by other authors to establish the implementation of the intervention 
from the staff and patient perspectives. However, it has also been discussed by 
previous authors that these processes prior to the evaluation stage are both cost 
and time intensive. Subsequently, with the lack of specific guidance provided by the 
framework, researchers have to judge the appropriate methods to be used, taking 
into account what is achievable within a specified time and budget, to ensure that 
the evaluation phase is not unduly delayed. 
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Consequently it can be clearly seen how although methodological issues were 
considered at each stage to ensure reliability and validity of the research findings, 
each chapter of this thesis could have been approached differently to further 
improve the methodological quality of the studies. These have been important 
learning points for the researcher throughout the thesis. 
 
8.3 Summary of study findings 
Following the introduction and aim of this thesis, Chapters 2 and 3 addressed the 
development phase of the MRC framework. More specifically, they aimed to 
systematically identify the evidence base and develop a theoretical framework on 
which to base future piloting and feasibility research. 
 
The systematic review, outlined in Chapter 2, identified nine articles presenting the 
results of 236 operatively, and 188 non-operatively managed patients using IWB 
rehabilitation protocols. As previously described by the Cochrane group, a wide 
variation was obviously evident. However, the results from this review enabled the 
identification of four components, which defined the interventions. These 
components consisted of; the type of AFO worn, the degree of restricted movement, 
the length of time for which the AFO is worn and the use of ROM exercises. 
However, it was not possible from this review to determine how these components 
or their interactions may affect treatment outcomes. Consequently, Chapter 3 aimed 
to provide further research to evaluate these identified components. 
 
The subsequent experimental design outlined in Chapter 3, trialled three AFOs with 
four heel wedge insert conditions to evaluate three hypotheses. These hypotheses 
were firstly, the effect of the AFO design regardless of the number of heel wedge 
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inserts, secondly, the effect of the heel wedge inserts regardless of the AFO design 
and thirdly, the interaction of the two conditions. 
 
The results demonstrated that AFOs that were restrictive in design, combined with a 
higher number of inserted heel wedges, prevented production of forefoot pressures, 
increased heel pressures and decreased the amount of time spent in the terminal 
stance and pre-swing phase of the gait cycle. Consequently, the choice of AFO 
design and the number of inserted heel wedges were shown to have a significant 
impact on planter pressure measurements and temporal gait parameters. These 
findings provided a theoretical framework on which to base feasibility and piloting 
procedures in a clinical setting. 
 
Chapters 4 and 5 relate specifically to the feasibility/piloting phase of the MRC 
framework. These chapters aimed to address a number of issues including the 
practicalities of implementing the interventions, compliance, estimating recruitment 
rates, follow up rates and parameters for determining sample size calculations. 
However, before this data can be used to move onto the next phase of evaluation 
and assessing effectiveness, the question regarding which outcome measure would 
be used and why required further investigation. 
 
Chapters 6 and 7 were designed to investigate this issue of outcome measures 
further. This was achieved by performing a systematic review to establish the 
PROMs reported in research articles and the evidence to support their use. From 
this review of the literature, the most appropriate PROM was chosen and aspects of 
its validity were developed further. 
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The results from these Chapters found that 21 PROMs had been reported in the 
literature pertaining to acute TA rupture management. However, only one disease 
specific outcome measure was found to have further evidence to support multiple 
facets of its validity. This outcome measure was the ATRS, which was investigated 
further within this thesis. The results of these further investigations supported the 
initial findings of the authors who developed the ATRS, and provided further 
evidence in relation to internal consistency, responsiveness, construct validity and 
criterion validity. 
 
In summary, the aim of this thesis was to develop an immediate weight bearing 
rehabilitation protocol, for patients who have sustained an acute rupture of their 
Achilles tendon, to inform a definitive evaluation of its effectiveness. To achieve this 
aim the MRC framework, for defining and developing interventions with several 
components, was used to underpin the structure of this thesis. This included the 
implementation of a range of study designs including systematic reviews, 
experimental designs, pilot clinical trials and outcome validation research. To 
achieve this, completion of this thesis has required demonstration of both research 
and personal development, overseen by expert supervisors.  
 
Using the MRC framework, the first chapters were focussed on the ‘pre-clinical’ 
development phase.  A systematic review of the evidence identified four 
components that defined immediate weight bearing rehabilitation. The first two were 
how long the AFO is worn and whether or not to include ROM exercises. Previous 
animal based research and an RCT have investigated tendon healing and the 
effects of early movement. This research has demonstrated that the proliferative 
phase of tendon healing lasts until approximately six weeks, at which point the 
healing tendon then enters a remodelling phase. Throughout these first weeks ROM 
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has been shown to have a preferential effect on these phases. The clinician can 
therefore justify wearing an AFO for at least six weeks whilst the patient 
simultaneously carries out ROM exercises from PF to neutral. 
 
This thesis therefore investigated the final two components, the type of AFO worn 
and the ankle position within it. These components were firstly evaluated in 
controlled gait analysis studies. The key findings showed that rigid orthoses designs 
with a large degree of plantarflexion, increased heel pressures, reduced forefoot 
pressures and decreased the amount of time spent in the terminal stance and pre-
swing phase of the gait cycle. However this research was conducted in healthy 
participants, not patients. 
 
The feasibility and piloting phases of these different combinations of AFO types and 
maintained ankle positions followed. These studies highlighted the balance that is 
needed between allowing sufficient flexibility and loaded movement against the 
clinical risk of tendon re-rupture. This was highlighted by the occurrence of three re-
ruptures in 15 patients during the second clinical phase using the more flexible 
AFO’s, which is higher than that reported in the literature. Furthermore this second 
clinical phase also included a greater proportion of non-operatively managed 
patient. This may also be a factor that influenced the observed higher re-rupture 
rate. However, previous RCT’s have shown immediate weight bearing in non-
operatively managed patients to be safe and a Cochrane review has shown lower 
re-rupture rates when compared to cast immobilisation. Therefore although the 
results in this research show higher than reported re-rupture rates, this is only a 
small sample and in the context of the wider literature it is established that 
immediate weight bearing interventions are safe and offer advantages over and 
above  immobilisation,  such as decreasing the risks of DVT’s. 
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This thesis defines the rehabilitation components, proposes a theoretical framework 
and tests this in practice. The results will ensure that rehabilitation after an acute 
Achilles tendon rupture is based on a systematically developed protocol rather than 
ad hoc practice. This will research will be used to inform future definitive research in 
this area. 
 
Consequently, it can be seen how each Chapter of this thesis has contributed to the 
overall aim of intervention development through to the next phase of evaluation. 
There are numerous advantages to the methods that have been used to achieve 
this progression. For example, these approaches have taken a step beyond the 
traditional approach of simply performing a systematic review prior to designing a 
full evaluation study64. They also adopt a pragmatic approach to evaluation that will 
lead to interventions that can work in practice and lead to a greater likelihood of 
success, secondary to focussing the intervention on the relevant components. 
 
However, these approaches have been based on the MRC framework, which has 
been subject to criticisms for not providing sufficient guidance to researchers 
regarding exactly how to achieve the aims of each phase144-145. For example, 
although each of these chapters is based on the framework, other methodologies 
could have been implemented such as qualitative interviews with patients and staff, 
either prior to the piloting phase and/or after this phase. Such methods have been 
implemented by other authors to establish the implementation of the intervention 
from the staff and patient perspectives144-145,149. However, it has also been 
discussed by previous authors that these processes prior to the evaluation stage 
are both cost and time intensive. Subsequently, with the lack of specific guidance 
provided by the framework, researchers have to judge the appropriate methods to 
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be used, taking into account what is achievable within a specified time and budget, 
to ensure that the evaluation phase is not unduly delayed142. 
 
8.4 Implications for future research 
The contribution to knowledge that this thesis has made is evidenced through a 
combination of activities. These include peer reviewed publications across 
orthopaedic, physiotherapy and sports medicine journals in addition to national and 
international presentations in the same field.  These have translated into clinical 
pathways locally and a debate surrounding the need for guidelines nationally. These 
knowledge contributions include the first steps towards systematically defining the 
intervention, proposing how to evaluate it (through validated PROM’s) and piloting 
the interventions in clinical practice. 
 
The work contained in this thesis has identified that IWB rehabilitation protocols vary 
within the literature, and has proposed a theoretical basis on which to develop 
rehabilitation interventions in practice. These interventions have been trialled in a 
clinical setting in a pilot/feasibility context, alongside further research investigating 
PROMs validity, to ensure that appropriate measures are used in the next 
evaluation phase. Therefore, the final logical conclusions of this thesis will be 
directed towards proposals for the next phase of evaluation. 
 
The first consideration needs to be directed towards defining the interventions to be 
trialled and why. This is because the greater the number of interventions to be 
evaluated, the greater the number of participants needed to reject the null 
hypotheses, which has a subsequent effect on resource allocation, recruitment time 
frames and ultimately the feasibility of conducting a definitive evaluative study. 
Inevitably, there are a number of methods to approaching this. 
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Firstly, interpreting the data collected and analysed across the healthy subject 
experimental study in Chapter 3, and the clinical pilot phases in Chapters 4 and 5, it 
is clear that three heel wedge inserts within either of the AFO designs results in both 
significantly altered gait parameters and decreased scores within the PROM’s data 
sets. Consequently, there is both theoretical context and preliminary clinical data on 
which to base the rejection of the three heel wedge insert condition. 
 
Rejecting this intervention then leaves four further options. These are the carbon 
fibre AFO with one or two heel wedge inserts or the rigid rocker bottom AFO with 
one or two heel wedge inserts. When these conditions were trialled within the 
experimental study design of healthy participants, there was a statistically significant 
affect with changing both the heel wedge insert condition and AFO design. Further 
evidence of this is seen within the randomised pilot work in Chapter 5, which 
demonstrates with PROMs data that scores improve with reduction in heel wedge 
inserts. However, it must be noted that this is only pilot work, and is therefore not 
sufficiently powered to accept or reject specific null hypotheses. Consequently, it 
would appear justified to evaluate these four options within a definitive evaluative 
study. Therefore at this stage it could be proposed that a four arm RCT could be 
designed to answer the following research question: 
 
‘Is there a difference in ATRS scores at nine months between four different IWB 
interventions for patients with an acute TA rupture?’ 
 
As discussed earlier in this thesis, the widely accepted ‘gold standard’ within trials of 
clinical effectiveness is the standard RCT. The aim of an RCT is to accept or reject 
the predefined null hypothesis. However, there is another possibility regarding trial 
design.  
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Instead of considering the interventions as one treatment block, they could be 
considered as an intervention consisting of two independent factors (AFO and heel 
wedge insert number) which have two levels within them (Flexible AFO/Rigid AFO 
and 1 heel wedge/2heel wedges). Consequently, using a factorial design would be 
another method in which the AFO design, heel wedge insert number and the 
interaction of these two factors could be investigated in one trial146. Furthermore, 
this trial design would enable definitive evaluation of which individual factor is most 
pertinent to the early rehabilitative phase. 
 
The advantages of factorial designs have been documented to include the need for 
smaller sample sizes than would be required to answer the questions individually. 
Consequently, this results in a more efficient use of time and resources147-148. The 
disadvantages have been discussed by authors as requiring a more detailed 
analysis plan, and consequently the possibility of overcomplicating subsequent 
reporting of the results. This in turn may then lead to losing clinically important 
messages. Therefore, to plan this next stage would require careful consideration of 
the analysis and reporting to ensure successful implementation was possible. 
 
For analysis purposes, the two heel wedge insert condition and rigid rocker bottom 
AFO would be considered the ‘standard treatment’. To explain the analysis plan 
further, the number of heel wedge inserts will be referred to as treatment A and the 
AFO design will be referred to as treatment B. By defining a standard treatment, the 
analysis can then be performed by what is termed an ‘at the margins’ approach 
(Table 8.1). This allows the efficacy of the treatment with two heel wedge inserts to 
be evaluated by comparing the outcomes of all the patients managed with two heel 
wedge inserts against all those not managed with one heel wedge insert and all 
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those managed with a rigid rocker bottom AFO against those not managed with the 
rigid rocker bottom AFO. This is widely accepted as the most powerful analysis for 
this trial design147. The analysis would then be performed using a two way analysis 
of variance. 
 
Table 8.1: Outline of factorial trial design and analysis 
Treatment B 
T
re
a
tm
e
n
t 
A
 
 Rigid (B2) Flexible (B1) Margin 
Two Wedges (A2) A2 and B2 A2 and B1 All A2 cells 
One Wedge (A1) A1 and B2 A1 and B1 All non A2 cells 
Margin All B2 cells All non B2 cells  
 
 
Montgomery et al146 published an article on the design considerations of factorial 
trial designs. Most importantly, the authors highlighted that traditionally factorial 
designs have only evaluated interactions as a secondary analysis (the primary 
analysis being that of treatments A and B). However, if an interaction is considered 
of primary importance then it is acceptable to include interactions as a primary 
analysis if the study has been sufficiently powered to perform this analysis. They 
discuss that to evaluate interactions, the sample size needs to increase fourfold to 
detect the same differences in effect size, for the reasons illustrated in the above 
table (only half as many patients can be included in the analysis compared to 
analysing the main factors alone). 
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Consequently, the decision to include the analysis of interactions as a primary 
question requires careful consideration. Within this thesis an interaction between the 
numbers of heel wedge inserts and the AFO type has been demonstrated.  
 
As an example, assuming approximate normality of the primary outcome measure 
(ATRS) and also assuming that analysis will be based on a standard ANOVA (‘at 
the margins analysis’), and assuming significance is set to 5%, the total number of 
participants for a minimum clinically important difference of 10 points is shown in 
Table 8.2 for 80% and 90% power for a range of standard deviations from 16 (the 
figure recorded at three months within Chapter 7) going up in units of two through to 
26 (demonstrating effect sizes of between 0.4 to 0.6). These would be divided 
equally amongst the 4 treatments groups (AFOs x wedges) and are adequately 
powered to detect an interaction twice as large as the main effects. 
Table 8.2: Sample size calculations for 80 and 90% power  
S.D 
Power 
80% 90% 
16 84 112 
18 104 140 
20 128 172 
22 156 208 
24 184 244 
26 216 288 
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So, for example, at 80% power and SD=20, 128 participants would be required (32 
in each of the four combinations of AFOs and wedges). This design assumes that 
interactions are not of primary interest, or if interactions were likely to be very large, 
very unlikely. If we thought interactions were important (the effect of wedges was 
likely to be different within each AFO) then we would want to multiply this by four 
times, to give 512 participants in total (128 in each group). 
 
So far, the options explored include developing a four armed RCT or implementing 
a 2X2 factorial design. However, an alternative method could be undertaken to 
further develop the proposed IWB interventions which was briefly discussed in 
Chapter 5, prior to further definitive research. This was the proposal to introduce a 
stream of qualitative research across all involved stakeholders (patients, health care 
professionals, charities and ethics committee members) to further qualitatively 
explore treatment priorities and attitudes towards the proposed trial interventions. 
This further research could also include a stream of survey research to ascertain if 
what has been documented within the literature regarding clinical practice is 
reflective of what actually occurs in UK practice. In doing this, both the quantitative 
and qualitative research could be integrated at the point of interpretation to 
determine the interventions that need to be trialled in a further definitive RCTs. 
 
This mixed methods approach to developing trial interventions is not uncommon, 
and ensures a pragmatic response to such complex health care questions142-143.  
Mixed methods research designs in this context use both quantitative and 
qualitative methods to either sequentially inform each subsequent stage of the 
interventional development or can be used in parallel and integrated at the point of 
interpretation. Based on my pilot clinical research there is a need to incorporate 
such work prior to undertaking any further definitive studies. 
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It is clear that this next stage of research would require not only the skills 
demonstrated throughout this PhD, but also many that require further development 
in new qualitative research areas and training to enable successful management, 
leadership and research impact. This initial outline will now form the basis for a 
post-doctoral fellowship application, to learn and develop these required skills under 
expert mentorship arrangements, using the outlined future research as a platform 
for achieving this. 
 
This series of studies has demonstrated the successful planning, implementation 
and dissemination of a broad range of research methods, within the context of the 
MRC complex interventions framework. These have included systematic reviews, 
experimental designs, pilot clinical trials and outcome validation research. The 
overall aim of which, was to facilitate the development of an evaluative study. To 
achieve this, completion of this thesis has required demonstration of both research 
and personal development, overseen by expert supervisors.  
 
The conclusions that can be drawn from this combined series of studies are firstly 
that rehabilitation of this injury is a complex intervention. The systematic review in 
the second chapter of this thesis demonstrated it is an intervention that consists of 
four components. These are the type of AFO worn, the degree of PF within it, how 
long it is worn for and whether or not to include ROM exercises.  
 
In relation to how long the AFO is worn for and whether or not to include ROM 
exercises, previous animal based research and an RCT have investigated tendon 
healing and the effects of early movement. This research demonstrated that the 
proliferative phase of tendon healing lasts until approximately six weeks, at which 
point the healing tendon then enters a remodelling phase. Throughout these first 
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weeks, ROM has been shown to have a preferential effect on these phases. The 
clinician can therefore justify wearing an AFO for at least six weeks whilst the 
patient simultaneously carries out ROM exercises from PF to neutral.  
 
In relation to which AFO should be worn and the degree maintained PF within it, the 
third chapter of this thesis demonstrated that the flexibility of the AFO and amount of 
maintained PF significantly correlated with the amount of forefoot and heel 
pressures produced. The results showed that the greater the restriction and the 
higher the degree of maintained PF, the greater the heel pressure production and 
lower the forefoot pressure production. However this research was conducted in 
healthy participants, not patients.  
 
Subsequent clinical research piloting these different combinations of AFO types and 
maintained PF highlighted the balance that is needed between allowing sufficient 
flexibility and loaded movement against the risk of tendon re-rupture. This was 
evident through the occurrence of three re-ruptures in 15 patients during the second 
clinical phase, which is higher than that reported in the literature. However this 
clinical research was only piloting/feasibility work and subsequently issues of safety 
could not be definitively concluded without a larger sample. Furthermore it 
contained a sample of both operatively and non-operatively managed patients, 
which is a confounding factor and further limitation of the study. 
 
However the combination of defining these components, providing a theoretical 
framework for what could work in clinical practice and then piloting these 
interventions are the first and only steps that have been taken to systematically 
develop this intervention.  Therefore although further research is clearly required, 
currently this is the best available published evidence and patients require 
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management today. Consequently this research has led to the development of a 
clinical pathway locally and opened up discussions with clinical interest groups 
directed at developing guidelines nationally and research priorities in this important 
area. 
 
The next steps personally, have resulted in planning of a subsequent fellowship 
application to facilitate future research leadership in this area, addressing the 
outstanding questions posed in this thesis (surrounding current UK practice and 
patient/clinician acceptability), alongside other important areas of rehabilitation in 
the field of trauma and orthopaedics. However there is clearly a wider need for 
healthcare researchers, who deliver complex interventions, to recognise the 
importance of defining the intervention components, identifying which of these 
components are important and why, ensuring acceptability of the intervention in 
practice to both patients and clinicians. These aims cannot be achieved with the 
traditional RCT, but instead require a mixed methods approach.’ 
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Non-operative management of Achilles tendon ruptures 
 
Jan 2011: WMS Symposium: Poster Presentation: An investigations into 
accelerated rehabilitation strategies following an Achilles tendon rupture 
 
Feb 2011: Society for Research in Rehabilitation: Poster Presentation: A systematic 
review of early rehabilitation methods following an Achilles tendon rupture 
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May 2011: British Trauma Society: Poster Presentation: The effect of maintained 
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parameters following an Achilles tendon rupture 
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p.11-39. 
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Participant Information Sheet 
 
 
Chief Investigator: Mr Matt Costa 
 
Background information  
Rupture of the Achilles tendon is a serious and disabling injury. The condition typically 
affects young active adults and is associated with prolonged periods off work and much 
longer abstinence from sporting activity. Prolonged hospital stay and delayed rehabilitation 
have significant financial and health implications for both the NHS and society as a whole. 
Therefore, it is important to find the best way to treat patients with this injury in order to get 
them back to their normal activity as quickly as possible. 
 
What is the purpose of this study? 
We are assessing foot pressure measurements taken inside an orthotic to determine the 
best treatment for acute Achilles tendon ruptures. This foot pressure data is important to 
inform and lead advancements in rehabilitation protocols. 
 
Why have I been chosen? 
Healthy subjects with no history of lower limb pathology working within the University 
Hospitals of Coventry and Warwickshire and Warwick University will be invited to take part in 
this trial. A total of 15 participants will be recruited. 
 
What will happen after I have been entered in the trial? 
You will be given an appointment to attend one research clinic. During this clinic a research 
physiotherapist will fit you with a walking boot containing three heel raises. Inside the boot 
thin plastic insoles will be used to measure foot pressure distributions. The range of 
movement you have at your ankle will also be assessed.  You will then be asked to walk ten 
metres down a flat corridor wearing the walking boot. This procedure will be repeated using 
different numbers of heel raises inside the boot. 
 
Do I have to take part? 
It is up to you whether or not to take part. If you decide to take part you will be given this 
information sheet to keep and be asked to sign a consent form. If you decide to take part 
you are still free to withdraw at any time and without giving a reason.  
 
What are the possible disadvantages and risks of taking part? 
There are no known disadvantages to taking part in this trial. 
 
What are the possible benefits of taking part? 
There is no specific advantage to you for taking part in the study. However, the information 
we get from this study may help us to treat future patients with Achilles tendon Ruptures. 
 
What if new information becomes available? 
Sometimes during the course of a research project, new information becomes available 
about the treatment that is being studied. If this happens, your research physiotherapist will 
tell you about it and discuss with you whether you want to continue in the study. If you 
decide to continue in the study you will be asked sign an updated consent form. 
Also, on receiving new information your research physiotherapist might consider it to be in 
your best interest to withdraw you from the study. If this happens He/she will explain the 
reasons. 
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What happens if something goes wrong? 
In the unlikely event of you being harmed by taking part in this research project, there are no 
special compensation arrangements. If you are harmed due to someone’s negligence, then 
you may have grounds for a legal action but you may have to pay for it. Regardless of this, if 
you wish to complain, or have any concerns about any aspect of the way you have been 
approached or treated during the course of this study, the normal National Health Service 
complaints mechanisms are available to you. Alternatively you can contact Mrs Ceri Jones 
at Research & Development Services, University Hospital Coventry and Warwickshire NHS 
trust, Clifford Bridge Road, Coventry, CV2 2DX. Direct telephone number 024 7696 6196. 
 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept 
strictly confidential. Any information about you which leaves the hospital will have your name 
and address removed so that you cannot be recognised from it.  
 
What will happen to the results of the research study? 
This study is expected to last 2 years. At the end of the study we will publish the findings in 
medical journals and at medical conferences. You will not be identified in any reports or 
publications resulting from the study. If you would like to obtain a copy of the published 
results, please ask your doctor. 
 
What will happen if I decide not to participate in the research study? 
There will be no action. 
 
Who has reviewed this study? 
This study has been reviewed by Coventry Research Ethics Committee. 
 
Contacts for further information 
If you would like further information please contact Mr Matt Costa who is leading the project 
by telephoning 02476 968618 or Dr Juul Achten who is responsible for the overall 
management of the study (02476 968614, J.Achten@warwick.ac.uk). 
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Consent Form
 
Trial Centre ID:                      Date (dd/mm/yy):  
Name of Patient:  D.O.B (dd/mm/yy):  
 
Chief Investigator   Mr Matt Costa 
1. I confirm that I have read and understand the information sheet 
dated 31
st
 of July 2008 for the above study. I have had the opportunity 
to consider the information, ask questions and have had these 
answered satisfactorily. 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical 
care or legal rights being affected. 
3. I understand that relevant sections of any of my medical notes and 
data collected during the study may be looked at by responsible 
individuals from regulatory authorities or from the NHS Trust, where it is 
relevant to my taking part in this research. I give permission for these 
individuals to have access to my records. 
4. I agree to take part in the above study. 
 
_______________________  ____________ ____________________ 
Name of Patient   Date   Signature 
 
_______________________  ____________ ____________________ 
Name of Person taking consent  Date   Signature 
_______________________ 
Role of Person taking consent
Please initial box 
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Participant Information Sheet 
Plantar pressures in Achilles tendon rupture 
Chief Investigator: Mr Matt Costa 
Background information 
Rupture of the Achilles tendon is a serious and disabling injury. The condition typically 
affects young active adults and is associated with prolonged periods off work and much 
longer abstinence from sporting activity. Prolonged hospital stay and delayed rehabilitation 
have significant financial and health implications for both the NHS and society as a whole. 
Therefore, it is important to find the best way to treat patients with this injury in order to get 
them back to their normal activity as quickly as possible. 
 
What is the purpose of this study? 
We are assessing foot pressure measurements taken inside an orthotic to determine the 
best treatment for acute Achilles tendon ruptures. This foot pressure data is important to 
inform and lead advancements in rehabilitation protocols. 
 
Why have I been chosen? 
All patients attending this hospital who present with an acute Achilles tendon rupture will be 
invited to take part in this trial. A total of 15 patients will be recruited. 
 
What will happen after I have been entered in the trial? 
Standard Practice: You will have the option to have your Achilles tendon operatively or non-
operatively managed. Regardless of the treatment option chosen, your injured leg will be 
placed in a walking boot to start the recovery process. You will need to attend a clinic every 
two weeks for twelve weeks and then two further appointments at six and nine months after 
your injury, this is normal clinical practice.  
 
Research Practice: If you take part in the trial, within the orthotic differing numbers of heel 
wedges are normally inserted, but at present we do not know what the optimum number is. If 
you take part in the trial the number of inserted heel wedges inside the orthotic will be 
allocated to you. At each of these visits a research physiotherapist will measure the range of 
movement you have at your ankle and foot pressure distributions inside your walking boot 
will be measured using thin plastic insoles. For this measurement, you will be asked to walk 
up and down a corridor five times. In addition, at each visit you will be asked to fill out 3 
questionnaires to assess how disabled you feel due to your injury, your current health status 
and your activity level.  
 
Do I have to take part? 
It is up to you whether or not to take part. If you decide to take part you will be given this 
information sheet to keep and be asked to sign a consent form. If you decide to take part 
you are still free to withdraw at any time and without giving a reason. A decision to withdraw 
at any time, or a decision not to take part will not affect the standard of care you receive; you 
will receive the same normal care as someone not invited to take part in the experiment.  
 
What are the possible disadvantages and risks of taking part? 
There are no known disadvantaged to taking part in this trial because your treatment will not 
change. 
 
What are the possible benefits of taking part? 
There is no specific advantage to you for taking part in the study. However, the information 
we get from this study may help us to treat future patients with Achilles tendon Ruptures. 
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What if new information becomes available? 
Sometimes during the course of a research project, new information becomes available 
about the treatment that is being studied. If this happens, your research physiotherapist will 
tell you about it and discuss with you whether you want to continue in the study. If you 
decide to withdraw your research physiotherapist will make arrangements for your care to 
continue. If you decide to continue in the study you will be asked sign an updated consent 
form. 
 
Also, on receiving new information your research physiotherapist might consider it to be in 
your best interest to withdraw you from the study. He/she will explain the reasons and 
arrange for your care to continue. 
 
What happens when the research study ends? 
You will be in the study for 9 months. If you are still having problems after this time, we will 
arrange for you to have an appointment with an appropriate specialist to continue your care. 
 
What happens if something goes wrong? 
In the unlikely event of you being harmed by taking part in this research project, there are no 
special compensation arrangements. If you are harmed due to someone’s negligence, then 
you may have grounds for a legal action but you may have to pay for it. Regardless of this, if 
you wish to complain, or have any concerns about any aspect of the way you have been 
approached or treated during the course of this study, the normal National Health Service 
complaints mechanisms are available to you. Alternatively you can contact Mrs Ceri Jones 
at Research & Development Services, University Hospital Coventry and Warwickshire NHS 
trust, Clifford Bridge Road, Coventry, CV2 2DX. Direct telephone number 024 7696 6196. 
 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept 
strictly confidential. Any information about you which leaves the hospital will have your name 
and address removed so that you cannot be recognised from it.  
 
What will happen to the results of the research study? 
This study is expected to last 3 years. At the end of the study we will publish the findings in 
medical journals and at medical conferences. You will not be identified in any reports or 
publications resulting from the study. If you would like to obtain a copy of the published 
results, please ask your doctor. 
 
What will happen if I decide not to participate in the research study? 
There will be no change to your treatment. 
 
Who has reviewed this study? 
This study has been reviewed by Coventry Research Ethics Committee. 
 
Contacts for further information 
If you would like further information please contact Mr Matt Costa who is leading the project 
by telephoning 02476 968618 or Dr Juul Achten who is responsible for the overall 
management of the study (02476 968614, J.Achten@warwick.ac.uk). 
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Flow chart of the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Injury 
Operation 
Range of movement, foot pressures 
at 2, 4, 6, 8,10,12, weeks post-injury, 6 
months and 9 months 
Questionnaires at baseline,2,6,12 
weeks post-injury, 6 and 9 months 
Walking boot rehabilitation 
program 
No operation 
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Appendix D Consent Form
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Consent Form 
 
Trial Centre ID:                     Date (dd/mm/yy):  
Name of Patient:  D.O.B (dd/mm/yy):  
 
Chief Investigator   Mr Matt Costa 
1. I confirm that I have read and understand the information sheet 
dated 31
st
 July 2008 for the above study. I have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily. 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical 
care or legal rights being affected. 
3. I understand that relevant sections of any of my medical notes and 
data collected during the study may be looked at by responsible 
individuals from regulatory authorities or from the NHS Trust, where it is 
relevant to my taking part in this research. I give permission for these 
individuals to have access to my records. 
4. I agree to take part in the above study. 
_______________________  ____________ ____________________ 
Name of patient    Date  Signature 
 
_______________________  ____________ ____________________ 
Name of person taking consent  Date  Signature 
 
_______________________ 
Role of person taking consent
Please initial box 
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Appendix E Achilles tendon Total Rupture Score 
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All questions refer to your limitations/difficulties related to your injured Achilles 
tendon. 
  
 
Mark with an X in the box which matches your level of limitation! 
 
 
 
1. Are you limited due to decreased strength in the calf/Achilles tendon/foot? 
 
0 = Major limitations/symptoms        10 = No limitations/symptoms 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
2. Are you limited due to fatigue in the calf/Achilles tendon/foot? 
 
0 = Major limitations/symptoms          0 = No limitations/symptoms 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
3. Are you limited due to stiffness in the calf/Achilles tendon/foot 
 
0 = Major limitations/symptoms        10 = No limitations/symptoms 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
4. Are you limited due to pain in the calf/Achilles tendon/foot? 
 
0 = Major limitations/symptoms        10 = No limitations/symptoms 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
5. Are you limited during activities of daily living? 
  
0 = Major limitations/symptoms        10 = No limitations/symptoms 
 
0 1 2 3 4 5 6 7 8 9 10 
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All questions refer to your limitations/difficulties related to your injured Achilles 
tendon. 
 
 
Mark with an X in the box which matches your level of limitation! 
 
 
6. Are you limited when walking on uneven surfaces? 
 
0 = Major limitations/symptoms        10 = No limitations/symptoms 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
7. Are you limited when walking quickly up the stairs or up a hill? 
 
0 = Major limitations/symptoms        10 = No limitations/symptoms 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
8. Are you limited during activities that include running? 
 
0 = Major limitations/symptoms        10 = No limitations/symptoms 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
9. Are you limited during activities that include jumping? 
 
0 = Major limitations/symptoms        10 = No limitations/symptoms 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
10 . Are you limited in performing hard physical labour? 
 
0 = Major limitations/symptoms        10 = No limitations/symptoms 
 
0 1 2 3 4 5 6 7 8 9 10 
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Appendix F Disability Rating Index 
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How do you manage the following activities? 
After each question, please mark ONE POINT on the line 
 
 
 
 
 
 
Without difficulty 
 
Dressing (without help) 
 
Out-door walks 
 
Climbing stairs 
 
Sitting longer time 
 
Standing bent over a sink 
 
Carrying a bag 
 
Making a bed 
 
Running 
 
Light work 
 
Heavy work 
 
Lifting heavy objects 
 
Participating in exercise/sports 
 
 
 
  
Not at all 
Without difficulty      Not at all 
 
 
      With some difficulty - With difficulty - With great difficulty       
 
   
Please answer ALL questions 
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Appendix G EQ-5D 
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PLANTERPRESSURE IN ACHILLES TENDON RUPTURE                                                                                 BASELINE QUESTIONNAIRE 
These questions refer to your health before your injury. Please answer this questionnaire based on 
how you were before your injury. By placing a cross in one box in each group below, please 
indicate which statement best describes your own health state today. 
 
Please put a cross in one box for each question 
 
Q1. Mobility: 
 
 I have no problems in walking about      1 
I have some problems in walking about     2 
I am confined to bed        3 
         
Q2.  Self-Care: 
 
I have no problems with self-care      1 
I have some problems washing or dressing myself    2 
I am unable to wash or dress myself      3 
      
Q3. Usual Activities (e.g. work, study, housework, family or leisure activities): 
 
I have no problems with performing my usual activities   1 
I have some problems with performing my usual activities   2 
I am unable to perform my usual activities     3  
   
Q4. Pain / Discomfort: 
I have no pain or discomfort       1 
I have moderate pain or discomfort      2 
I have extreme pain or discomfort      3 
 
      
Q5. Anxiety / Depression: 
 
I am not anxious or depressed                  1      
I am moderately anxious or depressed     2 
I am extremely anxious or depressed      3 
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Your own health state before your injury 
 
To help people say how good or bad a health state is, we 
have drawn a scale (rather like a thermometer) on which 
the best state you can imagine is marked 100 and the 
worst state you can imagine is marked 0. 
 
We would like you to indicate on this scale how good or 
bad your own health was before your injury, in your 
opinion. 
 
Please do this by drawing a line from the box below, to 
whichever point on the scale indicates how good or bad 
your current health state was before your injury. 
 
Your own health state 
before your injury 
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Appendix H Clinical Reporting Forms 
 
PLANTER PRESSURE IN ACHILLES TENDON RUPTURE                                                                                 BASELINE QUESTIONNAIRE 
PATIENT ID:      
Patient Screening Form
 
Trial Centre ID:                      Date (dd/mm/yy):  
Name of Patient:  D.O.B (dd/mm/yy):  
R.A. Name:    
 
Eligibility check list: 
 
Section 1: The answer must be “yes” to all the following questions for the patient to be eligible for 
the trial: 
 
 
Aged 18 years or over? Yes 
 
 No 
1 
  
2 
     
Acute TA Rupture (< 10 days after injury) Yes  No 
1 
  
2 
     
Able to give informed consent? Yes  No 
1 
  
2 
 
Section 2: The answer must be “no” to all the following questions for the patient to be eligible for the 
trial: 
 
Is this a re-rupture? Yes  No 
1 
  
2 
    
Any other serious injuries to either lower limb that would interfere 
with rehabilitation of the TA rupture? 
Yes  No 
1 
  
2 
    
Evidence that the patient would be unable to adhere to trial 
procedures, or complete questionnaires, such as dementia or IV 
drug abuse? 
 
If yes, please give details……………………………………. 
Yes  No 
1 
  
2 
    
 
Is the patient willing to participate in the trial?                              Yes □ 1    No □2       
 
  
If “no”, please ask the patient to identify reason: 
I feel being part of the trial will interfere too much with my 
work or daily routine 
  
 1 
 
I am not happy about being part of a research project 
  
 2 
 
I do not want to fill in the questionnaire 
  
 3 
 
 
Other – please state:………………………………………… 
  
 
 
4 
 
 
PLANTER PRESSURE IN ACHILLES TENDON RUPTURE                                                                                 BASELINE QUESTIONNAIRE 
PATIENT ID:      
Background Information 
 
 
Trial Centre ID:                      Date (dd/mm/yy):  
Name of Patient:  D.O.B (dd/mm/yy):  
R.A. Name:    
 
 
 
Section 1: Patient details
 
 
 
Patient’s Name: 
 
 
Patient’s Address: 
 
 
 
 
 
 
Post Code: 
 
Telephone:  
                   Home 
 
                    
                   Work 
 
                    
                   Mobile 
 
 
E – Mail Address: 
 
 
Preferred Method and 
Time of Contact: 
 
 
 
Is the participant able to answer questions in English?  
 
Yes  1 
 
No  2  
 
 
If no, which language would they choose to use?................................ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PLANTER PRESSURE IN ACHILLES TENDON RUPTURE                                                                                 BASELINE QUESTIONNAIRE 
PATIENT ID:      
 
 
Section 2: Medical History 
 
 
Patient’s height…………………..(cms) and weight…………………..(kgs) 
 
Current medication:  
Fluroquinolone Antibiotics Yes  1        No  2 
     
Steroids Yes  1       No  2 
     
DMARD’s Yes  1        No  2 
     
Diabetic Mediation Yes  1      No  2 
     
Other Please State:  
 
…………………………………………………………… 
    
Pre-existing: 
History of congenital or acquired condition leading to 
a gait abnormality? 
Yes  1   No  2 
     
Other…………………………………………………     
 
Lower Limb Pathology in either leg (For example 
hip/knee OA) 
Yes  1 No  2 
 
Give Details        
……………………………………………………….. 
    
      
Ipsilateral leg (pre-injury)      
 
Achilles Symptoms -  Pain Yes  1 No  2 
      
Achilles Symptoms - Swelling Yes  1 No  2 
      
Fusiform Swelling / Thickening Yes  1 No  2 
      
Use of Orthotics: Yes  1 No  2 
     
Contralateral leg (pre-injury)    
     
Achilles Symptoms -  Pain Yes  1 No  2 
     
Achilles Symptoms - Swelling Yes  1 No  2 
     
Fusiform Swelling / Thickening Yes  1 No  2 
 
  
PLANTER PRESSURE IN ACHILLES TENDON RUPTURE                                                                                 BASELINE QUESTIONNAIRE 
PATIENT ID:      
 
Section 3: Current Injury
 
 
Date of this injury:   --   /  --   / -- -- -- -- (dd/mm/yyyy) 
 
 
Side of Injury: Left / Right 
 
 
Management: Operative / Non-Operative 
 
 
Orthotic:…………………………………………. 
 
 
Mechanism of injury:  
 
Fall From Height Yes  1     No  2 
     
Sports Yes  1     No  2 
     
Walking / Stairs Yes  1     No  2 
     
Other      
 
Any new injury to: 
 
Ipsilateral Leg  Yes  1  No  2 
 
Give Details        ……………………………………………………….. 
    
      
Contra- lateral Leg  Yes  1  No  2 
 
Give Details        ……………………………………………………….. 
    
      
Any Other New Injury, 
 
Give Details        ……………………………………………………….. 
Yes  1 No  2 
  
 
 
  
PLANTER PRESSURE IN ACHILLES TENDON RUPTURE                                                                                 BASELINE QUESTIONNAIRE 
PATIENT ID:      
Baseline Information 
 
 
Trial Centre ID:                      Date (dd/mm/yy):  
Patient ID:  R.A. Name:  
 
 
 
 
1.  Do you smoke?   
 
Yes     1 
 
No     2 
 
If yes, how many cigarettes do you smoke per day___and how many years have you smoked___? 
 
 
If no, have you smoked regularly in the past?  
 
Yes     1 
 
No     2 
 
 
2. How many units of alcohol do you drink in a normal week? (One unit of alcohol is equivalent to ½ 
pint of ordinary beer, lager or cider; one small glass of wine, or one single pub measure of spirits).  
 
0-7 units    1 
 
8-14 units    2 
 
15-21 units    3 
 
 >21 units    4 
 
 
 
3. Please place a cross in the box that most closely describes your ethnic background:  
White 
 1 
Black 
Caribbean  
 
2 
Black 
African  3 
Black 
other  4 
            
Indian 
 5 
Pakistani 
 6 
Bangladeshi 
 7 
Chinese 
 8 
         
Other 
 9 
(Please specify) 
………………………………………………………………………… 
 
 
 
 
 
 
 
 
 
PLANTER PRESSURE IN ACHILLES TENDON RUPTURE                                                                                 BASELINE QUESTIONNAIRE 
PATIENT ID:      
Section 1: 
 
 
These questions refer to your health before your injury. Please answer this questionnaire based on 
how you were before your injury. By placing a cross in one box in each group below, please 
indicate which statement best describes your own health state today. 
 
Please put a cross in one box for each question 
 
Q1. Mobility: 
 
 I have no problems in walking about      1 
I have some problems in walking about     2 
I am confined to bed        3 
         
Q2.  Self-Care: 
 
I have no problems with self-care      1 
I have some problems washing or dressing myself    2 
I am unable to wash or dress myself      3 
      
Q3. Usual Activities (e.g. work, study, housework, family or leisure activities): 
 
I have no problems with performing my usual activities   1 
I have some problems with performing my usual activities   2 
I am unable to perform my usual activities     3  
   
Q4. Pain / Discomfort: 
I have no pain or discomfort       1 
I have moderate pain or discomfort      2 
I have extreme pain or discomfort      3 
 
      
Q5. Anxiety / Depression: 
 
I am not anxious or depressed                  1      
I am moderately anxious or depressed     2 
I am extremely anxious or depressed      3 
 
PLANTER PRESSURE IN ACHILLES TENDON RUPTURE                                                                                 BASELINE QUESTIONNAIRE 
PATIENT ID:      
 
Your own health state before your injury 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Your own health state  
before your injury 
 
 
To help people say how good or bad a health state is, 
we have drawn a scale (rather like a thermometer) on 
which the best state you can imagine is marked 100 and 
the worst state you can imagine is marked 0. 
 
We would like you to indicate on this scale how good or 
bad your own health was before your injury, in your 
opinion. 
 
Please do this by drawing a line from the box below, to 
whichever point on the scale indicates how good or 
bad your current health state was before your injury. 
 
PLANTER PRESSURES IN ACHILLES TENDON RUPTURES    TWO WEEKS 
PATIENT ID:   
 
Section 2: 
 
 
 
 
 
 
 
 
 
 
 
 
 
How do you manage the following activities? 
After each question, please mark ONE POINT on the line 
 
 
 
 
 
 
        
 
     Without difficulty                          
 
Dressing (without help) 
 
Out-door walks 
 
Climbing stairs 
 
Sitting longer time 
 
Standing bent over a sink 
 
Carrying a bag 
 
Making a bed 
 
Running 
 
Light work 
 
Heavy work 
 
Lifting heavy objects 
 
Participating in exercise/sports 
 
 
 
 
 
  
 
Without difficulty      Not at all 
 
 
 
 
      With some difficulty - With difficulty - With great difficulty       
Please answer ALL questions 
Not at all 
Example 
PLANTER PRESSURES IN ACHILLES TENDON RUPTURES    TWO WEEKS 
PATIENT ID:   
 
 
Section 3:  
 
 
All questions refer to your limitations/difficulties related to your injured Achilles tendon. 
  
 
Mark with an X in the box which matches your level of limitation! 
 
 
1. Are you limited due to decreased strength in the calf/Achilles tendon/foot? 
 
0 = Major limitations/symptoms          10 = No limitations/symptoms 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
 
2. Are you limited due to fatigue in the calf/Achilles tendon/foot? 
 
0 = Major limitations/symptoms          10 = No limitations/symptoms 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
 
3. Are you limited due to stiffness in the calf/Achilles tendon/foot? 
 
0 = Major limitations/symptoms          10 = No limitations/symptoms 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
4. Are you limited due to pain in the calf/Achilles tendon/foot? 
 
0 = Major limitations/symptoms          10 = No limitations/symptoms 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
5. Are you limited during activities of daily living? 
  
0 = Major limitations/symptoms          10 = No limitations/symptoms 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
 
 
 
 
 
PLANTER PRESSURES IN ACHILLES TENDON RUPTURES    TWO WEEKS 
PATIENT ID:   
All questions refer to your limitations/difficulties related to your injured Achilles tendon. 
 
 
Mark with an X in the box which matches your level of limitation! 
 
 
6. Are you limited when walking on uneven surfaces? 
 
0 = Major limitations/symptoms          10 = No limitations/symptoms 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
 
7. Are you limited when walking quickly up the stairs or up a hill? 
 
0 = Major limitations/symptoms          10 = No limitations/symptoms 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
 
8. Are you limited during activities that include running? 
 
0 = Major limitations/symptoms          10 = No limitations/symptoms 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
 
9. Are you limited during activities that include jumping? 
 
0 = Major limitations/symptoms          10 = No limitations/symptoms 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
 
10 . Are you limited in performing hard physical labour? 
 
0 = Major limitations/symptoms          10 = No limitations/symptoms 
 
0 1 2 3 4 5 6 7 8 9 10 
 
  
 
  
PLANTER PRESSURES IN ACHILLES TENDON RUPTURES    TWO WEEKS 
PATIENT ID:   
 
Follow Up Questionnaires
 
 
Trial Centre ID:                      Date (dd/mm/yy):  
Patient ID:  R.A. Name:  
 
 
 
1. Which treatment did the patient receive? 
 
  Operative  1 
 
  Non-operative  2 
 
 
2. Which orthotic and rehabilitation plan has the patient received and gait analysis details: 
 
 
Male/Female: 
 
 
 
Weight: 
 
 
 
Height: 
 
 
 
Left / Right TA rupture 
 
 
 
Orthotic type and rehab plan 
 
 
 
  
 
 
3. Wound Complications: answer “no” for those in the non-operative arm as appropriate”.  
 
a. Were the following complications present? Tick all that apply 
 
  Yes  No  
1 Erythema 
 
 1  2 
2 Persistent serous drainage longer than 14 days 
 
 1  2 
3 Purulent drainage 
 
 1  2 
4 Microbiological confirmation of infection 
 
 1  2 
5. Re-rupture 
 
 1  2 
  
 
 
 
 
PLANTER PRESSURES IN ACHILLES TENDON RUPTURES    TWO WEEKS 
PATIENT ID:   
Was patient treated with: 
  Yes  No  
1 Antibiotics 
 
 1  2 
2 Surgical management 
 
 1  2 
3 Conservative management 
 
 1  2 
 
 
b. If complications were treated surgically, give date and place of surgery and details: 
 
i. Date………………….. 
 
ii. Details……………………………………………………… 
 
 
4. Has the patient had a neurological injury? if patient had non-operative treatment, tick no 
 
Yes  1     
 
No  2    
 
 
 
5.  If Yes was this neurological injury: 
   
  Sural Nerve   1 
  
  Other    2 
 
 
 
6. Has the patient had a vascular injury? If patient had non-operative treatment, tick no 
 
Yes  1     
 
No  2    
 
 
 
7. Has the patient had a diagnosis of DVT or PE since discharge from hospital?  
 
Yes  1     
 
No  2    
 
If yes, give details of date -- / -- / -- -- -- -- (dd/mm/yyyy) 
 
Investigations…………………………………………………………………. 
 
Treatment given……………………………………………………………….. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PLANTER PRESSURES IN ACHILLES TENDON RUPTURES    TWO WEEKS 
PATIENT ID:   
8. Have there been any other complications or adverse events since last attendance at hospital?   
 
 
Yes  1     
 
No  2    
 
 
If yes, give details of date -- / -- / -- -- -- -- (dd/mm/yyyy) 
 
Investigations…………………………………………………………………. 
 
Treatment given……………………………………………………………….. 
 
 
9. Do documented complications qualify as a serious adverse event (SAE): 
 
a. Life-threatening 
 
b. Required hospitalisation or prolongation of existing hospitalisation 
 
c. Resulted in persistent or significant disability or incapacity 
 
d. Required medical intervention to prevent one of the above 
 
e. Otherwise considered medically significant by the investigator? 
 
 
Yes  1     
 
No  2    
 
If yes, complete the SAE report form. This form is to be sent to the central office Please ensure that 
this is done within 24 hours of the patient attending the follow-up clinic. 
 
 
For central office use only:  
 
 
a) Serious / not serious 
b) Mild / moderate / severe 
c) Probably related / possibly related / unlikely to be related / unrelated to treatment 
d) Expected / unexpected 
 
Signed (CI):    Reported to LREC: Yes / No / NA 
Date:      
 
 
10. Have any of the participant’s contact details changed, or are there likely to be   
any changes in the next 3 months?  
  
Yes          1 
 
If so, please give the new details……………………………………. 
 
…………………………………………………………………………… 
 
No          2 
  
 
 
 
 
 
 
PLANTER PRESSURES IN ACHILLES TENDON RUPTURES    TWO WEEKS 
PATIENT ID:   
Section 1: 
 
 
These questions refer to your health before your injury. Please answer this questionnaire based on 
how you were before your injury. By placing a cross in one box in each group below, please 
indicate which statement best describes your own health state today. 
 
Please put a cross in one box for each question 
 
Q1. Mobility: 
 
 I have no problems in walking about      1 
I have some problems in walking about     2 
I am confined to bed        3 
         
Q2.  Self-Care: 
 
I have no problems with self-care      1 
I have some problems washing or dressing myself    2 
I am unable to wash or dress myself      3 
      
Q3. Usual Activities (e.g. work, study, housework, family or leisure activities): 
 
I have no problems with performing my usual activities   1 
I have some problems with performing my usual activities   2 
I am unable to perform my usual activities     3  
   
Q4. Pain / Discomfort: 
I have no pain or discomfort       1 
I have moderate pain or discomfort      2 
I have extreme pain or discomfort      3 
 
      
Q5. Anxiety / Depression: 
 
I am not anxious or depressed                  1      
I am moderately anxious or depressed     2 
I am extremely anxious or depressed      3 
 
PLANTER PRESSURES IN ACHILLES TENDON RUPTURES    TWO WEEKS 
PATIENT ID:   
 
Your own health state before your injury 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Your own health state  
before your injury 
 
 
To help people say how good or bad a health state is, 
we have drawn a scale (rather like a thermometer) on 
which the best state you can imagine is marked 100 and 
the worst state you can imagine is marked 0. 
 
We would like you to indicate on this scale how good or 
bad your own health was before your injury, in your 
opinion. 
 
Please do this by drawing a line from the box below, to 
whichever point on the scale indicates how good or 
bad your current health state was before your injury. 
 
  
PATIENT ID: 
 
Section 2: 
 
 
 
 
 
 
 
 
 
 
 
 
 
How do you manage the following activities? 
After each question, please mark ONE POINT on the line 
 
 
 
 
 
 
        
 
     Without difficulty                          
 
Dressing (without help) 
 
Out-door walks 
 
Climbing stairs 
 
Sitting longer time 
 
Standing bent over a sink 
 
Carrying a bag 
 
Making a bed 
 
Running 
 
Light work 
 
Heavy work 
 
Lifting heavy objects 
 
Participating in exercise/sports 
 
 
 
 
 
  
 
Without difficulty      Not at all 
 
 
 
 
      With some difficulty - With difficulty - With great difficulty       
Please answer ALL questions 
Not at all 
Example 
  
PATIENT ID: 
 
Section 3:  
 
 
All questions refer to your limitations/difficulties related to your injured Achilles tendon. 
  
 
Mark with an X in the box which matches your level of limitation! 
 
 
10. Are you limited due to decreased strength in the calf/Achilles tendon/foot? 
 
0 = Major limitations/symptoms          10 = No limitations/symptoms 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
 
11. Are you limited due to fatigue in the calf/Achilles tendon/foot? 
 
0 = Major limitations/symptoms          10 = No limitations/symptoms 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
 
12. Are you limited due to stiffness in the calf/Achilles tendon/foot? 
 
0 = Major limitations/symptoms          10 = No limitations/symptoms 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
13. Are you limited due to pain in the calf/Achilles tendon/foot? 
 
0 = Major limitations/symptoms          10 = No limitations/symptoms 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
14. Are you limited during activities of daily living? 
  
0 = Major limitations/symptoms          10 = No limitations/symptoms 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
 
 
 
  
  
PATIENT ID: 
All questions refer to your limitations/difficulties related to your injured Achilles tendon. 
 
 
Mark with an X in the box which matches your level of limitation! 
 
 
15. Are you limited when walking on uneven surfaces? 
 
0 = Major limitations/symptoms          10 = No limitations/symptoms 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
 
16. Are you limited when walking quickly up the stairs or up a hill? 
 
0 = Major limitations/symptoms          10 = No limitations/symptoms 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
 
17. Are you limited during activities that include running? 
 
0 = Major limitations/symptoms          10 = No limitations/symptoms 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
 
18. Are you limited during activities that include jumping? 
 
0 = Major limitations/symptoms          10 = No limitations/symptoms 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
 
11 . Are you limited in performing hard physical labour? 
 
0 = Major limitations/symptoms          10 = No limitations/symptoms 
 
0 1 2 3 4 5 6 7 8 9 10 
 
  
  
  
PATIENT ID: 
Serious Adverse Event Reporting Form
 
 
Trial Centre ID:                     Date (dd/mm/yy):  
Patient ID:   R.A. Name:  
 
 
 
 
1. Date of event -- / -- / -- --  (dd/mm/yy) 
 
2. Nature of event: (please give as much information as possible, and if necessary 
attach a detailed report). Information must include incident, investigations and 
treatment given and outcome of the event (ongoing, resolved, resolved with 
sequelae tick boxes)  
 
……………………………………………………………………………………………………........... 
 
………………………………………………………………………………………………………….... 
 
Outcome: Ongoing    1 
 
  Resolved    2 
 
  Resolved with sequelae  3 
 
 
3. Was the event something that: (tick as appropriate) 
 
a. Resulted in death            1 
      
b. Is life-threatening            2 
 
c. Required hospitalisation or prolongation  
of existing hospitalisation           3 
 
d. Resulted in persistent or significant disability or incapacity       4 
 
e. Required medical intervention to prevent one of the above      5 
 
f. Is otherwise considered medically significant  
by the investigator?           6 
 
 
 
If the answer to any of Question 3 (parts a-f) is yes, this is a serious adverse event and must 
be reported to the Trial central office within 24 hours of the local investigator becoming 
aware of it.   
 
  
 
 
 
 
 
 
 
 
 
 
  
PATIENT ID: 
In the opinion of the Principal Investigator: 
Is this event related to the trial treatment  
 
Yes   1 
 
No    2 
 
 
Is it an expected 1   or unexpected    2 event?  
 
Date event reported to Principal Investigator……………………………… 
 
Research associate name…………………………………………………… 
 
Research associate signature………………………………………………. 
 
Principal Investigator name………………………………………………….. 
 
Principal Investigator signature……………………………………………… 
 
Date of signature……………………………………………………………… 
 
Date and time received by Trial central office……………………….. 
 
Outcome……………………………………………………………………….. 
 
Requirement for onward reporting?........................................................... 
 
Date?.......................................................................................................... 
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